



Heather Wakelee

Winston Chen and Phyllis Huang Professor
Medicine - Oncology

 Curriculum Vitae available Online

CLINICAL OFFICE (PRIMARY)

- **Thoracic Oncology**

875 Blake Wilbur Dr Rm 2233

MC 6512

Stanford, CA 94305

Tel (650) 498-6000 **Fax** (650) 498-5800

Bio

BIO

Dr. Heather Wakelee specializes in the treatment of lung cancer, thymoma and mesothelioma. She completed all post-graduate training at Stanford University and joined the faculty in 2003. For many years she was the physician lead for the thoracic malignancies clinical research group and has developed research programs related to lung cancer and thymoma across multiple areas including clinical trials, translation work and population sciences. She is the Principal Investigator on numerous clinical trials. In 2021 Dr. Wakelee took on the role of Deputy Director of the Stanford Cancer Institute and is the Division Chief of Medical Oncology. She is also active in many national and international organizations related to lung cancer and thymoma including leadership roles in the International Association for the Study of Lung Cancer (IASLC).

CLINICAL FOCUS

- Cancer > Thoracic Oncology
- Lung Cancer - Medical Oncology
- Investigational Therapeutics
- Medical Oncology
- thymoma
- Mesothelioma
- thymic carcinoma
- Thoracic Cancers - Medical Oncology
- Mesothelioma - Medical Oncology
- Oncology (Cancer)
- Thoracic Cancers

ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Medicine - Oncology
- Member, Stanford Cancer Institute

HONORS AND AWARDS

- Merit Award, American Society of Clinical Oncology (05/2003)
- Alpha Omega Alpha, Johns Hopkins University (06/1996)
- Teaching Award, Stanford University Division of Oncology (2007, 2008, 2009, 2011)
- Young Investigator Award, ECOG-ACRIN (2015)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University Division of Oncology (2003) CA
- Residency: Stanford University Internal Medicine Residency (1999) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2003)
- Medical Education: Johns Hopkins University School of Medicine (1996) MD
- M. D., Johns Hopkins University , Medicine (1996)
- A.B., Princeton University , Molecular Biology (1992)

LINKS

- Video Story: <https://stanfordhealthcare.org/stanford-health-care-now/why-i-got-into-medicine/why-medicine-heather-wakelee-md.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Dr. Wakelee is a clinical investigator with a focus in lung cancer and other thoracic malignancies. Along with her other colleagues in thoracic medical oncology at Stanford she is focused on clinical trials with agents that are specifically targeted to known mutations in lung cancer such as EGFR, ALK and other "driver" mutations with a particular focus on resistance mechanisms. Earlier work on anti-angiogenesis agents continues as well. The treatment of NSCLC revolves increasingly around the use of immune modulatory agents, particularly PD-(L)1 checkpoint inhibitors and the majority of current trials utilize these drugs including bringing them to patients with earlier stages of disease with a hope to improve cure rates.

Dr. Wakelee is an active member of the Eastern Cooperative Oncology Group (ECOG-ACRIN). Stanford University actively participates in trial design and recruitment of patients to ECOG-ACRIN trials. Dr. Wakelee also plays a leadership role in the International Association for the Study of Lung Cancer (IASLC) having served on the board of directors from 2015-2019) and was elected to the role of President-Elect in 2019 and her tenure as President started in 2021.

Thymic malignancies are an understudied rare disease and Dr. Wakelee has developed 2 clinical trials in this patient population and is involved in translational efforts with the disease.

Dr. Wakelee is also involved in several collaborative efforts with her colleagues in thoracic surgery, radiation oncology, pulmonary medicine, basic science and population sciences. Work with Max Diehn on circulating tumor DNA is leading towards the potential to improve surveillance and early detection of NSCLC amongst other applications.

CLINICAL TRIALS

- phase 2 parallel arm of sacituzumab govitecan-hziy in advanced thymoma and thymic carcinoma, Recruiting
- 18F FPPRGD2 PET/CT Imaging of avb3 Integrins Expression as a Biomarker of Angiogenesis, Not Recruiting
- A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer, Not Recruiting
- Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial , Not Recruiting
- Biomarker-Driven Master Protocol in Previously Treated Squamous Cell Lung Ca (Lung-MAP), Not Recruiting
- Expanded Access Intermediate-Size Patient Population Protocol, Not Recruiting

- Expanded Treatment Protocol LDK378 in NSCLC Characterized by ALK Positivity, Not Recruiting
- Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients, Not Recruiting
- Imaging and Biomarkers of Hypoxia in Solid Tumors, Not Recruiting
- Impact of Ethnic Origin on NSCLC Patients being Treated Second Line with Pemetrexed, Not Recruiting
- Phase 1 Glutaminase Inhibitor CB-839 in Advanced and/or Treatment-Refractory Solid Tumors, Not Recruiting
- Phase 2 Trial of Bevacizumab in Combination With Pemetrexed, Not Recruiting
- Phase I ACOO10MA in Previously Treated EGFRmut & Acquired T790M Mutation Non-Small Cell Lung Cancer, Not Recruiting
- Phase I Atezolizumab (MPDL3280A) IV - Single Agent in Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- Phase I AZD9291 & Necitumumab in EGFR-Mutant NSCLC After Progression on Previous EGFR TKI, Not Recruiting
- Phase I Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC), Not Recruiting
- Phase I MAGe-A10c796T in Stage IIIb / IV Non-Small Cell Lung Cancer, Not Recruiting
- Phase I PF-06647020 in Adult Advanced Solid Tumors, Not Recruiting
- Phase I Recombinant Human IL15 (rhIL15) in Advanced Solid Tumors: Melanoma, RCC, NSCLC, HNSCC, Not Recruiting
- Phase I/II Ciforadenant Single Agent & Combo w/ Atezolizumab in Selected Incurable Cancers, Not Recruiting
- Phase I/II Aflibercept in Combo with Pemetrexed and Cisplatin in Patients with Advanced Carcinoma, Not Recruiting
- Phase I/II Anti-Tumor Activity of Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in NSCLC, Not Recruiting
- Phase I/II Bexarotene + ZD 1839 in the 3rd Line Treatment of NSCLC, Not Recruiting
- Phase I/II BTK Inhibitor Ibrutinib in Combo with Durvalumab in Relapsed or Refractory Solid Tumors, Not Recruiting
- Phase I/II Cisplatin + Etoposide plus Veliparib (ABT-888) or Placebo in Extensive Stage SCLC, Not Recruiting
- Phase I/II Ipilimumab/Nivolumab/Brentuximab Vedotin Combos in Relapsed/Refractory Hodgkin Lymphoma, Not Recruiting
- Phase I/II MEDI4736 in Advanced Solid Tumors, Not Recruiting
- Phase I/II NKTR-214 +Nivolumab +/-Other Anti-Cancer Tx in LocallyAdvanced /Metastatic ST Malignancies, Not Recruiting
- Phase I/II of Nivolumab with Vorolanib in Refractory Thoracic Tumors, Not Recruiting
- Phase I/II Oral CO-1686 in Previously Treated Mutant EGFR NSCLC, Not Recruiting
- Phase I/II Selective RET Inhibitor TAS0953/HM06 in Advanced Solid Tumors w/ RET Gene Abnormalities, Not Recruiting
- Phase I/II X-396 in Advanced Solid Tumors & Expansion Phase in ALK+ Non-Small Cell Lung Cancer , Not Recruiting
- Phase Ib Atezolizumab + Cobimetinib in Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- Phase Ib Erlotinib and Momelotinib in Tx of EGFR, Mutated EGFR TKI Naive Metastatic NSCLC, Not Recruiting
- Phase Ib Immunomodulatory Talactoferrin in Select Relapsed or Refractory NSCLC and HNSCC, Not Recruiting
- Phase Ib PDR001 in Combo w/ Platinum-Doublet Chemotherapy & Other Agents in PD-L1 Metastatic NSCLC, Not Recruiting
- Phase Ib/II Grapiprant +/- Pembrolizumab in Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma, Not Recruiting
- Phase Ib/II XL184 with or without Erlotinib for NSCLC, Not Recruiting
- Phase II Adjuvant Erlotinib in Resected Early Stage NSCLC with Mutations in the EGFR, Not Recruiting
- Phase II Amrubicin in Relapsed or Refractory Thymic Malignancies, Not Recruiting
- Phase II ARQ 197 +/- Erlotinib in Papillary Renal Cell Carcinoma, Not Recruiting
- Phase II Atezolizumab in PD-L1-Positive Locally Advanced or Metastatic NSCLC, Not Recruiting
- Phase II AZD0530 for Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma), Not Recruiting
- Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer, Not Recruiting
- Phase II BYM338 for Cachexia Treatment in Stage IV NSCLC or Stage III/IV Pancreas Adenocarcinoma, Not Recruiting

- Phase II Carboplatin + Pemetrexed + Bevacizumab +/- Atezolizumab in Stage IV Non-Squamous NSCLC, Not Recruiting
- Phase II Carboplatin+Paclitaxel Combo w/ Cetuximab, IMC-A12 or Both for Advanced NSCLC, Not Recruiting
- Phase II Cisplatin + Etoposide +/- GDC-0449 or IGF-IR MoAB IMC-A12 in Extensive Stage SCLC, Not Recruiting
- Phase II Concise vs Prolonged Adjuvant Afatinib in Resected Stage I-III NSCLC with EGFR Mutation, Not Recruiting
- Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC, Not Recruiting
- Phase II Erlotinib+ARQ197 vs Chemo in KRAS Mutation Positive w/ Locally Advanced or Metastatic NSCLC, Not Recruiting
- Phase II Erlotinib/Cabozantinib/Erlotinib +Cabozantinib as 2nd / 3rd Line Tx in EGFR Wild-Type NSCLC, Not Recruiting
- Phase II Etrintecan Pegol in Refractory Brain Metastases & Advanced Lung CA / Metastatic Breast CA, Not Recruiting
- Phase II Individualized Combined Modality Therapy for Stage III NSCLC, Not Recruiting
- Phase II L-BLP25 and Bevacizumab in Unresectable Stage IIIA, IIIB Non-Squamous NSCLC After ChemoXRT, Not Recruiting
- Phase II LDK378 in ALK-Activated NSCLC Previously Treated with Chemotherapy and Crizotinib, Not Recruiting
- Phase II Maintenance Pemetrexed vs Observation in Malignant Pleural Mesothelioma w/o Progression, Not Recruiting
- Phase II MetMAb + Paclitaxel + Cisplatin/Carboplatin as 1st Line Tx in Stage IIIB or IV Sq NSCLC, Not Recruiting
- Phase II MPDL3280A in PD-L1-Positive Locally Advanced or Metastatic NSCLC, Not Recruiting
- Phase II Onartuzumab Combo Bevacizumab +Platinum +Paclitaxel or Pemetrexed +Platinum in Non-SQ NSCLC, Not Recruiting
- Phase II Oral Ceritinib Tx in ALK-Positive NSCLC Metastatic to the Brain and/or to Leptomeninges, Not Recruiting
- Phase II Osimertinib Induction Tx Prior to CRT & Maint Osimertinib in EGFR Mutation+ Stage III NSCLC, Not Recruiting
- Phase II Pazopanib vs. Placebo in Progressive Carcinoid Tumors, Not Recruiting
- Phase II Pembrolizumab in Metastatic NSCLC Examining Circulating Tumor DNA Levels, Not Recruiting
- Phase II PF 02341066 in Advanced NSCLC Harboring Translocation/Inversion with ALK Gene Locus, Not Recruiting
- Phase II PreOp ChemoXRT +/- Panitumumab Followed by Chemotherapy in Locally Advanced NSCLC, Not Recruiting
- Phase II Radical RADiotherapy & Immunotherapy for Metastatic CAncer of the Lung (RRADICAL), Not Recruiting
- Phase II Regorafenib in Combo w/ Oral Methotrexate in KRAS Mutated Non-Small Cell Lung Cancer(NSCLC), Not Recruiting
- Phase II Study Tisotumab Vedotin in Locally Advanced or Metastatic Disease in Solid Tumors, Not Recruiting
- Phase II Surgery + Low/Std Dose IMRT in Resectable p16+ Locally Advanced Oropharynx CA, Not Recruiting
- Phase II Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer w/ Safety Run-in Dose-Dense Regimen, Not Recruiting
- Phase II Trial of Individualized Adaptive RT Using During-Tx FDG-PET/CT & Modern Technology in NSCLC, Not Recruiting
- Phase II XL647 for NSCL Progression Responses to Gefitinib or Erlotinib Treatments , Not Recruiting
- Phase III Adjuvant Chemo +/- Bevacizumab in Completely Resected Stage IB-IIIA NSCLC, Not Recruiting
- Phase III ASA404 + Docetaxel in 2nd Line Tx for Locally Advanced or Metastatic (Stage IIIB/IV) NSCLC, Not Recruiting
- Phase III Atezolizumab (Anti-PD-L1 Antibody) vs Best Supportive Care in Non Small Cell Lung Cancer, Not Recruiting
- Phase III Atezolizumab&Tiragolumab vsDurvalumab in StageIII NSCLC w/o ProgressionAfterChemoradiation, Not Recruiting
- Phase III Bevacizumab, Pemetrexed, or Combo after Carboplatin, Paclitaxel and Bevacizumab in NSCLC, Not Recruiting
- Phase III Chemo +/-Pembrolizumab as Neoadjuvant/Adjuvant Tx Resectable Stage II / IIIA / IIIB NSCLC, Not Recruiting
- Phase III Crizotinib vs Observation in Tumors with Anaplastic Lymphoma Kinase (ALK) Fusion Protein, Not Recruiting
- Phase III Doxorubicin & Cyclophosphamide then Paclitaxel+Bevacizumab or Placebo in Node+/- Breast CA, Not Recruiting
- Phase III Doxorubicin/Cytoxan/Taxol +/- Trastuzumab for Her2 Node + Breast Cancer, Not Recruiting
- Phase III Erlotinib vs Observation in Resected Epidermal Growth Factor Receptor (EGFR) Mutant NSCLC, Not Recruiting
- Phase III Nivolumab After Surgical Resection & Adjuvant Chemotherapy in Non-Small Cell Lung Cancers, Not Recruiting

- Phase III Nivolumab vs Investigator's Choice Chemo in Stage IV /Recurrent PD-L1+ NSCLC , Not Recruiting
- Phase III Nivolumab vs Investigator's Choice in Recurrent/Metastatic Platinum-refractory SCCHN, Not Recruiting
- Phase III Nivolumab+Ipilimumab vs Nivolumab in Previously Treated Stage IV Squamous Cell Lung Cancer, Not Recruiting
- Phase III Oral Rociletinib Monotherapy vs Cytotoxic Chemotherapy in Mutant EGFR NSCLC, Not Recruiting
- Phase III PF-02341066 vs SoC Chemo in NSCLC + Anaplastic Lymphoma Kinase (ALK) Gene Locus, Not Recruiting
- Phase III Sorafenib in Relapsed or Refractory Advanced Non Squamous NSCLC, Not Recruiting
- Phase III Standard-Dose Combo Chemo or High-Dose Combo Chemo +Stem Cell T-plant in Germ Cell Tumors, Not Recruiting
- Phase III Trial of CHOP vs CHOP & Chimeric Anti-CD20 Monoclonal Antibody NHL, Not Recruiting
- Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer, Not Recruiting
- Screening for Tumor Antigen Expression Profiling & HLA Typing in Solid & Hematological Malignancies, Not Recruiting
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial), Not Recruiting
- CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL, Not Specified
- Phase I GS-5745 as Monotherapy and in Combination with Chemotherapy in Advanced Solid Tumors, Not Specified
- Phase IB HGS1036 in Combination With Chemotherapy in Advanced Solid Malignancies, Not Specified

Teaching

STANFORD ADVISEES

Postdoctoral Faculty Sponsor

Pamela Basto

Publications

PUBLICATIONS

- **Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Felip, E., Altorki, N., Zhou, C., Vallières, E., Csomos, T., Vynnychenko, I. O., Goloborodko, O., Rittmeyer, A., Reck, M., Martinez-Marti, A., Kenmotsu, H., Chen, Y. M., Chella, et al
2025: JCO2401681
- **Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer.** *Cancer discovery*
Moding, E. J., Shahrokh Esfahani, M., Jin, C., Hui, A. B., Nabet, B. Y., Liu, Y., Chabon, J. J., Binkley, M. S., Kurtz, D. M., Hamilton, E. G., Chaudhuri, A. A., Liu, C. L., Li, et al
2025: OF1-OF21
- **Elevated risk of lung cancer among asian American females who have never smoked: an emerging cancer disparity.** *Journal of the National Cancer Institute*
Gomez, S. L., DeRouen, M., Chen, M. S., Wakelee, H., Velotta, J. B., Sakoda, L. C., Shariff-Marco, S., Reynolds, P., Cheng, I.
2024
- **Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.** *The New England journal of medicine*
Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S. H., Gao, S., Chen, K. N., Dooms, C., Majem, M., Eigendorff, E., Martinengo, G. L., Bylicki, O., Rodríguez-Abreu, et al
2023
- **Integrating genomic features for non-invasive early lung cancer detection** *NATURE*
Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., Schroers-Martin, J., Nabet, B. Y., Chen, B., Chaudhuri, A. A., Liu, C., Hui, A. B., Jin, et al
2020

- **Keynote Address: When Breath Becomes Air-As Physician Becomes Patient** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Kalanithi, L., Wakelee, H., Carlson, R. W.
2017; 15 (5.5): 696–98
- **Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors.** *Journal of thoracic oncology*
Padda, S. K., Riess, J. W., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., West, R. B., Wakelee, H. A.
2015; 10 (3): 500-508
- **Lung cancer incidence in never smokers** *JOURNAL OF CLINICAL ONCOLOGY*
Wakelee, H. A., Chang, E. T., Gomez, S. L., Keegan, T. H., Feskanich, D., Clarke, C. A., Holmberg, L., Yong, L. C., Kolonel, L. N., Gould, M. K., West, D. W.
2007; 25 (5): 472–78
- **Corrigendum to 'Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes' [JTO Clinical and Research Reports 6 (2025) 100914].** *JTO clinical and research reports*
Singhal, S., Hui, C., Neal, J. W., Nagpal, S., Roy, M., Das, M., Ramchandran, K., Pollom, E., Selvaggi, G., Wakelee, H. A., Myall, N. J.
2026; 7 (6): 100992
- **Corrigendum to "KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status" [Cancer Treatment and Research Communications 47 (2026) 101227].** *Cancer treatment and research communications*
Xu, Z., Aredo, J. V., Su, C. C., Myall, N. J., Roy, M., Ramchandran, K. J., Wakelee, H. A., Neal, J. W.
2026: 101240
- **Air pollution and the risk of second primary lung cancer among lung cancer survivors: the prospective UK Biobank cohort study.** *British journal of cancer*
Choi, E., Luo, S., Ding, V. Y., Graber-Nadich, A., Wu, J. T., Popat, R., Cheng, I., Neal, J. W., Wakelee, H. A., Han, S. S.
2026
- **KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status.** *Cancer treatment and research communications*
Xu, Z., Aredo, J. V., Su, C. C., Myall, N. J., Roy, M., Ramchandran, K. J., Wakelee, H. A., Neal, J. W.
2026; 47: 101227
- **Evaluating Tumor Burden as a Predictive Biomarker for Epidermal Growth Factor Receptor Targeted Kinase Inhibitor Therapy in Advanced Non-Small Cell Lung Cancer.** *JCO precision oncology*
Terashima, R., Fan, J., Gunturkun, F., Nieda, G., Fan, X., Rodriguez, E. M., Tan, A. X., Thottunkal, S., Shaw, M., Su, C. C., Khan, A., Ding, V. Y., Luo, et al
2026; 10 (4): e2500884
- **A subgroup analysis of perioperative pembrolizumab in clinical stage II non-small-cell lung cancer from the randomized keynote-671 study.** *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery*
Tsuboi, M., Wakelee, H., Garassino, M. C., Gao, S., Luft, A., Chen, K. N., Spicer, J. D., Zhu, Y., Saji, H., Okada, M., Vanakesa, T., Chen, H., Zhao, et al
2026
- **Participation in lung cancer biospecimen studies: an analysis of the ECOG-ACRIN phase 3 E1505 and E5508 clinical trials.** *Lung cancer (Amsterdam, Netherlands)*
Wang, Y., Sun, Z., Sridhar, A., Ramalingam, S. S., Wakelee, H. A., Gerber, D. E.
2026; 214: 109304
- **Global advances and future directions in lung cancer care: expert consensus and strategic priorities.** *ESMO open*
Meyer, M. L., Peters, S., Jänne, P. A., Mok, T. S., Bunn, P. A., Abdel Karim, N., Altorki, N. K., Arrieta, O., Bar, J., Cappuzzo, F., Carbone, D., Dacic, S., Diehn, et al
2026; 11 (2): 106034
- **Loss of payload sensitivity and other mechanisms of resistance to T-DXd in HER2-mutant NSCLC: implications for subsequent responsiveness to HER2 TKIs.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Nilsson, M. B., Le, X., Poteete, A., Yu, X., He, J., Huang, Q., Shibata, Y., Liu, X., Moran, C., Alizadeh, A. A., Diehn, M., Wakelee, H., Almanza, et al
2026

- **Osimertinib (osi) before and after chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFRm NSCLC: Phase II NEOLA study interim analysis (IA)**
Chen, M., Wakelee, H., Aperribay, E., Peled, N., Higgins, K., Le, V. Q., Chen, L., Kim, H. R., Youk, J., Ahn, M., Ninh, T., Wang, H., Bi, et al
ELSEVIER.2025
- **Eligibility and Prognostic Performance of Smoking Duration-Based Versus Pack-Year-Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups.** *Annals of internal medicine*
Su, C. C., Ding, V. Y., Ten Haaf, K., Wu, J. T., Freedman, N. D., Backhus, L. M., Leung, A. N., Lui, N. S., Haiman, C. A., Park, S. L., Neal, J. W., Meza, R., Tammemägi, et al
2025
- **Reply to: "Improving the Reporting of Long-Term Effects in the IMpower010 Trial" and "Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity".** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Felip, E., Wakelee, H. A., Fu, C., Deng, Y., Masson, F., Gitlitz, B.
2025: JCO2502102
- **Perioperative pembrolizumab in early-stage non-small-cell lung cancer (NSCLC): 5-year follow-up from the KEYNOTE-671 global study and Asian subgroup**
Tsuboi, M., Wakelee, H., Spicer, J. D., Gao, S., Liberman, M., Kato, T., Chen, K., Dooms, C., Majem, M., Martinengo, G. L., Bylicki, O., Abreu, D., Halmos, et al
ELSEVIER.2025
- **Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes.** *JTO clinical and research reports*
Singhal, S., Hui, C., Neal, J. W., Nagpal, S., Roy, M., Das, M., Ramchandran, K., Pollom, E., Selvaggi, G., Wakelee, H. A., Myall, N. J.
2025; 6 (12): 100914
- **DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy.** *JTO clinical and research reports*
Aredo, J. V., Singhal, S., Berry, G. J., Moradi, F., Wakelee, H. A., Myall, N. J., Ramchandran, K. J., Das, M., Suarez, C. J., Neal, J. W., Riess, J. W.
2025; 6 (12): 100913
- **DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy** *JTO CLINICAL AND RESEARCH REPORTS*
V. Aredo, J., Singhal, S., Berry, G. J., Moradi, F., Wakelee, H. A., Myall, N. J., Ramchandran, K. J., Das, M., Suarez, C. J., Neal, J. W., Riess, J. W.
2025; 6 (12)
- **Leveraging large language models to extract smoking history from clinical notes for lung cancer surveillance.** *NPJ digital medicine*
Luo, I., Graber-Naidich, A., Zhang, M., Kaushik, R., Nieda, G. M., Chen, T., Gu, B., Choi, E., Ding, V. Y., Gunturkun, F., Satoyoshi, M., Bhat, A., Lee, et al
2025; 8 (1): 731
- **Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol.** *Future oncology (London, England)*
Aredo, J. V., Peled, N., Arriola, E., Wakelee, H., Ahn, M. J., Kwint, M. H., Taylor, R., van der Gronde, T., Nasirova, F., Chen, M.
2025: 1-7
- **RAS-precision medicine (RAS-PM) trans-atlantic partnership: Focus on the characteristics and outcomes of advanced KRAS-G12D non-small cell lung cancer patients**
Parreira, A. M., Adderley, H., Woodhouse, L., Brown, K. D., Carter, M., Monaca, F., Netto, D., Ward, R., Aredo, J. V., Marinello, A., Serra, N., Wakelee, H., Nadal, et al
ELSEVIER.2025
- **Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671.** *The Annals of thoracic surgery*
Liberman, M., Jones, D. R., Wakelee, H., Gao, S., Halmos, B., Nadal, E., Łowczak, A., Reck, M., Novello, S., Matias, D., Luft, A., Hui, R., Lee, et al
2025
- **Molecularly Targeted Cancer Medications and Kidney Health.** *JAMA network open*
Ziolkowski, S., Long, J., Zhong, Y., Morgan-Cooper, H., Wakelee, H., Khaki, A., Riaz, F., Reddy, S., Leonard, M., Anand, S.

2025; 8 (11): e2541221

- **Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System- Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes** *JTO CLINICAL AND RESEARCH REPORTS*
Singhal, S., Hui, C., Neal, J. W., Nagpal, S., Roy, M., Das, M., Ramchandran, K., Pollom, E., Selvaggi, G., Wakelee, H. A., Myall, N. J.
2025; 6 (12)
- **Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer** *CLINICAL LUNG CANCER*
Sun, F., Nagpal, S., Singhal, S., Neal, J. W., Wakelee, H. A., Myall, N. J., Bolan, P., Riess, J. W., Gandara, D. R., Das, M. S.
2025; 26 (7)
- **Bridging the gap in lung cancer: A comprehensive global strategy for change.** *European journal of cancer (Oxford, England : 1990)*
Syrigos, K. N., Bussell, M. E., Al-Shamsi, H. O., Khorshid, O., Herbst, R. S., Agelaki, S., Leighl, N., Hirsch, F., Wakelee, H.
2025: 116069
- **The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Zheng, M. M., Xia, Y., Pan, K., Sun, F., Tan, A. C., Dong, X. R., Tu, H. Y., Tang, L. B., Li, Y. S., Yin, K., Borgeaud, M., Singhal, S., Zhu, et al
2025
- **Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression \geq 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.** *Lung cancer (Amsterdam, Netherlands)*
Cortellini, A., Garbo, E., La Cava, G., Citarella, F., Santo, V., Brunetti, L., Pinato, D. J., Naidoo, J., Loza, M., Genova, C., Gettinger, S., Kim, S. Y., Jayakrishnan, et al
2025; 209: 108799
- **Perioperative Pembrolizumab in Non-Small Cell Cancer (NSCLC): 4-Year Outcomes by Nodal Status in the KEYNOTE-671 Study**
Wakelee, H., Demedts, I., Langleben, A., Yan, X., Faehling, M., Lo Russo, G., Han, J., Levchenko, E., Ursol, G., Cronemberger, E., Wang, S., Zurawski, B., Voitko, et al
ELSEVIER SCIENCE INC.2025
- **Initial Results From Phase 1/2 Study of the RET-Selective Inhibitor Vepafestinib in Patients With RET-Aberrant Solid Tumors**
Yoh, K., Shinno, Y., Velcheti, V., Subbiah, V., Lakhani, N., Ohashi, K., Gadgeel, S., Kitano, S., Johnson, M., Wakelee, H., Ono, A., Nishino, K., Miyauchi, et al
ELSEVIER SCIENCE INC.2025
- **Large Language Models to Extract Smoking History From Clinical Notes in EHR to Evaluate Lung Cancer Surveillance Strategies**
Luo, I., Graber-Naidich, A., Kaushik, R., Nieda, G. M., Choi, E., Ding, V. Y., Gunturkun, F., Satoyoshi, M., Bhat, A., Chen, T., Zhang, M., Lee, T., Su, et al
ELSEVIER SCIENCE INC.2025
- **Socioeconomic Inequalities and Lung Cancer Outcomes: Evidence From an Integrated EHR Database and State Cancer Registry Data**
Lee, T. Y., Su, C. C., Choi, E., Ding, V. Y., Satoyoshi, M., Bhat, A., Chen, T., Luo, I., Liu, Y., Henry, S., Backhus, L. M., Ellis-Caleo, T. J., Gomez, et al
ELSEVIER SCIENCE INC.2025
- **Gender Differences in Lung Cancer Diagnosis, Treatment Patterns and Outcomes: A Systematic Literature Review**
Karim, N., Aggarwal, C., Kobayashi, A., Pompili, C., Molena, D., Shum, E., Friedrich, G., Wakelee, H., Brahmer, J. R., Woldmann, L., Boron, M., Florez, N., Garrido, et al
ELSEVIER SCIENCE INC.2025
- **Long-Term Outcomes From Pembrolizumab in Patients With Advanced PD-L1=50% NSCLC and Poor PS: A Transformer-Based AI Approach**
Cortellini, A., Garbo, E., La Cava, G., Santo, V., Brunetti, L., Pinato, D. J., O'reilly, D., Loza, M., Genova, C., Kim, S. Y., Jayakrishnan, R., El Zarif, T., Pecci, et al
ELSEVIER SCIENCE INC.2025
- **Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 \geq 50%: insights from the pembrolizumab 5-year global registry.** *Journal for immunotherapy of cancer*
Cortellini, A., Santo, V., Brunetti, L., Garbo, E., Pinato, D. J., La Cava, G., Naidoo, J., Katz, A., Loza, M., Neal, J. W., Genova, C., Gettinger, S., Kim, et al
2025; 13 (9)

- **Nativity status and non-small cell lung cancer outcomes**
Aredo, J. V., Neal, J. W., Kunder, C. A., Ramchandran, K. J., Myall, N. J., Roy, M., Wakelee, H. A.
AMER ASSOC CANCER RESEARCH.2025: B144
- **Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.** *Lung cancer (Amsterdam, Netherlands)*
Sun, F., Banwait, M. K., Singhal, S., Herrmann, A., Piotrowska, Z., Yun, K., Bazhenova, L., Ullah, A. T., Guo, E. W., Wakelee, H. A., Neal, J. W., Das, M. S., Ramchandran, et al
2025; 208: 108747
- **Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024.** *Cancer*
Florez, N., Patel, S., Wakelee, H. A., Rotow, J., Shum, E., Sands, J., Salgia, R., Hirsch, F. R., Peters, S., Sabari, J., Husain, H., Bazhenova, L., Massarelli, et al
2025; 131 (17): e70060
- **Targeting KRAS codon 13 mutations using combinations with RMC-8839, a novel RAS(ON) G13C-selective, tricomplex inhibitor, in non-small cell lung cancer**
Lindsay, C. R., Adderley, H., Mcdaid, W., Zhuang, Y., Woodhouse, L., Brown, K. D., Carter, M., Parreira, A. M., Aldea, M., Marinello, A., Aredo, J. V., Besse, B., Wakelee, et al
ELSEVIER.2025
- **Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed Analysis.** *JTO clinical and research reports*
Lee, J. M., Brunelli, A., Cummings, A. L., Felip, E., Shu, C. A., Solomon, B. J., Tsuboi, M., Wakelee, H., Saqi, A., Wu, Y. L., Li, P. C., Gitlitz, B. J.
2025; 6 (9): 100866
- **Etirinotecan Pegol (NKTR-102) in Patients With Active Brain Metastases From Lung or Breast Cancer.** *Cancer reports (Hoboken, N.J.)*
Nagpal, S., Nguyen, K. S., Bertrand, S., Cunanan, K. M., Padda, S. K., Pagtama, J. Y., Tisch, A. H., Coffey, G., Thomas, R. P., Sledge, G. W., Gruber, J., Telli, M. L., Pegram, et al
2025; 8 (9): e70330
- **Brief Report: Prospective Trial of Pembrolizumab Monotherapy in Metastatic NSCLC Evaluating Circulating Tumor DNA as a Surrogate Biomarker of Response.** *JTO clinical and research reports*
van 't Erve, I., Blanchard, I., Pagtama, J. Y., Holmes Tisch, A. J., Alizadeh, A. A., Ramchandran, K., Wakelee, H. A., Padda, S. K., Diehn, M., Neal, J. W.
2025; 6 (9): 100877
- **Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy.** *JACC. CardioOncology*
Cheng, E., Ivanovic, M., Chan, A., Xu, S., Franquiz, M., Lee, C., You, J., Fazal, M., Le Guen, Y., Batchelder, R., Reddy, S. A., Katsumoto, T., Ramchandran, et al
2025
- **Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer.** *Clinical lung cancer*
Sun, F., Nagpal, S., Singhal, S., Neal, J. W., Wakelee, H. A., Myall, N. J., Bolan, P., Riess, J. W., Gandara, D. R., Das, M. S.
2025
- **Smoking Trends in KRAS-Mutated Non-Small Cell Lung Cancer at a Tertiary Referral Center**
Aredo, J., Neal, J. W., Ramchandran, K. J., Das, M. S., Myall, N. J., Wakelee, H. A.
ELSEVIER SCIENCE INC.2025
- **Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed Analysis** *JTO CLINICAL AND RESEARCH REPORTS*
Lee, J. M., Brunelli, A., Cummings, A. L., Felip, E., Shu, C. A., Solomon, B. J., Tsuboi, M., Wakelee, H., Saqi, A., Wu, Y., Li, P., Gitlitz, B. J.
2025; 6 (9)
- **Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer.** *Journal for immunotherapy of cancer*
Miller, N. J., Baik, C., Neal, J. W., Sun, F., Santana-Davila, R., Lee, S., Eaton, K. D., Martins, R. G., Rodriguez, C., Wakelee, H., Padda, S. K., Sotillo, E., Konnick, et al

2025; 13 (7)

- **Automatic Abstraction of Computed Tomography Imaging Indication Using Natural Language Processing for Evaluation of Surveillance Patterns in Long-Term Lung Cancer Survivors.** *JCO clinical cancer informatics*
Khan, A., Choi, E., Su, C., Graber-Naidich, A., Henry, S., Satoyoshi, M. L., Bhat, A., Kurian, A. W., Liang, S. Y., Neal, J., Gould, M., Leung, A., Wakelee, et al
2025; 9: e2400279
- **Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Aredo, J. V., Jamali, A., Zhu, J., Heater, N., Wakelee, H. A., Vaklavas, C., Anagnostou, V., Lu, J.
2025; 45 (3): e481114
- **Oncoshare-Lung: Novel three-way linkage of neighboring academic and community medical centers to state cancer registry for lung cancer.**
Su, C., Choi, E., Satoyoshi, M., Bhat, A., Chen, T., Ding, V., Khan, A., Lee, T., Wu, J., Henry, S., Desai, M., Neal, J. W., Backhus, et al
LIPPINCOTT WILLIAMS & WILKINS.2025: e23292
- **IMpower010: Genomic profiling and clinical outcomes with adjuvant atezolizumab in early-stage non-small cell lung cancer (eNSCLC).**
Wakelee, H. A., Felip, E., Zhou, C., Vallieres, E., Reck, M., Altorki, N. K., Rittmeyer, A., Csomzi, T., Vynnychenko, I. O., Chella, A., Gayevskiy, V., Zou, W., Gitlitz, et al
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic Carcinoma** *CLINICAL LUNG CANCER*
Marks, J. A., Ahn, J., Reuss, J. E., Barbie, D., Altan, M., Gutierrez, M. E., Garassino, M. C., Riely, G. J., Wakelee, H., Liu, S. V., Kim, C.
2025; 26 (3): 165-167
- **An ultrasensitive method for detection of cell-free RNA.** *Nature*
Nesselbush, M. C., Luca, B. A., Jeon, Y. J., Jabara, I., Meador, C. B., Garofalo, A., Binkley, M. S., Hui, A. B., van 't Erve, I., Xu, N., Shi, W. Y., Liu, K. J., Sugio, et al
2025
- **IMpower010: Digital pathology (DP) vs manual SP263 PD-L1 tumour cell (TC) scoring on whole imaging slides from patients (pts) with stage II-IIIa PD-L1 TC ≥50% NSCLC**
Reck, M., Felip, E., Altorki, N. K., Wakelee, H., Vallieres, E., Liersch, R., Oizumi, S., Tanaka, H., Novello, S., Ruderman, D., Nabet, B., Brunner, L., Hennek, et al
ELSEVIER SCIENCE INC.2025
- **Differential effect of proton pump inhibitors (PPIs) and antibiotics (ATB) on clinical outcomes from immunotherapy or placebo in patients with locally advanced, unresectable NSCLC who have not progressed following chemoradiation therapy (cCRT): A post-hoc analysis of the PACIFIC trial**
Brunetti, L., Santo, V., Pinato, D., Ricciuti, B., Naidoo, J., Nassar, A., Wakelee, H., Takada, K., Naqash, A., Abushukair, H., Garassino, M., Greco, C., Ramella, et al
ELSEVIER SCIENCE INC.2025
- **Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.** *Nature*
Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Cobo, A. G., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., Juan, J. M., Min, C., Yu, et al
2025
- **Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis.** *Circulation research*
Huang, Y. V., Sun, Y., Chou, H., Wagner, N., Vitale, M. R., Bayer, A. L., Xu, B., Lee, D., Lin, Z., Branche, C., Waliyany, S., Neal, J. W., Wakelee, et al
2025
- **Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.** *Journal for immunotherapy of cancer*
Cortellini, A., Brunetti, L., Di Fazio, G. R., Garbo, E., Pinato, D. J., Naidoo, J., Katz, A., Loza, M., Neal, J. W., Genova, C., Gettinger, S., Kim, S. Y., Jayakrishnan, et al
2025; 13 (2)
- **Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors.** *JTO clinical and research reports*
Myall, N. J., Whisenant, J. G., Neal, J. W., Iams, W. T., Reckamp, K. L., York, S., Berry, L. D., Shyr, Y., Horn, L., Wakelee, H. A., Padda, S. K.

2025; 6 (2): 100757

- **Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors** *JTO CLINICAL AND RESEARCH REPORTS*
Myall, N. J., Whisenant, J. G., Neal, J. W., Iams, W. T., Reckamp, K. L., York, S., Berry, L. D., Shyr, Y., Horn, L., Wakelee, H. A., Padda, S. K.
2025; 6 (2)
- **Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma: a case report.** *Cancer chemotherapy and pharmacology*
Gezelius, E., Planck, M., Hazem, B., Nagpal, S., Wakelee, H.
2024; 95 (1): 6
- **Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic Carcinoma.** *Clinical lung cancer*
Marks, J. A., Ahn, J., Reuss, J. E., Barbie, D., Altan, M., Gutierrez, M. E., Garassino, M. C., Riely, G. J., Wakelee, H., Liu, S. V., Kim, C.
2024
- **Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC** *JTO CLINICAL AND RESEARCH REPORTS*
Aredo, J., Wakelee, H. A., Ramchandran, K. J., Neal, J. W., Diehn, M., Hui, A., Salahudeen, A., Kwong, B., Berry, G. J., Guo, H., Cunanan, K., Vali, S., Pancirer, et al
2024; 5 (12)
- **Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC.** *JTO clinical and research reports*
Aredo, J. V., Wakelee, H. A., Ramchandran, K. J., Neal, J. W., Diehn, M., Hui, A. B., Salahudeen, A., Kwong, B., Berry, G. J., Guo, H. H., Cunanan, K., Vali, S., Pancirer, et al
2024; 5 (12): 100741
- **Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study** *CLINICAL LUNG CANCER*
Graber-Naidich, A., Choi, E., Wu, J. T., Ellis-Caleo, T. J., Neal, J., Wakelee, H. A., Kurian, A. W., Han, S. S.
2024; 25 (8)
- **The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer.** *Molecular cancer*
McDaid, W. J., Wilson, L., Adderley, H., Martinez-Lopez, A., Baker, M. J., Searle, J., Ginn, L., Budden, T., Aldea, M., Marinello, A., Aredo, J. V., Viros, A., Besse, et al
2024; 23 (1): 253
- **CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.** *Nature*
Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Cobo, A. G., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., Juan, J. M., Min, C., Yu, et al
2024
- **A Phase 2 Single-Arm Trial of High-Dose Radiotherapy Added to Immunotherapy for Patients with Metastatic Non Small Cell Lung Cancer**
Kotha, N. V., Vitzthum, L., Chin, A. L., Jackson, S., Prapatneni, A., Le-Budka, M. L., Brown, E., Barnick, K., Wakelee, H. A., Das, M., Ramchandran, K. J., Myall, N., Padda, et al
ELSEVIER SCIENCE INC.2024: S60
- **Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC**
Jones, D. R., Wakelee, H., Spicer, J. D., Liberman, M., Kato, T., Tsuboi, M., Lee, S., Wang, W., Chen, H., Dooms, C., Majem, M., Eigendorff, E., Martinengo, et al
ELSEVIER SCIENCE INC.2024: S8
- **NEOLA: Phase II Study of Osimertinib Treatment Before and after Chemoradiotherapy in Unresectable Stage III EGFRm NSCLC**
Wakelee, H., Arriola, E., Chen, M., Peled, N., Kwint, M. H., Taylor, R., van der Gronde, T., Nasirova, F., Aredo, J. V.
ELSEVIER SCIENCE INC.2024: S341
- **Central Nervous System (CNS) Progression on CNS Penetrable ALK TKI: Real-World Practice Patterns and Patient Outcomes**
Singhal, S., Hui, C., Neal, J., Roy, M., Das, M., Ramchandran, K., Pollom, E., Selvaggi, G., Wakelee, H., Myall, N.
ELSEVIER SCIENCE INC.2024: S200-S201
- **Effect of De Novo Co-Mutations on Clinical Outcomes in Patients Receiving First-Line Osimertinib for EGFR Mutated NSCLC**
Sun, F., Banwait, M. K., Herrmann, A., Piotrowska, Z., Yun, K., Bazhenova, L. A., Wakelee, H. A., Neal, J. W., Das, M. S., Ramchandran, K. J., Roy, M., Diehn, M., Myall, et al

ELSEVIER SCIENCE INC.2024: S196-S197

- **Gender Differences in Lung Cancer Incidence Among Patients Who Never Smoked Cigarettes: A Systematic Literature Review**
Molena, D., Aggarwal, C., Florez, N., Peters, S., Brahmer, J., Shum, E., Salomonsen, R., Chaieb, J., Chau, M., Shenolikar, R., Luciani-Silverman, L., Guy, D., Woldmann, et al
ELSEVIER SCIENCE INC.2024: S299
- **A Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients with Advanced Thymoma and Thymic Carcinoma**
Marks, J. A., Agarwal, S., Ahn, J., Reuss, J. E., Altan, M., Nabel, C., Gutierrez, M. E., Garassino, M. C., Riely, G. J., Wakelee, H., Liu, S. V., Kim, C.
ELSEVIER SCIENCE INC.2024: S280
- **Gender Disparities in Lung Cancer Screening: A Systematic Literature Review**
Shum, E., Florez, N., Brahmer, J., Aggarwal, C., Wakelee, H., Chau, M., Shenolikar, R., Salomonsen, R., Chaieb, J., Luciani-Silverman, L., Guy, D., Woldmann, L., Ciritel, et al
ELSEVIER SCIENCE INC.2024: S371
- **Impact of Using Smoking Duration in Place of PackYears as Eligibility Criteria for Lung Cancer Screening to Reduce Racial and Ethnic Disparities**
Su, C. C., Ding, V. Y., Haaf, K. T., Wu, J. T., Freedman, N. D., Backhus, L. M., Leung, A. N., Lui, N. S., Haiman, C. A., Park, S. L., Neal, J. W., Meza, R., Tammemagi, et al
ELSEVIER SCIENCE INC.2024: S49
- **Natural History Model for Second Primary Lung Cancer Among Lung Cancer Survivors: Utilizing the US SEER Cancer Registries**
Choi, E., Ritter, V., Lee, J. H., Wu, J. T., ten Haaf, K., Su, C. C., Backhus, L. M., Leung, A. N., Wakelee, H. A., Han, S. S.
ELSEVIER SCIENCE INC.2024: S375
- **IMpower010 5-y Subgroup Analysis and Relapse Patterns: Phase 3 Study of Atezolizumab vs BSC in Stage II-III NSCLC**
Felip, E., Wakelee, H. A., Vallieres, E., Martinez-Marti, A., Goloborodko, O., Zhou, C., Rittmeyer, A., Chella, A., Reck, M., Csomzi, T., Bondarenko, I., Kenmotsu, H., Schutte, et al
ELSEVIER SCIENCE INC.2024: S8-S9
- **Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer**
Adderley, H., McDaid, W., Woodhouse, L., Carter, M., Aldea, M., Marinello, A., Seamon, K., Holderfield, M., Singh, M., Smith, J., Aredo, J., Besse, B., Wakelee, et al
ELSEVIER SCI LTD.2024: S47-S48
- **A phase 2 single-arm trial of high-dose precision targeted radiotherapy added to immunotherapy for patients with metastatic non-small cell lung cancer. *International journal of radiation oncology, biology, physics***
Gensheimer, M. F., Kotha, N. V., Vitzthum, L. K., Chin, A. L., Jackson, S., 't Erve, I. v., Pratapneni, A., Le-Budka, M. L., Wong, S., Brown, E., Barnick, K., Wakelee, H. A., Das, et al
2024
- **Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet (London, England)***
Spicer, J. D., Garassino, M. C., Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S., Chen, K., Dooms, C., Majem, M., Eigendorff, E., Martinengo, G. L., Bylicki, et al
2024
- **Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer***
Nassar, A. H., Jayakrishnan, R., Feng, J., Shepherd, F., Adib, E., Cheung, J. M., Lin, J. J., Liu, Y., Lin, S. H., Parikh, K., Sridhar, A., Shakya, P., Dilling, et al
2024
- **Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study. *Clinical lung cancer***
Graber-Naidich, A., Choi, E., Wu, J. T., Ellis-Caleo, T. J., Neal, J., Wakelee, H. A., Kurian, A. W., Han, S. S.
2024
- **Proceedings of the 1st biannual bridging the gaps in lung cancer conference. *The oncologist***

- Florez, N., Patel, S. P., Wakelee, H., Bazhenova, L., Massarelli, E., Salgia, R., Stiles, B., Peters, S., Malhotra, J., Gadgeel, S. M., Nieva, J. J., Afkhami, M., Hirsch, et al
2024
- **Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer** *CLINICAL LUNG CANCER*
Shah, A. T., Blanchard, I., Padda, S. K., Wakelee, H. A., Neal, J. W.
2024; 25 (6): 550-559
 - **Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: Subgroup analyses of the phase III KEYNOTE-671 study**
Garassino, M. C., Gao, S., Liberman, M., Spicer, J. D., Chen, K., Vanakesa, T., Thiberville, L., Chaves, F. F., Liu, G., Okada, M., Saji, H., Laktionov, K., Rittmeyer, et al
ELSEVIER.2024: S778-S779
 - **IMpower010: Characterisation of patients (pts) with stage II-III A PD-L1 TC \geq 50% NSCLC who were disease-free at 5 years (5yDF) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after resection and adjuvant (adj) chemotherapy (chemo)**
Felip, E., Vallieres, E., Gologordko, O., Martinez-Marti, A., Zhou, C., Altorki, N. K., Rittmeyer, A., Chella, A., Reck, M., Schuette, W., Okada, M., Liersch, R., Teixeira, et al
ELSEVIER.2024: S780-S781
 - **IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)**
Wakelee, H., Reck, M., Felip, E., Altorki, N. K., Vallieres, E., Liersch, R., Oizumi, S., Tanaka, H., Hamm, J. T., McCune, S., Bennett, E., Gitlitz, B. J., McNally, et al
ELSEVIER.2024: S779-S780
 - **Racial and Ethnic Differences in Second Primary Lung Cancer Risk among Lung Cancer Survivors.** *JNCI cancer spectrum*
Choi, E., Hua, Y., Su, C. C., Wu, J. T., Neal, J. W., Leung, A. N., Backhus, L. M., Haiman, C., Le Marchand, L., Liang, S., Wakelee, H. A., Cheng, I., Han, et al
2024
 - **Ancestry-, Sex-, and Age-Based Differences of Gene Alterations in NSCLC: From the Real-World Data of Cancer Genomic Profiling Tests.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Miura, K., Shukuya, T., Greenstein, R., Kaplan, B., Wakelee, H., Kurokawa, K., Furuta, K., Kato, S., Suh, J., Sivakumar, S., Sokol, E. S., Carbone, D. P., Takahashi, et al
2024: 1-10
 - **Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.** *Clinical lung cancer*
Shah, A. T., Blanchard, I., Padda, S. K., Wakelee, H. A., Neal, J. W.
2024
 - **Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): Consensus Recommendations from the International Association for the Study of Lung Cancer (IASLC).** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Spicer, J. D., Cascone, T., Wynes, M. W., Ahn, M. J., Dacic, S., Felip, E., Forde, P. M., Higgins, K. A., Kris, M. G., Mitsudomi, T., Provencio, M., Senan, S., Solomon, et al
2024
 - **IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after \geq 5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-III A non-small cell lung cancer (NSCLC).** *JOURNAL OF CLINICAL ONCOLOGY*
Wakelee, H. A., Altorki, N. K., Zhou, C., Csozsi, T., Vynnychenko, I. O., Goloborodko, O., Rittmeyer, A., Reck, M., Martinez-Marti, A., Kenmotsu, H., Chen, Y., Chella, A., Sugawara, et al
2024; 42 (17_SUPPL): LBA8035
 - **Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)**
Garassino, M., Wakelee, H. A., Spicer, J., Liberman, M., Kato, T., Tsuboi, M., Lee, S., Chen, K., Dooms, C., Majem, M., Eigendorff, E., Martinengo, G. L., Bylicki, et al
LIPPINCOTT WILLIAMS & WILKINS.2024

- **Association of napsin A-specific T cell clonotypes with durable clinical benefit to immunotherapy in patients with metastatic NSCLC**
Miller, N. J., Baik, C. S., Neal, J. W., Houghton, A., Nair, V. S., Santana-Davila, R., Lee, S., Eaton, K. D., Martins, R. G., Wakelee, H. A., Padda, S., Chiou, S., Tseng, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Top advances of the year: Perioperative therapy for lung cancer.** *Cancer*
Aredo, J. V., Wakelee, H. A.
2024
- **A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors.** *JTO clinical and research reports*
Beckermann, K. E., Bestvina, C. M., El Osta, B., Sanborn, R. E., Borghaei, H., Lammers, P. E., Selvaggi, G., Whisenant, J. G., Heimann-Nichols, E., Berry, L., Hsu, C. Y., Shyr, Y., Horn, et al
2024; 5 (2): 100619
- **Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Nassar, A. H., Kim, S. Y., Aredo, J. V., Feng, J., Shepherd, F., Xu, C., Kaldas, D., Gray, J. E., Dilling, T. J., Neal, J. W., Wakelee, H. A., Liu, Y., Lin, et al
2024
- **Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry.** *Scientific reports*
Karacosta, L. G., Pancirer, D., Preiss, J. S., Benson, J. A., Trope, W., Shrager, J. B., Sung, A. W., Neal, J. W., Bendall, S. C., Wakelee, H., Plevritis, S. K.
2023; 13 (1): 21781
- **Chemotherapy and immunotherapy in early-stage NSCLC: neoadjuvant vs adjuvant therapy.** *Clinical advances in hematology & oncology : H&O*
Wakelee, H.
2023; 21 (12): 648-651
- **Chemotherapy and Immunotherapy in Early-Stage NSCLC: Neoadjuvant vs Adjuvant Therapy** *CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY*
Wakelee, H.
2023; 21 (12): 648-651
- **Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series** *JACC: CardioOncology*
Franquiz, M., Waliyany, S., Xu, A., Hnatiuk, A., Wu, S., Cheng, P., Wakelee, H., Neal, J., Witteles, R., Zhu, H.
2023: 839-841
- **BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC).** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Wang, K., Du, R., Myall, N. J., Lewis, W. E., Uy, N., Hong, L., Skoulidis, F., Byers, L. A., Tsao, A., Cascone, T., Pozadzides, J., Tu, J., Negrao, et al
2023
- **Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer.** *Clinical lung cancer*
Hui, C., Marquez, C., Lau, B., Das, M., Myall, N. J., Roy, M., Wakelee, H. A., Neal, J. W., Kovalchuk, N., Chin, A., Diehn, M., Loo, B. W., Xiang, et al
2023
- **Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).** *Lung cancer (Amsterdam, Netherlands)*
Burns, L., Hsu, C. Y., Whisenant, J. G., Marmarelis, M. E., Presley, C. J., Reckamp, K. L., Khan, H., Jo Fidler, M., Bestvina, C. M., Brahmer, J., Puri, S., Patel, J. D., Halmos, et al
2023; 186: 107423
- **Personalized Accelerated ChEemoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.** *Clinical lung cancer*
Hui, C., Brown, E., Wong, S., Das, M., Wakelee, H., Neal, J., Ramchandran, K., Myall, N. J., Pham, D., Xing, L., Yang, Y., Kovalchuk, N., Yuan, et al
2023

- **Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked.** *JAMA network open*
Choi, E., Su, C. C., Wu, J. T., Aredo, J. V., Neal, J. W., Leung, A. N., Backhus, L. M., Lui, N. S., Le Marchand, L., Stram, D. O., Liang, S. Y., Cheng, I., Wakelee, et al
2023; 6 (11): e2343278
- **Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening**
Aredo, J. V., Neal, J. W., Kunder, C. A., Ramchandran, K. J., Das, M. S., Myall, N. J., Han, S. S., Wakelee, H. A.
ELSEVIER SCIENCE INC.2023: S102-S103
- **IMpower010: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC**
Felip, E., Srivastava, M., Reck, M., Wakelee, H., Altorki, N., Vallieres, E., Liersch, R., Oizumi, S., Tanaka, H., Hamm, J. T., Novello, S., McCune, S., Molinero, et al
ELSEVIER SCIENCE INC.2023: S139
- **Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.** *JAMA oncology*
Choi, E., Ding, V. Y., Luo, S. J., Ten Haaf, K., Wu, J. T., Aredo, J. V., Wilkens, L. R., Freedman, N. D., Backhus, L. M., Leung, A. N., Meza, R., Lui, N. S., Haiman, et al
2023
- **Asian American Women's Experiences of Discrimination and Health Behaviors during the COVID-19 Pandemic.** *Journal of immigrant and minority health*
Wang, K., Guan, A., Seto, J., Oh, D. L., Lau, K., Duffy, C., Castillo, E., McGuire, V., Wadhwa, M., Tepper, C. G., Wakelee, H. A., DeRouen, M. C., Shariff-Marco, et al
2023
- **Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.** *Cancer*
Choi, E., Luo, S. J., Ding, V. Y., Wu, J. T., Kumar, A. V., Wampfler, J., Tammemägi, M. C., Wilkens, L. R., Aredo, J. V., Backhus, L. M., Neal, J. W., Leung, A. N., Freedman, et al
2023
- **Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.** *Journal for immunotherapy of cancer*
Zhou, C., Srivastava, M. K., Xu, H., Felip, E., Wakelee, H., Altorki, N., Reck, M., Liersch, R., Kryzhanivska, A., Oizumi, S., Tanaka, H., Hamm, J., McCune, et al
2023; 11 (10)
- **CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC**
Hui, C., Wakelee, H. A., Neal, J. W., Ramchandran, K. J., Das, M., Nagpal, S., Roy, M., Huang, J., Pollom, E., Myall, N.
ELSEVIER SCIENCE INC.2023: E110
- **CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC.** *International journal of radiation oncology, biology, physics*
Hui, C., Wakelee, H. A., Neal, J. W., Ramchandran, K. J., Das, M., Nagpal, S., Roy, M., Huang, J., Pollom, E., Myall, N.
2023; 117 (2S): e110
- **Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer NSCLC)**
Spicer, J. D., Gao, S., Liberman, M., Kato, T., Tsuboi, M., Lee, S. H., Chen, K. N., Dooms, C., Majem, M., Eigendorff, E., Martinengo, G., Bylicki, O., Garassino, et al
ELSEVIER.2023: S1297-S1298
- **RAS-precision medicine trans-atlantic partnership: Comparative analysis of KRAS codon 12 and 13 mutations in non-small cell lung cancer**
Adderley, H., McDaid, W., Searle, J., Wilson, L., Marinello, A., Aldea, M., Aredo, J., Wakelee, H., Besse, B., Malliri, A., Lindsay, C. R.
ELSEVIER.2023: S1159-S1160
- **IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)**
Altorki, N. K., Reck, M., Wakelee, H., Felip, E., Vallieres, E., Liersch, R., Oizumi, S., Tanaka, H., Novello, S., McCune, S., Li, H., Molinero, L., Mueller, et al
ELSEVIER.2023: S732-S733

- **Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.** *JAMA oncology*
Gensheimer, M. F., Gee, H., Shirato, H., Taguchi, H., Snyder, J. M., Chin, A. L., Vitzthum, L. K., Maxim, P. G., Wakelee, H. A., Neal, J., Das, M., Chang, D. T., Kidd, et al
2023
- **Genomic characterization of thymic epithelial tumors in a real-world dataset.** *ESMO open*
Kurokawa, K., Shukuya, T., Greenstein, R. A., Kaplan, B. G., Wakelee, H., Ross, J. S., Miura, K., Furuta, K., Kato, S., Suh, J., Sivakumar, S., Sokol, E. S., Carbone, et al
2023; 8 (5): 101627
- **Software Application Profile: dynamicLM-a tool for performing dynamic risk prediction using a landmark supermodel for survival data under competing risks.** *International journal of epidemiology*
Fries, A. H., Choi, E., Wu, J. T., Lee, J. H., Ding, V. Y., Huang, R. J., Liang, S., Wakelee, H. A., Wilkens, L. R., Cheng, I., Han, S. S.
2023
- **Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non-Small Cell Lung Cancer.** *JAMA network open*
Su, C. C., Wu, J. T., Choi, E., Myall, N. J., Neal, J. W., Kurian, A. W., Stehr, H., Wood, D., Henry, S. M., Backhus, L. M., Leung, A. N., Wakelee, H. A., Han, et al
2023; 6 (9): e2335813
- **The IASLC Early Lung Imaging Confederation (ELIC) Open-Source Deep Learning and Quantitative Measurement Initiative.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Lam, S., Wynes, M. W., Connolly, C., Ashizawa, K., Atkar-Khattra, S., Belani, C. P., DiNatale, D., Henschke, C. I., Hochhegger, B., Jacomelli, C., Jelitto, M., Jirapatnakul, A., Kelly, et al
2023
- **Optimizing Lung Cancer Screening With Risk Prediction: Current Challenges and the Emerging Role of Biomarkers.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Wu, J. T., Wakelee, H. A., Han, S. S.
2023: JCO2301060
- **Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIa non-small cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Felip, E., Altorki, N., Zhou, C., Vallieres, E., Martínez-Martí, A., Rittmeyer, A., Chella, A., Reck, M., Goloborodko, O., Huang, M., Belleli, R., McNally, V., Srivastava, et al
2023
- **Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Bestvina, C. M., Garassino, M. C., Neal, J. W., Wakelee, H. A., Diehn, M., Vokes, E. E.
2023: JCO2300258
- **KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC** *JOURNAL OF CLINICAL ONCOLOGY*
Wakelee, H. A., Liberman, M., Kato, T., Tsuboi, M., Lee, S., He, J., Gao, S., Chen, K., Dooms, C., Majem, M., Eigendorff, E., Martinengo, G., Bylicki, et al
2023; 41 (17_SUPPL): LBA100
- **KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.**
Wakelee, H. A., Liberman, M., Kato, T., Tsuboi, M., Lee, S., He, J., Gao, S., Chen, K., Dooms, C., Majem, M., Eigendorff, E., Martinengo, G., Bylicki, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC)**
Nassar, A., Adib, E., Feng, J., Aredo, J. V., Parikh, K., Harris, J., Manana, A., Ragavan, M., Lin, J., Piotrowska, Z., Fitzgerald, B., Grohe, C., Sankar, et al
LIPPINCOTT WILLIAMS & WILKINS.2023

- **IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-III NSCLC treated with adjuvant atezolizumab vs best supportive care**
Reck, M., Srivastava, M. K., Wakelee, H. A., Felip, E., Altorki, N. K., Csoszi, T., Moiseyenko, V., Akopov, A., Smolin, A., Chella, A., Vallieres, E., Martinez-Marti, A., Zou, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).**
Nassar, A., Adib, E., Feng, J., Aredo, J. V., Parikh, K., Harris, J., Velazquez Manana, A. I., Ragavan, M., Lin, J., Piotrowska, Z., Fitzgerald, B., Grohe, C., Sankar, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-III NSCLC treated with adjuvant atezolizumab vs best supportive care**
Reck, M., Srivastava, M. K., Wakelee, H. A., Felip, E., Altorki, N. K., Csoszi, T., Moiseyenko, V., Akopov, A., Smolin, A., Chella, A., Vallieres, E., Martinez-Marti, A., Zou, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.** *The Lancet. Digital health*
Saad, M. B., Hong, L., Aminu, M., Vokes, N. I., Chen, P., Salehjehromi, M., Qin, K., Sujit, S. J., Lu, X., Young, E., Al-Tashi, Q., Qureshi, R., Wu, et al
2023
- **Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked.** *Clinical lung cancer*
Bodor, J. N., Patel, J. D., Wakelee, H. A., Levy, B. P., Borghaei, H., Pellini, B., Costello, M. R., Dowell, J. E., Finley, G., Huang, C. H., Neal, J. W., Nieva, J. J., Puri, et al
2023
- **Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Lau, B., Wu, Y. F., No, H. J., Ko, R. B., Devine, M., Das, M. S., Neal, J. W., Wakelee, H. A., Ramchandran, K., Gensheimer, M. F., Diehn, M., Chin, A. L., Loo, et al
2023
- **Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC.** *Cancer discovery*
Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., Hines, J., Aredo, J. V., Dennis, et al
2023
- **Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors.** *JTO clinical and research reports*
Sun, T. Y., Nguyen, B., Chen, S. B., Natkunam, Y., Padda, S., van de Rijn, M., West, R., Neal, J. W., Wakelee, H., Riess, J. W.
2023; 4 (4): 100498
- **Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging.** *Frontiers in oncology*
Alhusaini, S., Lanman, T. A., Ko, R. B., Therkelsen, K. E., Eyben, R. V., Diehn, M., Soltys, S. G., Pollom, E. L., Chin, A., Vitzthum, L., Wakelee, H. A., Padda, S. K., Ramchandran, et al
2023; 13: 1139940
- **Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study.** *JTO clinical and research reports*
Ji, J., Aredo, J. V., Piper-Vallillo, A., Huppert, L., Rotow, J. K., Husain, H., Stewart, S., Cobb, R., Wakelee, H. A., Blakely, C. M., Wong, M. L., Gubens, M. A., Madani, et al
2023; 4 (3): 100459
- **Second Primary Lung Cancer among Lung Cancer Survivors Who Never Smoked**
Choi, E., Su, C., Wu, J., Aredo, J., Neal, J., Leung, A., Backhus, L., Marchand, L., Liang, S. Y., Cheng, I., Wakelee, H., Han, S.
ELSEVIER SCIENCE INC.2023: E1
- **A hybrid modelling approach for abstracting CT imaging indications by integrating natural language processing from radiology reports with structured data from electronic health records.**
Khan, A., Wu, J., Choi, E., Graber-Naidich, A., Henry, S., Wakelee, H. A., Kurian, A. W., Liang, S., Leung, A., Langlotz, C., Backhus, L. M., Han, S. S.

AMER ASSOC CANCER RESEARCH.2023

- **Risk factors for second primary lung cancer among breast cancer survivors**
Choi, E., Lee, J., Wu, J. T., Wakelee, H. A., Schapira, L., Kurian, A. W., Han, S. S.
AMER ASSOC CANCER RESEARCH.2023
- **Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.** *JCO oncology practice*
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., Rogers, B., Hansen, J., DeNofrio, J., Shah, et al
2022: OP2200128
- **Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer.** *Cancer treatment and research communications*
Aredo, J. V., Wakelee, H. A., Hui, A. B., Padda, S. K., Joshi, N. D., Guo, H. H., Chaudhuri, A., Diehn, M., Loo, B. W., Neal, J. W.
2022; 33: 100659
- **Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIa NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 study**
Felip, E., Altorki, N., Zhou, C., Vallieres, E., Vynnychenko, I., Akopov, A., Martinez-Marti, A., Chella, A., Bondarenko, I., Ursol, G., Levchenko, E., Kislov, N., Liersch, et al
KARGER.2022: 146-147
- **Local Control of Brain Metastases with Osimertinib Alone in Patients with EGFR-Mutant Non-Small Cell Lung Cancer**
Hui, C., Qu, V., Wang, J. Y., Von Eyben, R., Chang, Y. C., Chiang, P. L., Liang, C. H., Lin, J. Y., Lu, J. T., Li, G., Hayden, M., Myall, N., Soltys, et al
ELSEVIER SCIENCE INC.2022: E54-E55
- **Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.** *Journal of neuro-oncology*
Hui, C., Qu, V., Wang, J. Y., von Eyben, R., Chang, Y. C., Chiang, P. L., Liang, C. H., Lu, J. T., Li, G., Hayden-Gephart, M., Wakelee, H., Neal, J., Ramchandran, et al
2022
- **Racial diversity and reporting in United States Food and Drug Administration registration trials for thoracic malignancies from 2006-2020.** *Cancer investigation*
Chiang, R. S., Desai, A., Glover, M. J., Hui, G., Ramchandran, K. J., Wakelee, H., Lythgoe, M. P., Khaki, A. R.
2022: 1-6
- **Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes.** *JCO precision oncology*
Wu, J., Ding, V., Luo, S., Choi, E., Hellyer, J., Myall, N., Henry, S., Wood, D., Stehr, H., Ji, H., Nagpal, S., Hayden Gephart, M., Wakelee, et al
2022; 6: e2200220
- **High Levels of CD47 Expression in Thymic Epithelial Tumors**
Sun, T. Y., Nguyen, B., Chen, S., Natkunam, Y., Padda, S., Van De Rijn, M., Wakelee, H., Riess, J.
ELSEVIER SCIENCE INC.2022: S79
- **IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC**
Wakelee, H., Altorki, N., Felip, E., Vallieres, E., Vynnychenko, I. O., Akopov, A., Martinez-Marti, A., Chella, A., Bondarenko, I., Sugawara, S., Fan, Y., Kenmotsu, H., Chen, et al
ELSEVIER SCIENCE INC.2022: S2
- **Phenotyping Malignant Pleural Effusions with Mass Cytometry: Evidence of EMT and MET States in Late-Stage NSCLC**
Karacosta, L. G., Pancirer, D., Preiss, J., Shrager, J. B., Sung, A. W., Neal, J. W., Bendall, S. C., Wakelee, H., Plevritis, S. K.
ELSEVIER SCIENCE INC.2022: S577-S578
- **Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment.** *JCO precision oncology*
Giustini, N. P., Patel, S. P., Myall, N. J., Fernando do Prado Moura, J., Kulkarni, A., Chao, R. C., Wakelee, H., Bazhenova, L.
2022; 6: e2100551

- **Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.** *Practical radiation oncology*
Devine, M., Merriott, D. J., No, H. J., Lau, B., Say, C., Yoo, C., Yi, E., Ko, R. B., Neal, J. W., Wakelee, H. A., Das, M., Loo, B. W., Diehn, et al
2022
- **A brief report on the mutational landscape in non-small cell lung cancer of South Asian patients: Comparison at a US and an Indian Institution.** *Lung India : official organ of Indian Chest Society*
Roy, M., Bal, A., Gupta, N., Prasad, K. T., Wakelee, H. A., Singh, N.
2022; 39 (4): 315-318
- **IMpower010: results from Asian patients in a phase 3 study of adjuvant atezolizumab in resected stage IB-III NSCLC**
Kenmotsu, H., Zhou, C., Altorki, N., Felip, E., Vallieres, E., Sugawara, S., Sakai, H., Saito, H., Tao, M., Kawaguchi, K., Liu, Y., Yu, C., Wu, et al
ELSEVIER.2022: S464
- **Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.** *Circulation*
Zhu, H., Galdos, F. X., Lee, D., Waliyany, S., Vivian Huang, Y., Ryan, J., Dang, K., Neal, J. W., Wakelee, H. A., Reddy, S. A., Srinivas, S., Lin, L. L., Witteles, et al
2022: 101161CIRCULATIONAHA121056730
- **Long term effect of radiotherapy on risk of second primary lung cancer and overall mortality among lung cancer patients**
Choi, E., Lam, V. T., Aredo, J. A., Kumar, A. V., Wampfler, J., Wu, J. T., Christiani, D. C., Cheng, I., Amos, C. I., Hung, R. J., Backhus, L. M., Neal, J. W., Wakelee, et al
AMER ASSOC CANCER RESEARCH.2022
- **Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.** *Clinical lung cancer*
Waliyany, S., Wakelee, H., Ramchandran, K., Das, M., Huang, J., Myall, N., Li, C., Pagtama, J., Tisch, A. H., Neal, J. W.
2022
- **High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.** *JTO clinical and research reports*
Piper-Vallillo, A. J., Rotow, J. K., Aredo, J. V., Shaverdashvili, K., Luo, J., Carlisle, J. W., Husain, H., Muzikansky, A., Heist, R. S., Rangachari, D., Ramalingam, S. S., Wakelee, H. A., Yu, et al
2022; 3 (6): 100328
- **Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.**
Riess, J. W., Krailo, M. D., Padda, S., Groshen, S. G., Wakelee, H. A., Reckamp, K. L., Koczywas, M., Piotrowska, Z., Steuer, C., Kim, C., Paweletz, C. P., Sholl, L. M., Heavey, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Genomic characterization of thymic epithelial tumor from real-world data.**
Kurokawa, K., Shukuya, T., Greenstein, R., Kaplan, B. G., Wakelee, H. A., Miura, K., Furuta, K., Suh, J., Sokol, E., Carbone, D., Takahashi, K.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Ancestry-based differences in gene alterations in non-small cell lung cancer: Realworld data using genetic ancestry analysis.**
Miura, K., Shukuya, T., Greenstein, R., Kaplan, B. G., Wakelee, H. A., Kurokawa, K., Furuta, K., Suh, J., Carbone, D., Takahashi, K.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **CD47 expression patterns in thymic epithelial tumors.**
Sun, T., Nguyen, B., Chen, S., Natkunam, Y., Padda, S., De Rijn, M., Wakelee, H. A., Riess, J. W.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.** *International journal of radiation oncology, biology, physics*
No, H. J., Raja, N., Von Eyben, R., Das, M., Roy, M., Myall, N., Neal, J., Wakelee, H., Chin, A., Diehn, M., Loo, B. W., Chang, D. T., Pollom, et al
2022
- **COVID-19 Outcomes, Patient Vaccination Status, and Cancer-Related Delays during the Omicron Wave: A Brief Report from the TERAVOLT Analysis.** *JTO clinical and research reports*
Bestvina, C. M., Whisenant, J. G., Torri, V., Cortellini, A., Wakelee, H., Peters, S., Roca, E., De Toma, A., Hirsch, F. R., Mamdani, H., Halmos, B., Arrieta, O., Metivier, et al
2022: 100335

- **Racial and Ethnic Disparities in Lung Cancer Screening by the 2021 USPSTF Guidelines Versus Risk-Based Criteria: The Multiethnic Cohort Study.** *JNCI cancer spectrum*
Aredo, J. V., Choi, E., Ding, V. Y., Tammemagi, M. C., Ten Haaf, K., Luo, S. J., Freedman, N. D., Wilkens, L. R., Le Marchand, L., Wakelee, H. A., Meza, R., Park, S. L., Cheng, et al
2022; 6 (3)
- **Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors.** *JTO clinical and research reports*
Singhal, S., Hellyer, J., Ouseph, M. M., Wakelee, H. A., Padda, S. K.
2022; 3 (5): 100323
- **Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIa NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study**
Felip, E., Altorki, N. K., Zhou, C., Vallieres, E., Vynnychenko, I. O., Akopov, A., Martinez-Marti, A., Chella, A., Bondarenko, I., Ursol, G., Levchenko, E., Kislov, N., Liersch, et al
ELSEVIER.2022: S71
- **Bevacizumab's Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC.** *JTO clinical and research reports*
Varlotto, J. M., Wang, Y., Sun, Z., Wakelee, H. A., Ramalingam, S., Schiller, J.
2022; 3 (3): 100274
- **Adjuvant therapy for early-stage non-small cell lung cancer: The breaking of a new dawn.** *The Journal of thoracic and cardiovascular surgery*
Altorki, N., Villena-Vargas, J., Wakelee, H.
2022
- **International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Smeltzer, M. P., Scagliotti, G. V., Wakelee, H. A., Mitsudomi, T., Roy, U. B., Clark, R. C., Arndt, R., Pruet, C. D., Kelly, K. L., Ujhazy, P., Johnson, M. L., Eralp, Y., Barrios, et al
2022
- **In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Thomas, N. J., Myall, N. J., Sun, F., Patil, T., Mushtaq, R., Yu, C., Sinha, S., Pollom, E. L., Nagpal, S., Camidge, D. R., Rusthoven, C. G., Braunstein, S. E., Wakelee, et al
1800; 17 (2): e12-e14
- **ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Chow, L. Q., Barlesi, F., Bertino, E. M., van den Bent, M. J., Wakelee, H. A., Wen, P. Y., Chiu, C., Orlov, S., Chiari, R., Majem, M., McKeage, M., Yu, C., Garrido, et al
1800
- **A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERA-VOLT registry.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Whisenant, J. G., Baena, J., Cortellini, A., Huang, L., Lo Russo, G., Porcu, L., Wong, S. K., Bestvina, C. M., Hellmann, M. D., Roca, E., Rizvi, H., Monnet, I., Boudjemaa, et al
2022
- **Progression Versus Radiation Treatment Changes After Stereotactic Ablative Radiation Therapy of a Liver Metastasis** *PRACTICAL RADIATION ONCOLOGY*
No, H. J., Negrete, L. M., Pollom, E. L., Wakelee, H. A., Chang, D. T., Vitzthum, L. K.
2022; 12 (1): 1-2
- **ITMIG 2021 Tumor Board: a case of a 37-year-old man with TNM stage IVA thymoma.** *Mediastinum (Hong Kong, China)*
Zielinski, M., Roden, A. C., Truong, M. T., Van Raemdonck, D., Komaki, R., Wakelee, H., Szolkowska, M.
2022; 6: 26
- **Impact of the COVID-19 Pandemic on Global Lung Cancer Clinical Trials: Why it matters to people with lung cancer.** *JTO clinical and research reports*
Roy, U. B., Baird, A., Ciupek, A., Fox, J., Manley, E. J., Norris, K., Scagliotti, G. V., Wakelee, H. A., Mitsudomi, T., Clark, R. C., Arndt, R., Hirsch, F. R., Bunn, et al

1800: 100269

- **Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.** *Cancer treatment and research communications*
Aredo, J. V., Wakelee, H. A., Neal, J. W., Padda, S. K.
1800; 30: 100497
- **IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIa NSCLC**
Zhou, C., Das Thakur, M., Srivastava, M. K., Zou, W., Xu, H., Ballinger, M., Felip, E., Wakelee, H., Altorki, N. K., Reck, M., Liersch, R., Kryzhanivska, A., Harada, et al
ELSEVIER.2021: S1374
- **Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Aredo, J. V., Hellyer, J. A., Neal, J. W., Wakelee, H. A.
2021; 16 (12): 1994-1998
- **A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.** *Cancer chemotherapy and pharmacology*
Padda, S. K., Reckamp, K. L., Koczywas, M., Neal, J. W., Kawashima, J., Kong, S., Huang, D. B., Kowalski, M., Wakelee, H. A.
2021
- **Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.** *Clinical lung cancer*
White, M. N., Piper-Vallillo, A. J., Gardner, R. M., Cunanan, K., Neal, J. W., Das, M., Padda, S. K., Ramchandran, K., Chen, T. T., Sequist, L. V., Piotrowska, Z., Wakelee, H. A.
2021
- **Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies.** *Neuro-oncology advances*
Myall, N. J., Yu, H., Soltys, S. G., Wakelee, H. A., Pollom, E.
2021; 3 (Suppl 5): v52-v62
- **SKYSCRAPER-03: A Phase III, Open-Label, Randomized Study of Atezolizumab Plus Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable, Stage III NSCLC Who Have Not Progressed After Platinum-Based Concurrent Chemoradiation**
Dzadzadzuszko, R., Ahn, M. J., Kelly, K., Popat, S., Wakelee, H. A., Baird, A. M., Rooney, I., Afshari, M., Coleman, S., Zhang, Z., Kiruki, H., Patil, N., Wen, et al
ELSEVIER SCIENCE INC.2021: E420-E421
- **A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR)**
Gensheimer, M. F., Gee, H. E., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., Brown, E., Nguyen, N., Liang, R., Maxim, P. G., Wakelee, H. A., Neal, J. W., Das, et al
ELSEVIER SCIENCE INC.2021: S89-S90
- **Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer**
Devine, M., Merriott, D. J., Say, C., Yoo, C., Yi, E., Lau, B., Ko, R. B., Shaheen, S., Neal, J. W., Wakelee, H. A., Das, M., Loo, B. W., Diehn, et al
ELSEVIER SCIENCE INC.2021: E435
- **Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents**
Lau, B., No, H. J., Wu, Y. F., Ko, R. B., Devine, M., Das, M., Neal, J. W., Ramchandran, K. J., Wakelee, H. A., Shaheen, S., Diehn, M., Chin, A. L., Loo, et al
ELSEVIER SCIENCE INC.2021: E423
- **A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR).** *International journal of radiation oncology, biology, physics*
Gensheimer, M. F., Gee, H. E., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., Brown, E., Nguyen, N., Liang, R., Maxim, P. G., Wakelee, H. A., Neal, J. W., Das, et al
2021; 111 (3S): S89-S90
- **Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.** *International journal of radiation oncology, biology, physics*

- Devine, M., Merriott, D. J., Say, C., Yoo, C., Yi, E., Lau, B., Ko, R. B., Shaheen, S., Neal, J. W., Wakelee, H. A., Das, M., Loo, B. W., Diehn, et al
2021; 111 (3S): e435
- **SKYSCRAPER-03: A Phase III, Open-Label, Randomized Study of Atezolizumab Plus Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable, Stage III NSCLC Who Have Not Progressed After Platinum-Based Concurrent Chemoradiation.** *International journal of radiation oncology, biology, physics*
Dzadzadzuszko, R., Ahn, M. J., Kelly, K., Popat, S., Wakelee, H. A., Baird, A. M., Rooney, I., Afshari, M., Coleman, S., Zhang, Z., Kiruki, H., Patil, N., Wen, et al
2021; 111 (3S): e420-e421
 - **Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer.** *JCO precision oncology*
Padda, S. K., Aredo, J. V., Vali, S., Singh, N. K., Vasista, S. M., Kumar, A., Neal, J. W., Abbasi, T., Wakelee, H. A.
2021; 5: 153-162
 - **Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.** *Clinical lung cancer*
Hellyer, J. A., White, M. N., Gardner, R. M., Cunanan, K., Padda, S. K., Das, M., Ramchandran, K., Neal, J. W., Wakelee, H. A.
2021
 - **Racial diversity and reporting in FDA registration trials for thoracic malignancies from 2006 to 2020**
Chiang, R. S., Glover, M., Hui, G., Desai, A., Wakelee, H. A., Lythgoe, M., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2021
 - **The Association of Bevacizumab with a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505 in Completely Resected Stage IB-IIIa NSCLC**
Varlotto, J., Wang, Y., Sun, Z., Wakelee, H., Ramalingam, S., Schiller, J.
ELSEVIER SCIENCE INC.2021: S944
 - **Survival After Distant Recurrent Versus De Novo Stage IV Metastatic Lung Cancer Under Low-Dose Computed Tomography Screening**
Su, C., Choi, E., Wu, J., Neal, J., Kurian, A., Backhus, L., Leung, A., Wakelee, H., Han, S.
ELSEVIER SCIENCE INC.2021: S1177-S1178
 - **International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials**
Smeltzer, M., Bunn, P. A., Clark, R., Arndt, R., Pruett, C., Roy, U., Hirsch, F., Mitsudomi, T., Wakelee, H., Scagliotti, G.
ELSEVIER SCIENCE INC.2021: S847-S848
 - **IMpower010: Characterization of Stage IB-IIIa NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab**
Altorki, N., Felip, E., Zhou, C., Vallieres, E., Moiseyenko, V., Smolin, A., Rittmeyer, A., Vereshchako, R., Perol, M., Schutte, W., Fang, J., Tao, M., Teixeira, et al
ELSEVIER SCIENCE INC.2021: S845-S846
 - **A Predictive Model to Guide Brain MRI Surveillance in Patients With Metastatic Lung Cancer: Impact on Real World Outcomes**
Wu, J., Ding, V., Luo, S., Choi, E., Hellyer, J., Myall, N., Henry, S., Wood, D., Stehr, H., Ji, H., Nagpal, S., Gephart, M., Wakelee, et al
ELSEVIER SCIENCE INC.2021: S1177
 - **Smoking Cessation After Lung Cancer Diagnosis and the Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study.** *JNCI cancer spectrum*
Luo, S. J., Choi, E., Aredo, J. V., Wilkens, L. R., Tammemagi, M. C., Le Marchand, L., Cheng, I., Wakelee, H. A., Han, S. S.
2021; 5 (5): pkab076
 - **Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents**
Lau, B., No, H., (Fred) Wu, Y., Devine, M., Ko, R., Loo, B., Diehn, M., Chin, A., Vitzthum, L.
LIPPINCOTT WILLIAMS & WILKINS.2021: S105
 - **Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer.** *Journal of patient-reported outcomes*
Generalova, O., Roy, M., Hall, E., Shah, S. A., Cunanan, K., Fardeen, T., Velazquez, B., Chu, G., Bruzzone, B., Cabot, A., Fisher, G. A., Srinivas, S., Fan, et al
2021; 5 (1): 91

- **Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.** *JAMA oncology*
Horn, L., Wang, Z., Wu, G., Poddubskaya, E., Mok, T., Reck, M., Wakelee, H., Chiappori, A. A., Lee, D. H., Breder, V., Orlov, S., Cicin, I., Cheng, et al
2021
- **Radiological tumor classification across imaging modality and histology.** *Nature machine intelligence*
Wu, J., Li, C., Gensheimer, M., Padda, S., Kato, F., Shirato, H., Wei, Y., Schönlieb, C. B., Price, S. J., Jaffray, D., Heymach, J., Neal, J. W., Loo, et al
2021; 3: 787-798
- **Brain Metastases in EGFR- and ALK-positive Non-Small Cell Lung Cancer: Outcomes of CNS Penetrant Tyrosine Kinase Inhibitors (TKIs) Alone versus in Combination with Radiation.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Thomas, N. J., Myall, N. J., Sun, F., Patil, T., Mushtaq, R., Yu, C., Sinha, S., Pollom, E. L., Nagpal, S., Camidge, D. R., Rusthoven, C. G., Braunstein, S. E., Wakelee, et al
2021
- **Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Waliany, S., Zhu, H., Wakelee, H., Padda, S. K., Das, M., Ramchandran, K., Myall, N. J., Chen, T., Witteles, R. M., Neal, J. W.
2021
- **Radiological tumour classification across imaging modality and histology** *NATURE MACHINE INTELLIGENCE*
Wu, J., Li, C., Gensheimer, M., Padda, S., Kato, F., Shirato, H., Wei, Y., Schonlieb, C., Price, S., Jaffray, D., Heymach, J., Neal, J. W., Loo, et al
2021
- **Incidence of Lung Cancer Among Never-Smoking Asian American, Native Hawaiian, and Pacific Islander Females.** *Journal of the National Cancer Institute*
DeRouen, M. C., Canchola, A. J., Thompson, C. A., Jin, A., Nie, S., Wong, C., Lichtensztajn, D., Allen, L., Patel, M. I., Daida, Y. G., Luft, H. S., Shariff-Marco, S., Reynolds, et al
2021
- **A Moving Target: Integration of Smoking Cessation Into Screening for Second Primary Lung Cancer.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Aredo, J. V., Wakelee, H. A., Han, S. S.
2021; 16 (8): e59-e60
- **EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.** *Clinical lung cancer*
Shah, M. P., Aredo, J. V., Padda, S. K., Ramchandran, K. J., Wakelee, H. A., Das, M. S., Neal, J. W.
2021
- **Development and Validation of a Risk Prediction Tool for Second Primary Lung Cancer.** *Journal of the National Cancer Institute*
Choi, E., Sanyal, N., Ding, V. Y., Gardner, R. M., Aredo, J. V., Lee, J., Wu, J. T., Hickey, T. P., Barrett, B., Riley, T. L., Wilkens, L. R., Leung, A. N., Le Marchand, et al
2021
- **Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC).** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Rolfo, C., Mack, P., Scagliotti, G. V., Aggarwal, C., Arcila, M. E., Barlesi, F., Bivona, T., Diehn, M., Dive, C., Dziadziuszko, R., Leigh, N., Malapelle, U., Mok, et al
2021
- **Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type.** *Oncotarget*
Padda, S. K., Gokmen-Polar, Y., Hellyer, J. A., Badve, S. S., Singh, N. K., Vasista, S. M., Basu, K., Kumar, A., Wakelee, H. A.
2021; 12 (12): 1178-1186
- **Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts.**
Wong, S. K., Whisenant, J. G., Bestvina, C. M., Berry, L. D., Owonikoko, T. K., Sanborn, R. E., Lammers, P., El Osta, B., Ramalingam, S. S., Carlisle, J. W., Steuer, C., Borghaei, H., Selvaggi, et al
LIPPINCOTT WILLIAMS & WILKINS.2021

- **Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).**
Varlotto, J. M., Sun, Z., Ramalingam, S. S., Wakelee, H. A., Lovly, C. M., Oettel, K. R., Masters, G. A., Pennell, N.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIa non-small cell lung cancer (NSCLC).**
Wakelee, H. A., Altorki, N. K., Zhou, C., Csomzi, T., Vynnychenko, I. O., Goloborodko, O., Luft, A., Akopov, A., Martinez-Marti, A., Kenmotsu, H., Chen, Y., Chella, A., Sugawara, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Integrating electronic health record, cancer registry, and geospatial data to study lung cancer in Asian American, Native Hawaiian and Pacific Islander ethnic groups.** *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*
DeRouen, M. C., Thompson, C. A., Canchola, A. J., Jin, A., Nie, S., Wong, C., Jain, J., Lichtensztajn, D. Y., Li, Y., Allen, L., Patel, M. I., Daida, Y. G., Luft, et al
2021
- **Immune Checkpoint Inhibitor Pneumonitis: Heterogeneity in Clinical Management**
Filsoof, D., Padda, S. K., Garcia, P., Stedman, M., Neal, J. W., Wakelee, H. A., Ramchandran, K., Das, M., Ramsey, M., Bedi, H. S., Sung, A., Raj, R., Anand, et al
AMER THORACIC SOC.2021
- **The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer**
Choi, E., Luo, S., Aredo, J., Wilkens, L., Leung, A., Le Marchand, L., Cheng, I., Wakelee, H., Han, S.
AMER THORACIC SOC.2021
- **Pragmatic Application of Computed Tomography Lung Texture Analysis in Immune Checkpoint Inhibitor Pneumonitis: An Exploratory Study**
Filsoof, D., Im, J., Garcia, P., Stedman, M., Anand, S., Neal, J. W., Wakelee, H. A., Ramchandran, K., Das, M., Padda, S. K., Sharifi, H., Mooney, J. J., Tsai, et al
AMER THORACIC SOC.2021
- **Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib**
White, M., Neal, J. W., Gardner, R. M., Cunanan, K. M., Das, M., Padda, S. K., Ramchandran, K., Chen, T. T., Wakelee, H.
ELSEVIER SCIENCE INC.2021: S773–S774
- **Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer.**
Moding, E. J., Liu, Y., Hui, A. B., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, Z., Das, M., Ramchandran, K. J., Padda, S. K., Neal, et al
AMER ASSOC CANCER RESEARCH.2021
- **Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer.**
Binkley, M. S., Jeon, Y., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D., Yoo, C., Kurtz, D. M., Owen, S., Backhus, L. M., Berry, M. F., Shrager, J. B., Ramchandran, et al
AMER ASSOC CANCER RESEARCH.2021
- **Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo.** *Cancer discovery*
Foggetti, G., Li, C., Cai, H., Hellyer, J. A., Lin, W., Ayeni, D., Hastings, K., Choi, J., Wurtz, A., Andrejka, L., Maghini, D. G., Rashleigh, N., Levy, et al
2021
- **Metabolomic profiling for second primary lung cancer: A pilot case-control study.** *Lung cancer (Amsterdam, Netherlands)*
Aredo, J. V., Purington, N., Su, L., Luo, S. J., Diao, N., Christiani, D. C., Wakelee, H. A., Han, S. S.
2021; 155: 61–67
- **Women in cancer research and oncology** *CANCER CELL*
Joyce, J., Wakelee, H., Davis, M. B., Teo, S., Bell, S., Rendo, V.
2021; 39 (3): 285–87
- **Healthcare Utilization with an Electronic Patient Reported Outcome (ePRO) tool for Symptom Management in Thoracic Cancers**
Roy, M., Fardeen, T., Generalova, O., Hall, E., Cunanan, K., Das, M., Neal, J., Padda, S., Wakelee, H. A., Ramchandran, K.
ELSEVIER SCIENCE INC.2021: S170–S171

- **Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.** *JACC CardioOncology*
Waliyany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., Padda, S. K., Fan, A. C., Colevas, A. D., Wu, S. M., Witteles, R. M., Zhu, H.
2021; 3 (1): 137–39
- **Coping Strategy Influences Quality of Life in Patients With Advanced Lung Cancer by** *CLINICAL LUNG CANCER*
Shah, A. T., Bernardo, R. J., Berry, G. J., Kudelko, K., Wakelee, H. A.
2021; 22 (2): E153–E156
- **Time to First Progression in Patients with NSCLC with Brain Metastases Receiving 3rd Generation TKI alone vs TKI plus Brain Radiation**
Thomas, N., Myall, N., Sun, F., Patil, T., Mushtaq, R., Yu, C., Pollom, E., Nagpal, S., Camidge, R., Rusthoven, C., Braunstein, S., Wakelee, H. A., Mccoach, et al
ELSEVIER SCIENCE INC.2021: S591–S592
- **Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.**
Selvaggi, G., Wu, Y., Wang, Z., Wu, G., Poddubskaya, E., Reck, M., Mok, T., Chiappori, A., Lee, D. H., Breder, V., Orlov, S., Cicin, I., Cheng, et al
ELSEVIER SCIENCE INC.2021: S232–S233
- **RAS Precision Medicine Trans-Atlantic Partnership: Multi-Centre Pooled Analysis of RAS Pathway Mutations in Advanced NSCLC**
Adderley, H., Aldea, M., Aredo, J., Carter, M., Church, M., Blackhall, F., Krebs, M. G., Wakelee, H. A., Besse, B., Planchard, D., Vasseur, D., Massard, C., Lindsay, et al
ELSEVIER SCIENCE INC.2021: S696
- **The Mutational Landscape in South Asian Patients with Non-Small Cell Lung Cancer at an US Academic Medical Center**
Roy, M., Wakelee, H. A.
ELSEVIER SCIENCE INC.2021: S428
- **COVID-19 Outcomes in Patients With Thoracic Malignancies According to Gender and Ethnicity (TERAVOLT)**
Whisenant, J., Wong, S., Torri, V., Revuelta, J., Halmos, B., Ceresoli, G., Monnet, I., Popat, S., Arrieta, O., Azab, M., Dingemans, A., Spasic, J., Van Meerbeeck, et al
ELSEVIER SCIENCE INC.2021: S297
- **Impact of Medicaid Enrollment on Mortality in Elderly Dual-Eligible Lung Cancer Patients**
Ragavan, M., Gardner, R., Cunanan, K., Wakelee, H., Han, S.
ELSEVIER SCIENCE INC.2021: S306
- **Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis: Secondary Analysis of NLST**
Su, C. C., Wu, J., Neal, J., Popat, R., Backhus, L., Leung, A., Nagpal, S., Wakelee, H. A., Han, S.
ELSEVIER SCIENCE INC.2021: S149–S150
- **Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors**
Padda, S., Whisenant, J., Neal, J., York, S., Iams, W., Neuss, M., Reckamp, K., Preiss, J., Berry, L., Shyr, Y., Wakelee, H., Horn, L.
ELSEVIER SCIENCE INC.2021: S626
- **Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma**
Aredo, J., Wakelee, H. A., Neal, J., Padda, S.
ELSEVIER SCIENCE INC.2021: S619
- **A review of immunotherapy for stage 3 and metastatic NSCLC & the rationale for the ECOG-ACRIN EA5181 study.** *The oncologist*
Varlotto, J. M., Sun, Z., Ky, B., Upshaw, J., Katz, S. I., Fitzgerald, T. J., Wakelee, H., Diehn, M., Mankoff, D. A., Lovly, C., Belani, C., Oettel, K., Masters, et al
2021
- **Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study.** *JTO clinical and research reports*
Yang, J. C., Reckamp, K. L., Kim, Y., Novello, S., Smit, E. F., Lee, J., Su, W., Akerley, W. L., Blakely, C. M., Groen, H. J., Bazhenova, L., Carcereny Costa, E., Chiari, et al
2021; 2 (2): 100114

- **Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer** *JCO PRECISION ONCOLOGY*
Padda, S. K., Aredo, J., Vali, S., Singh, N. K., Vasista, S. M., Kumar, A., Neal, J. W., Abbasi, T., Wakelee, H. A.
2021; 5: 153–62
- **Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery.** *Immunity*
Chiou, S. H., Tseng, D. n., Reuben, A. n., Mallajosyula, V. n., Molina, I. S., Conley, S. n., Wilhelmy, J. n., McSween, A. M., Yang, X. n., Nishimiya, D. n., Sinha, R. n., Nabet, B. Y., Wang, et al
2021; 54 (3): 586–602.e8
- **Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring.** *Clinical chemistry*
Nesvet, J. C., Antilla, K. A., Pancirer, D. S., Lozano, A. X., Preiss, J. S., Ma, W. n., Fu, A. n., Park, S. M., Gambhir, S. S., Fan, A. C., Neal, J. W., Padda, S. K., Das, et al
2021
- **Tobacco Smoking and Risk of Second Primary Lung Cancer.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Aredo, J. V., Luo, S. J., Gardner, R. M., Sanyal, N. n., Choi, E. n., Hickey, T. P., Riley, T. L., Huang, W. Y., Kurian, A. W., Leung, A. N., Wilkens, L. R., Robbins, H. A., Riboli, et al
2021
- **RAS precision medicine trans-Atlantic partnership: Multi-centre analysis of RAS and NF1 co-mutations in advanced NSCLC**
Adderley, H., Aldea, M., Aredo, J., Carter, M., Church, M., Ghaus, A., Planchard, D., Vasseur, D., Massard, C., Krebs, M. G., Steele, N., Blackhall, F. H., Wakelee, et al
ELSEVIER.2021: S1221
- **SKYSCRAPER-03: Phase III, open-label randomised study of atezolizumab plus tiragolumab vs durvalumab in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based concurrent chemoradiation (cCRT)**
Dziedziszko, R., Ahn, M., Kelly, K. A., Popat, S., Wakelee, H., Baird, A., Rooney, I. A., Afshari, M., Yao, E. S., Zhang, Z., Kuriki, H., Patil, N. S., Wen, et al
ELSEVIER.2021: S947-S948
- **IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIa NSCLC**
Felip, E., Vallieres, E., Zhou, C., Wakelee, H., Bondarenko, I., Sakai, H., Saito, H., Ursol, G., Kawaguchi, K., Liu, Y., Levchenko, E., Kislov, N., Reck, et al
ELSEVIER.2021: S1319
- **The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer.** *Journal of the National Cancer Institute*
Choi, E., Luo, S. J., Aredo, J. V., Backhus, L. M., Wilkens, L. R., Su, C. C., Neal, J. W., Le Marchand, L., Cheng, I., Wakelee, H. A., Han, S. S.
2021
- **Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Hellyer, J. A., Aredo, J. V., Das, M. n., Ramchandran, K. n., Padda, S. K., Neal, J. W., Wakelee, H. A.
2021
- **Smoking Behavior in Patients with Early Stage NSCLC: A Report from ECOG-ACRIN 1505 Trial.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Steuer, C. E., Jegede, O. A., Dahlberg, S. E., Wakelee, H. A., Keller, S. M., Tester, W. J., Gandara, D. R., Graziano, S. L., Adjei, A. A., Butts, C. A., Ramalingam, S. S., Schiller, J. H.
2021
- **Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy**
Aredo, J. V., Hellyer, J. A., Neal, J. W., Padda, S. K., McCoach, C. E., Riess, J. W., Cabebe, E. C., Loo, B. W., Diehn, M., Wakelee, H. A.
ELSEVIER SCIENCE INC.2021: S15
- **Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.** *Journal of neuro-oncology*

- Zhang, M. n., Rodrigues, A. J., Pollom, E. L., Gibbs, I. C., Soltys, S. G., Hancock, S. L., Neal, J. W., Padda, S. K., Ramchandran, K. J., Wakelee, H. A., Chang, S. D., Lim, M. n., Hayden Gephart, et al
2021
- **Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.** *Clinical lung cancer*
White, M. N., Piotrowska, Z. n., Stirling, K. n., Liu, S. V., Banwait, M. K., Cunanan, K. n., Sequist, L. V., Wakelee, H. A., Hausrath, D. n., Neal, J. W.
2021
 - **Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Aredo, J. V., Mambetsariev, I. n., Hellyer, J. A., Amini, A. n., Neal, J. W., Padda, S. K., McCoach, C. E., Riess, J. W., Cabebe, E. C., Naidoo, J. n., Abuali, T. n., Salgia, R. n., Loo, et al
2021
 - **Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series.** *Translational lung cancer research*
Myall, N. J., Lei, A. Q., Wakelee, H. A.
2021; 10 (1): 487–95
 - **Smoking Cessation After Lung Cancer Diagnosis and Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study**
Choi, E., Luo, S., Tammemagi, M., Aredo, J., Marchand, L., Cheng, I., Wakelee, H., Han, S.
ELSEVIER SCIENCE INC.2021: S40–S41
 - **Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring.** *Clinical chemistry*
Nesvet, J. C., Antilla, K. A., Pancirer, D. S., Lozano, A. X., Preiss, J. S., Ma, W. n., Fu, A. n., Park, S. M., Gambhir, S. S., Fan, A. C., Neal, J. W., Padda, S. K., Das, et al
2021
 - **Tobacco Smoking and Risk of Second Primary Lung Cancer.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Aredo, J. V., Luo, S. J., Gardner, R. M., Sanyal, N. n., Choi, E. n., Hickey, T. P., Riley, T. L., Huang, W. Y., Kurian, A. W., Leung, A. N., Wilkens, L. R., Robbins, H. A., Riboli, et al
2021
 - **Two Cases of Pulmonary Tumor Thrombotic Microangiopathy Associated with ROS1-Rearranged Non-Small-Cell Lung Cancer.** *Clinical lung cancer*
Shah, A. T., Bernardo, R. J., Berry, G. J., Kudelko, K., Wakelee, H. A.
2020
 - **Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer.** *Clinical lung cancer*
Park, M., Ho, D. Y., Wakelee, H. A., Neal, J. W.
2020
 - **Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3**
Selvaggi, G., Wakelee, H. A., Mok, T., Wu, Y., Reck, M., Chiappori, A., Cicin, I., Lee, D. H., Breder, V., Fan, Y., Orlov, S., Poddubskaya, E., Wang, et al
ELSEVIER SCIENCE INC.2020: E41–E42
 - **Late Breaking Abstract - Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival**
van Meerbeeck, J., Dingemans, A., Horn, L., Torri, V., Whisenant, J., Wakelee, H., Peters, S., Garassino, M., Cadranet, J., Chorostowska, J.
EUROPEAN RESPIRATORY SOC JOURNALS LTD.2020
 - **Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies.**
Cortellini, A., Dingemans, A. C., Arrieta, O., Baena, J., Brighenti, M., Filip, E., Garassino, M., Garrido, P., Genova, C., Grosso, F., Horn, L., Huang, L., Van Meerbeeck, et al
AMER ASSOC CANCER RESEARCH.2020
 - **Perioperative pembrolizumab plus platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: The phase III KEYNOTE-671 study**

- Tsuboi, M., Luft, A., Ursol, G., Kato, T., Levchenko, E., Eigendorff, E., Berard, H., Zurawski, B., Demedts, I., Garassino, M. C., Yang, J., Makarious, K., Keller, et al
ELSEVIER.2020: S801–S802
- **Defining COVID-19 outcomes in thoracic cancer patients: TERA-VOLT (Thoracic cancerS international coVID 19 cOLlaboraTion)**
Baena Espinar, J., Torri, V., Whisenant, J., Hirsch, F. R., Rogado, J., de Castro Carpeno, J., Halmos, B., Ceresoli, G. L., Gomez Rueda, A., Tiseo, M., Felip, E., Majem Tarruella, M., Monnet, et al
ELSEVIER.2020: S1204–S1205
 - **A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer**
Nabet, B. Y., Esfahani, M. S., Hamilton, E. G., Chabon, J. J., Moding, E. J., Rizvi, H., Steen, C. B., Chaudhuri, A. A., Liu, C., Hui, A. B., Stehr, H., Goljenola, L., Jin, et al
AMER ASSOC CANCER RESEARCH.2020
 - **Association of baseline systemic corticosteroid use with time to next treatment in patients with advanced melanoma, non-small cell lung cancer or urothelial cancer receiving cancer immunotherapy in US clinical practice**
Drakaki, A., Dhillon, P. K., Wakelee, H., Chui, S. Y., Shim, J., Kent, M., Degaonkar, V., Tien Hoang, McNally, V., Luhn, P., Gutzmer, R.
AMER ASSOC CANCER RESEARCH.2020
 - **Association of baseline systemic corticosteroid use with time to next treatment in patients with advanced melanoma, non-small cell lung cancer or urothelial cancer receiving cancer immunotherapy in US clinical practice**
Drakaki, A., Dhillon, P. K., Wakelee, H., Chui, S. Y., Shim, J., Kent, M., Degaonkar, V., Hoang, T., McNally, V., Luhn, P., Gutzmer, R.
AMER ASSOC CANCER RESEARCH.2020
 - **Is smoking a risk factor for second primary lung cancer**
Aredo, J., Luo, S. J., Gardner, R., Hickey, T. P., Riley, T. L., Wilkens, L. R., Le Marchand, L., Amos, C., Hung, R. J., Johansson, M., Cheng, I., Wakelee, H. A., Han, et al
AMER ASSOC CANCER RESEARCH.2020
 - **Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival**
Whisenant, J. G., Torri, V., Huang, L., Trama, A., Paz-Ares, L. G., Felip, E., Pancaldi, V., De Toma, A., Tiseo, M., Garrido, P., Genova, C., Cadranell, J., Michelin, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
 - **Lung cancer incidence and risk factors in never-smoking Asian American, Native Hawaiian, and Pacific Islander women: The development of a multilevel integrated dataset of EHR, cancer registry, and environmental data**
DeRouen, M. C., Shariff-Marco, S., Lichtensztajn, D., Jin, A., Daida, Y. G., Canchola, A. J., Li, Y., Jain, J., Allen, L., Nie, S., Wong, C., Haile, R., Patel, et al
AMER ASSOC CANCER RESEARCH.2020
 - **Lung cancer incidence and risk factors in never-smoking Asian American, Native Hawaiian, and Pacific Islander women: A multilevel dataset of electronic health record, cancer registry, and environmental data**
DeRouen, M. C., Thompson, C., Canchola, A. J., Jin, A., Nie, S., Jain, J., Shariff-Marco, S., Lichtensztajn, D. Y., Daida, Y., Wong, C., Li, Y., Patel, M., Wakelee, et al
AMER ASSOC CANCER RESEARCH.2020
 - **Phase I/II study of vorolanib plus nivolumab in patients with thoracic malignancies: immunotherapy (IO) correlates to differentiate responders from nonresponders.**
Beckermann, K., Bestvina, C. M., Whisenant, J. G., Borghaei, H., Owonikoko, T., Berry, L. D., Shyr, Y., Liang, C., Selvaggi, G., Wakelee, H. A., Horn, L.
LIPPINCOTT WILLIAMS & WILKINS.2020
 - **High-dose osimertinib for CNS progression in EGFR plus non-small cell lung cancer (NSCLC): A multi-institutional experience.**
Piper-Vallillo, A., Rotow, J. K., Aredo, J., Shaverdashvili, K., Luo, J., Carlisle, J. W., Husain, H., Muzikansky, A., Heist, R., Rangachari, D., Ramalingam, S. S., Wakelee, H. A., Yu, et al
AMER SOC CLINICAL ONCOLOGY.2020
 - **Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.**
Ji, J., Aredo, J., Piper-Vallillo, A., Huppert, L., Rotow, J. K., Husain, H., Stewart, S. L., Cobb, R., Wakelee, H. A., Blakely, C., Wong, M. L., Gubens, M. A., Chen, et al
AMER SOC CLINICAL ONCOLOGY.2020

- **A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.**
Moding, E. J., Esfahani, M., Nabet, B., Liu, Y., Chabon, J. J., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, Z. X., Das, M., Ramchandran, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.**
Binkley, M. S., Jeon, Y., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D. S., Yoo, C., Kurtz, D., Owen, S., Backhus, L., Berry, M. F., Shrager, J. B., Ramchandran, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **Discovery of a novel shared tumor antigen in human lung cancer.**
Tseng, D., Chiou, S., Yang, X., Reuben, A., Wilhelmy, J., McSween, A., Conley, S., Sinha, R., Nabet, B., Wang, C., Shrager, J. B., Berry, M. F., Backhus, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **Phase II randomized trial of carboplatin plus pemetrexed plus bevacizumab, plus /- atezolizumab in stage IV non-squamous non-small lung cancer (NSCLC) patients who harbor a sensitizing EGFR mutation or have never smoked.**
Bodor, J., Patel, J. D., Ross, E. A., Litwin, S., Clapper, M., Levy, B., Wakelee, H. A., Borghaei, H., Treat, J.
LIPPINCOTT WILLIAMS & WILKINS.2020
- **TERAVOLT: Thoracic Cancers International COVID-19 Collaboration.** *Cancer cell*
Whisenant, J. G., Trama, A., Torri, V., De Toma, A., Viscardi, G., Cortellini, A., Micheilin, O., Barlesi, F., Dingemans, A. C., Van Meerbeeck, J., Pancaldi, V., Soo, R. A., Leigh, et al
2020
- **Integrating genomic features for non-invasive early lung cancer detection.** *Nature*
Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., Schroers-Martin, J., Nabet, B. Y., Chen, B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., Jin, et al
2020; 580 (7802): 245-251
- **Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.** *Nature cancer*
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Yoo, C. H., Gojenola, L., Jones, C. D., He, J., Qiao, et al
2020; 1 (2): 176-183
- **US phase 1 first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Papadopoulos, K. P., Borazanci, E. n., Shaw, A. T., Katayama, R. n., Shimizu, Y. n., Zhu, V. W., Sun, T. Y., Wakelee, H. A., Madison, R. n., Schrock, A. B., Senaldi, G. n., Nakao, N. n., Hanzawa, et al
2020
- **Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report.** *Clinical lung cancer*
Aredo, J. V., Diehn, M. n., Berry, G. J., Wakelee, H. A.
2020
- **Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Hellmann, M. D., Nabet, B. Y., Rizvi, H. n., Chaudhuri, A. A., Wells, D. K., Dunphy, M. P., Chabon, J. J., Liu, C. L., Hui, A. B., Arbour, K. C., Luo, J. n., Preeshagul, I. R., Moding, et al
2020
- **A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS.** *Cancer treatment and research communications*
Riess, J. W., Jahchan, N. S., Das, M. n., Zach Koontz, M. n., Kunz, P. L., Wakelee, H. A., Schatzberg, A. n., Sage, J. n., Neal, J. W.
2020; 23: 100174
- **KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.** *Cancer discovery*
Binkley, M. S., Jeon, Y. J., Nesselbush, M. n., Moding, E. J., Nabet, B. Y., Almanza, D. n., Kunder, C. n., Stehr, H. n., Yoo, C. H., Rhee, S. n., Xiang, M. n., Chabon, J. J., Hamilton, et al
2020

- **Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERA-VOLT Experience.** *Cancer cell*
Trama, A. n., Proto, C. n., Whisenant, J. G., Torri, V. n., Cortellini, A. n., Michielin, O. n., Barlesi, F. n., Dingemans, A. C., Van Meerbeeck, J. n., Pancaldi, V. n., Mazieres, J. n., Soo, R. A., Leigh, et al
2020
- **Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma** *ONCOIMMUNOLOGY*
Drakaki, A., Dhillon, P. K., Wakelee, H., Chui, S. Y., Shim, J., Kent, M., Degaonkar, V., Hoang, T., McNally, V., Luhn, P., Gutzmer, R.
2020; 9 (1)
- **Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer** *NATURE CANCER*
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Gojenola, L., Jones, C. D., He, J., Qiao, Y., Heymach, et al
2020; 1: 176–183
- **Clinical implications of KEAP1-NFE2L2 mutations in non-small cell lung cancer.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Hellyer, J. A., Padda, S. K., Diehn, M. n., Wakelee, H. A.
2020
- **PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review.** *Clinical lung cancer*
Zhou, M. n., Joshi, N. n., Raj, K. P., Wakelee, H. n., Neal, J. W.
2020
- **Everolimus in the treatment of metastatic thymic epithelial tumors.** *Lung cancer (Amsterdam, Netherlands)*
Hellyer, J. A., Ouseph, M. M., Padda, S. K., Wakelee, H. A.
2020; 149: 97–102
- **Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.** *Cell*
Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H. n., Steen, C. B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., Almanza, D. n., Stehr, H. n., Gojenola, et al
2020
- **PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review.** *Clinical lung cancer*
Zhou, M. n., Joshi, N. n., Raj, K. P., Wakelee, H. n., Neal, J. W.
2020
- **Everolimus in the treatment of metastatic thymic epithelial tumors.** *Lung cancer (Amsterdam, Netherlands)*
Hellyer, J. A., Ouseph, M. M., Padda, S. K., Wakelee, H. A.
2020; 149: 97–102
- **Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.** *Cell*
Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H. n., Steen, C. B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., Almanza, D. n., Stehr, H. n., Gojenola, et al
2020
- **Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice**
Drakaki, A., Luhn, P., Wakelee, H., Dhillon, P. K., Kent, M., Shim, J., Degaonkar, V., Hoang, T., McNally, V., Chui, S. Y., Gutzmer, R.
OXFORD UNIV PRESS.2019: 16–17
- **Evaluating the Role of Targeted Therapy in Lung Cancer** *ONCOLOGY-NEW YORK*
Wakelee, H.
2019; 33 (12): 482–86
- **Checkpoint Inhibitor Combinations Among Themselves and with Chemotherapy**

Mathias, C., Wakelee, H.

ELSEVIER SCIENCE INC.2019: S1166

● **Evaluating Racial Differences in KRAS-Mutant Non-Small Cell Lung Cancer**

Aredo, J., Padda, S., Kunder, C., Han, S., Wakelee, H.

ELSEVIER SCIENCE INC.2019: S1133

● **Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)**

Leal, T., Wakelee, H., Reckamp, K. L., Chiappori, A., Oxnard, G. R., Waqar, S. N., Patel, S. P., Blumenschein, G. R., Neal, J. W., Harrow, K., Holzhausen, A., Selvaggi, G., Zhou, et al

ELSEVIER SCIENCE INC.2019: S1171–S1172

● **Adjuvant PD-(L)1 Checkpoint Inhibitors**

Hellyer, J., Wakelee, H.

ELSEVIER SCIENCE INC.2019: S156–S157

● **Making the Most of WCLC: A Guide for First Time Attendees**

Wakelee, H., Bunn, B.

ELSEVIER SCIENCE INC.2019: S1115–S1116

● **Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC) metastatic to the brain**

Chow, L. Q., Barlesi, F., Bertino, E. M., van den Bent, M. J., Wakelee, H., Wen, P. Y., Chiu, C., Orlov, S., Majem, M., Chiari, R., McKeage, M., Yu, C., Hurtado, et al

OXFORD UNIV PRESS.2019: 602–3

● **Outcome Disparities in American Indian/Alaskan Natives with Advanced Stage Lung Cancer**

Hellyer, J., Cunanan, K., Wakelee, H., Han, S.

ELSEVIER SCIENCE INC.2019: S668

● **E1505: Adjuvant Chemotherapy plus +/- Bevacizumab for Early Stage NSCLC: Updated Chemotherapy Subset Analysis**

Wakelee, H., Dahlberg, S., Keller, S., Tester, W., Aisner, S., Rothman, J., Patel, J., Delaune, R., Mcdermott, S., Shafqat, A., Perez-Soler, R., Chapman, A., Kasbari, et al

ELSEVIER SCIENCE INC.2019: S271

● **Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LW: Results from the phase II, ASCEND-7 study**

Barlesi, F., Kim, D., Bertino, E. M., van den Bent, M. J., Wakelee, H., Wen, P. Y., Garrido Lopez, P., Orlov, S., Majem, M., McKeage, M., Yu, C., Hurtado, F. K., Arratia, et al

OXFORD UNIV PRESS.2019: 143-+

● **Role of mTOR Inhibitor Everolimus in the Treatment of Metastatic Thymic Epithelial Tumors**

Hellyer, J., Padda, S., Vali, S., Das, A., Sikora, H., Husain, Z., Kumar, A., Abbasi, T., Wakelee, H.

ELSEVIER SCIENCE INC.2019: S580

● **A Single-Cell Resolution Map of EMT and Drug Resistance States for Evaluating NSCLC Clinical Specimens**

Karacosta, L., Anchang, B., Ignatiadis, N., Kimmey, S., Benson, J., Shrager, J., Sung, A., Neal, J., Wakelee, H., Tibshirani, R., Bendall, S., Plevritis, S.

ELSEVIER SCIENCE INC.2019: S226–S227

● **Phase I/II Study of Nivolumab and Voreloxin in Patients with Refractory Thoracic Tumors**

Whisenant, J., Beckermann, K., Borghaei, H., Owonikoko, T., Patel, J., Berry, L., Shyr, Y., Harrow, K., Liang, C., Holzhausen, A., Selvaggi, G., Wakelee, H., Horn, et al

ELSEVIER SCIENCE INC.2019: S445–S446

● **STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC**

Skoulidis, F., Arbour, K., Hellmann, M., Patil, P., Marmarelis, M., Owen, D., Awad, M., Murray, J., Levy, B., Hellyer, J., Gainor, J., Stewart, T., Goldberg, et al

ELSEVIER SCIENCE INC.2019: S294–S295

- **Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK plus) Non-Small Cell Lung Cancer Patients Treated with Ensartinib**
Wakelee, H., Reckamp, K., Leal, T., Chiappori, A., Waqar, S., Zeman, K., Neal, J., Liang, C., Harrow, K., Holzhausen, A., Zhou, J., Selvaggi, G., Horn, et al
ELSEVIER SCIENCE INC.2019: S566
- **Feasibility and design of a cloud-based digital platform in patients with advanced cancer.**
Roy, M., Hall, E., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., San Pedro-Salcedo, M., Wakelee, H. A., Neal, J. W., Padda, S., Das, M., Fan, A. C., Srinivas, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Impact of dual-eligible status on survival in Medicare patients with lung cancer.**
Ragavan, M., Gardner, R., Cunanan, K., Sundaram, V., Wakelee, H. A., Han, S. S.
AMER SOC CLINICAL ONCOLOGY.2019
- **Circulating Tumor DNA Changes During Chemoradiation for Lung Cancer Predict Patient Outcomes**
Moding, E. J., Nabet, B. Y., Liu, Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Binkley, M. S., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, et al
ELSEVIER SCIENCE INC.2019: S113
- **Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer***
Horn, L., Whisenant, J. G., Wakelee, H., Reckamp, K. L., Qiao, H., Leal, T. A., Du, L., Hernandez, J., Huang, V., Blumenschein, G. R., Waqar, S. N., Patel, S. P., Nieva, et al
2019
- **Phase I/II study to evaluate the safety and preliminary activity of nivolumab in combination with vorolanib in patients with refractory thoracic tumors**
Whisenant, J. G., Beckerman, K., Borghaei, H., Owonikoko, T., Patel, J., Shyr, Y., Harrow, K., Liang, C., Holzhausen, A., Wakelee, H., Horn, L.
AMER ASSOC CANCER RESEARCH.2019
- **Characterization of circulating tumor cells and its PD-L1 expression with high-sensitivity liquid biopsy panel in non-small cell lung cancer patients**
Liu, X., Ao, Z., Preiss, J. S., Neal, J., Zhou, L., Sambucetti, L., Wakelee, H. A.
AMER ASSOC CANCER RESEARCH.2019
- **Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study *ONCOLOGIST***
Xie, L., Nagpal, S., Wakelee, H. A., Li, G., Soltys, S. G., Neal, J. W.
2019; 24 (6): 836–43
- **Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib *ANTI-CANCER DRUGS***
Wang, S. X. Y., Zhang, B. M., Wakelee, H. A., Koontz, M. Z., Pan, M., Diehn, M., Kunder, C. A., Neal, J. W.
2019; 30 (5): 537–41
- **Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Annals of oncology : official journal of the European Society for Medical Oncology***
Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., Thai, A. A., Mascaux, C., Couraud, S., Veillon, R., Van Den Heuvel, M., Neal, J., Peled, et al
2019
- **ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer.**
Moding, E. J., Liu, Y., Nabet, B., Chabon, J. J., Chaudhuri, A., Hui, A. B., He, J., Qiao, Y., Heymach, J., Tsao, A. S., Liao, Z. X., Gomez, D., Ramchandran, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC:An ETCTN California cancer consortium phase I study.**
Riess, J. W., Groshen, S. G., Reckamp, K. L., Wakelee, H. A., Oxnard, G. R., Padda, S., Koczywas, M., Piotrowska, Z., Sholl, L. M., Paweletz, C. P., Lau, C. J., Kolesar, J., Mack, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.**
Neal, J. W., Hausrath, D., Wakelee, H. A., Cunanan, K., Liu, S. V., Banwait, M., Sequist, L. V., Stirling, K., Piotrowska, Z.

AMER SOC CLINICAL ONCOLOGY.2019

- **Role of mTOR Inhibitor Everolimus in the Treatment of Metastatic Thymic Epithelial Tumors**
Hellyer, J., Padda, S., Wakelee, H. A.
ELSEVIER SCIENCE INC.2019: 239
- **Increased Galectin-1 Expression in Thymic Epithelial Tumors** *CLINICAL LUNG CANCER*
Riess, J. W., Kong, C. S., West, R. B., Padda, S. K., Neal, J. W., Wakelee, H. A., Le, Q.
2019; 20 (3): E356–E361
- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers** *JOURNAL OF CLINICAL ONCOLOGY*
Sikic, B., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
2019; 37 (12): 946+
- **Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC)**
Horn, L., Whisenant, J. G., Wakelee, H., Reckamp, K. L., Qiao, H., Du, L., Hernandez, J., Huang, V., Waqar, S. N., Patel, S., Sanborn, R. E., Shaffer, T., Garg, et al
OXFORD UNIV PRESS.2019: 44
- **Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).** *Annals of oncology : official journal of the European Society for Medical Oncology*
Horn, L., Whisenant, J. G., Wakelee, H., Reckamp, K. L., Qiao, H., Du, L., Hernandez, J., Huang, V., Waqar, S. N., Patel, S., Sanborn, R. E., Shaffer, T., Garg, et al
2019; 30 Suppl 2: ii48
- **Tumor heterogeneity and testing discrepancy confound ROS1 detection in NSCLC.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Sun, T. Y., Stehr, H., Suarez, C. J., Wakelee, H. A.
2019
- **Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer** *CLINICAL LUNG CANCER*
Myall, N. J., Henry, S., Wood, D., Neal, J. W., Han, S. S., Padda, S. K., Wakelee, H. A.
2019; 20 (2): E208–E217
- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
2019: JCO1802018
- **Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.** *Anti-cancer drugs*
Wang, S. X., Zhang, B. M., Wakelee, H. A., Koontz, M. Z., Pan, M., Diehn, M., Kunder, C. A., Neal, J. W.
2019
- **Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.** *Lung cancer (Amsterdam, Netherlands)*
Horn, L., Bauml, J., Forde, P. M., Davis, K. L., Myall, N. J., Sasane, M., Dalal, A., Culver, K., Wozniak, A. J., Baik, C. S., Mutebi, A., Zhang, P., Wakelee, et al
2019; 128: 74–90
- **Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer** *JOURNAL OF THORACIC ONCOLOGY*
Sun, T., Niu, X., Chakraborty, A., Neal, J. W., Wakelee, H. A.
2019; 14 (2): E21–E24
- **Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer** *LUNG CANCER*

- Horn, L., Bauml, J., Forde, P. M., Davis, K. L., Myall, N. J., Sasane, M., Dalal, A., Culver, K., Wozniak, A. J., Baik, C. S., Mutebi, A., Zhang, P., Wakelee, et al
2019; 128: 74–90
- **Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".** *Lung cancer (Amsterdam, Netherlands)*
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., Wakelee, H. A.
2019
 - **Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.** *Lung cancer (Amsterdam, Netherlands)*
Hellyer, J. A., Gubens, M. A., Cunanan, K. M., Padda, S. K., Burns, M. n., Spittler, A. J., Riess, J. W., San Pedro-Salcedo, M. n., Ramchandran, K. J., Neal, J. W., Wakelee, H. A., Loehrer, P. J.
2019; 137: 71–75
 - **Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Jeong, Y. n., Hellyer, J. A., Stehr, H. n., Hoang, N. T., Niu, X. n., Das, M. n., Padda, S. K., Ramchandran, K. n., Neal, J. W., Wakelee, H. A., Diehn, M. n.
2019
 - **A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.** *Oncology*
Hong, D. n., Rasco, D. n., Veeder, M. n., Luke, J. J., Chandler, J. n., Balmanoukian, A. n., George, T. J., Munster, P. n., Berlin, J. D., Gutierrez, M. n., Mita, A. n., Wakelee, H. n., Samakoglu, et al
2019: 1–10
 - **Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Hann, C. L., Scherpereel, A. n., Hellyer, J. A., Wakelee, H. A.
2019: 543–52
 - **Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.** *Lung cancer (Amsterdam, Netherlands)*
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., Wakelee, H. A.
2019; 133: 144–50
 - **Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.** *Lung cancer (Amsterdam, Netherlands)*
Hellyer, J. A., Stehr, H. n., Das, M. n., Padda, S. K., Ramchandran, K. n., Neal, J. W., Diehn, M. n., Wakelee, H. A.
2019; 134: 42–45
 - **Increased Galectin-1 Expression in Thymic Epithelial Tumors.** *Clinical lung cancer*
Riess, J. W., Kong, C. S., West, R. B., Padda, S. K., Neal, J. W., Wakelee, H. A., Le, Q.
2018
 - **EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Marcoux, N., Gettinger, S. N., O'Kane, G., Arbour, K. C., Neal, J. W., Husain, H., Evans, T. L., Brahmer, J. R., Muzikansky, A., Bonomi, P. D., Del Prete, S., Wurtz, A., Farago, et al
2018: JCO1801585
 - **Case closed: another prophylactic cranial irradiation trial for stage 3 non-small cell lung cancer fails to improve overall survival.** *Annals of translational medicine*
Moghavem, N., Wakelee, H. A., Nagpal, S.
2018; 6 (Suppl 2): S118
 - **Case closed: another prophylactic cranial irradiation trial for stage 3 non-small cell lung cancer fails to improve overall survival** *ANNALS OF TRANSLATIONAL MEDICINE*
Moghavem, N., Wakelee, H. A., Nagpal, S.
2018; 6

- **SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Pennell, N. A., Neal, J. W., Chافت, J. E., Azzoli, C. G., Janne, P. A., Govindan, R., Evans, T. L., Costa, D. B., Wakelee, H. A., Heist, R. S., Shapiro, M. A., Muzikansky, A., Murthy, et al
2018: JCO1800131
- **Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam** *JOURNAL OF GLOBAL ONCOLOGY*
Nguyen, K. H., Stehr, H., Zhou, L., Anh-Hoa Nguyen, Pham Nhu Hiep, Nguyen Van Cau, Phan Canh Duy, Thorp, R., Wakelee, H. A., Diehn, M., Neal, J. W.
2018; 4
- **Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam.** *Journal of global oncology*
Nguyen, K. H., Stehr, H., Zhou, L., Nguyen, A., Hiep, P. N., Van Cau, N., Duy, P. C., Thorp, R., Wakelee, H. A., Diehn, M., Neal, J. W.
2018: 1–9
- **EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rocicetinib, an EGFR Tyrosine Kinase Inhibitor.** *JCO precision oncology*
Goldman, J. W., Karlovich, C., Sequist, L. V., Melnikova, V., Franovic, A., Gadgeel, S. M., Reckamp, K. L., Camidge, D. R., Pérol, M., Ou, S. I., Liu, S. V., Yu, H. A., Soria, et al
2018; 2: 1-13
- **Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.** *Clinical lung cancer*
Myall, N. J., Henry, S., Wood, D., Neal, J. W., Han, S. S., Padda, S. K., Wakelee, H. A.
2018
- **How I Treat Advanced Stage Thymic Malignancy Patients**
Wakelee, H.
ELSEVIER SCIENCE INC.2018: S222–S223
- **eXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Horn, L., Wu, Y., Reck, M., Wakelee, H., Liang, C., Harrow, K., Oertel, V., Mok, T.
2018; 29 Suppl 8: viii543
- **Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC).** *Annals of oncology : official journal of the European Society for Medical Oncology*
Wakelee, H., Reckamp, K. L., Leal, T. A., Patel, S. P., Blumenschein, G., Shum, E., Nieva, J., Oxnard, G., Sanborn, R. E., Waqar, S., Zeman, K., Dukart, G., Harrow, et al
2018; 29 Suppl 8: viii541–viii542
- **Prediction of PD-1 immunotherapy (IO) response for KRAS mutated non-small cell lung cancer (NSCLC) based on co-mutations using a computational biological model.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Wakelee, H., Aredo, J., Vali, S., Singh, N. K., Vasista, S. V., Mitra, U., Abbasi, T., Padda, S. K.
2018; 29 Suppl 8: viii510–viii511
- **Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK plus) non-small cell lung cancer (NSCLC)**
Wakelee, H., Reckamp, K. L., Leal, T. A., Patel, S. P., Blumenschein, G., Shum, E., Nieva, J., Oxnard, G., Sanborn, R. E., Waqar, S., Zeman, K., Dukart, G., Harrow, et al
OXFORD UNIV PRESS.2018
- **eXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients**
Horn, L., Wu, Y., Reck, M., Wakelee, H., Liang, C., Harrow, K., Oertel, V., Mok, T.
OXFORD UNIV PRESS.2018
- **Prediction of PD-1 immunotherapy (IO) response for KRAS mutated non-small cell lung cancer (NSCLC) based on co-mutations using a computational biological model**
Wakelee, H., Aredo, J., Vali, S., Singh, N. K., Vasista, S. V., Mitra, U., Abbasi, T., Padda, S. K.

OXFORD UNIV PRESS.2018

- **Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma** *ANNALS OF ONCOLOGY*
Krug, A. K., Enderle, D., Karlovich, C., Priewasser, T., Bentink, S., Spiel, A., Brinkmann, K., Emenegger, J., Grimm, D. G., Castellanos-Rizaldos, E., Goldman, J. W., Sequist, L. V., Soria, et al
2018; 29 (10): 2143
- **Identification of Molecular Subtypes of Thymic Epithelial Tumors and Novel Treatments Using a Computational Biological Model**
Padda, S., Gokmen-Polar, Y., Badve, S., Vasista, S., Basu, K., Kumar, A., Vali, S., Abbasi, T., Wakelee, H.
ELSEVIER SCIENCE INC.2018: S606
- **Computational Biological Model Prediction of PD-L1 Expression and Immunotherapy Response for KRAS Mutated Lung Cancer Based on Co-Mutations**
Padda, S., Aredo, J., Vali, S., Singh, N., Vasista, S., Mitra, U., Abbasi, T., Wakelee, H.
ELSEVIER SCIENCE INC.2018: S533
- **Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center**
Myall, N., Henry, S., Wood, D., Neal, J., Wakelee, H.
ELSEVIER SCIENCE INC.2018: S489–S490
- **Evolving Immunotherapy Practice Patterns in Advanced NSCLC: Analysis of an Online Treatment Decision Tool**
Gandara, D., Quill, T., Edelman, M., Ramalingam, S., Wakelee, H., Fea, H., Obholz, K.
ELSEVIER SCIENCE INC.2018: S421
- **Ensartinib Treatment Beyond Disease Progression in Stage IV ALK plus Non-Small Cell Lung Cancer**
Horn, L., Pate, S., Waqar, S., Blumenschein, G., Harrow, K., Holzhausen, A., Liang, C., Dukart, G., Wakelee, H.
ELSEVIER SCIENCE INC.2018: S583
- **Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry**
Gautschi, O., Drilon, A., Milia, J., Lusque, A., Mhanna, L., Li, B., Sabari, J., Cortot, A., Besse, B., Mezquita, L., Solomon, B., Thai, A., Couraud, et al
ELSEVIER SCIENCE INC.2018: S367
- **Effect of Induction Chemotherapy in the PACIFIC Study**
Spigel, D., Vansteenkiste, J., Reck, M., Wakelee, H., Ozguroglu, M., Daniel, D., Villegas, A., Vicente, D., Hui, R., Murakami, S., Paz-Ares, L., Poole, L., Wadsworth, et al
ELSEVIER SCIENCE INC.2018: S629
- **Metabolomic Profiling for Second Primary Lung Cancer Among Lung Cancer Survivors**
Han, S., Su, L., Diao, N., Christiani, D., Wakelee, H.
ELSEVIER SCIENCE INC.2018: S567
- **eXalt3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients**
Horn, L., Wu, Y., Reck, M., Wakelee, H., Liang, C., Harrow, K., Oertel, V., Mok, T.
ELSEVIER SCIENCE INC.2018: S582
- **Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Sun, T. Y., Niu, X., Chakraborty, A., Neal, J. W., Wakelee, H. A.
2018
- **Caution Needed for Analyzing the Risks of Second Cancers** *JOURNAL OF THORACIC ONCOLOGY*
Han, S. S., Plevritis, S. K., Wakelee, H. A.
2018; 13 (9): E172–E173
- **Three-dimensional organoid model for acquired drug resistance in non-small cell lung cancer**
Shukla, N. D., Salahudeen, A. A., Padda, S. K., Neal, J. W., Wakelee, H. A., Kuo, C. J.
AMER ASSOC CANCER RESEARCH.2018

- **Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy** *CLINICAL LUNG CANCER*
Shukla, N. D., Salahudeen, A. A., Taylor, G. A., Ramalingam, S. S., Vokes, E. E., Goss, G. D., Decker, R. H., Kelly, K., Scagliotti, G. V., Mok, T. S., Wakelee, H. A.
2018; 19 (5): 377–86
- **Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer** *CLINICAL LUNG CANCER*
Chin, A. L., Kumar, K. A., Guo, H. H., Maxim, P. G., Wakelee, H., Neal, J. W., Diehn, M., Loo, B. W., Gensheimer, M. F.
2018; 19 (5): E581–E588
- **A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Das, M., Padda, S. K., Frymoyer, A., Molina, J., Adjei, A., Lensing, J. L., Miles, D., Sikic, B. I., Wakelee, H. A.
2018; 82 (3): 541–50
- **Caution Needed for Analyzing the Risks of Second Cancers.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Han, S. S., Plevritis, S. K., Wakelee, H. A.
2018; 13 (9): e172–e173
- **Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC** *JOURNAL OF THORACIC ONCOLOGY*
Rolfo, C., Mack, P. C., Scagliotti, G. V., Baas, P., Barlesi, F., Bivona, T. G., Herbst, R. S., Mok, T. S., Peled, N., Pirker, R., Raez, L. E., Reck, M., Riess, et al
2018; 13 (9): 1248–68
- **Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data**
Leal, T., Wakelee, H., Reckamp, K., Waqar, S., Patel, S., Blumenschein, G., Neal, J., Harrow, K., Holzhausen, A., Liang, C., Dukart, G., Horn, L.
ELSEVIER SCIENCE INC.2018: S156
- **Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer** *ANNALS OF ONCOLOGY*
Bonomi, P. D., Gandara, D., Hirsch, F. R., Kerr, K. M., Obasaju, C., Paz-Ares, L., Bellomo, C., Bradley, J. D., Bunn, P. A., Culligan, M., Jett, J. R., Kim, E. S., Langer, et al
2018; 29 (8): 1701–9
- **A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies.** *Cancer chemotherapy and pharmacology*
Das, M., Padda, S. K., Frymoyer, A., Molina, J., Adjei, A., Lensing, J. L., Miles, D., Sikic, B. I., Wakelee, H. A.
2018
- **Development of a multilevel integrated dataset to study lung cancer incidence and risk factors in never-smoking Asian American, Native Hawaiian, and Pacific Islander females.**
DeRouen, M. C., Shariff-Marco, S., Lichtensztajn, D., Jin, A., Daide, Y., Canchola, A. J., Li, Y., Jain, J., Hertz, A., Allen, L., Nie, S., Wong, C. P., Haile, et al
AMER ASSOC CANCER RESEARCH.2018: 81–82
- **Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies** *CLINICAL LUNG CANCER*
Hirsch, F. R., Kerr, K. M., Bunn, P. A., Kim, E. S., Obasaju, C., Perol, M., Bonomi, P., Bradley, J. D., Gandara, D., Jett, J. R., Langer, C. J., Natale, R. B., Novello, et al
2018; 19 (4): 331–39
- **Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study** *CLINICAL CANCER RESEARCH*
Horn, L., Infante, J. R., Reckamp, K. L., Blumenschein, G. R., Leal, T. A., Waqar, S. N., Gitlitz, B. J., Sanborn, R. E., Whisenant, J. G., Du, L., Neal, J. W., Gockerman, J. P., Dukart, et al
2018; 24 (12): 2771–79

- **Oral bisphosphonate use and lung cancer incidence among postmenopausal women** *ANNALS OF ONCOLOGY*
Tao, M. H., Chen, S., Freudenheim, J. L., Cauley, J. A., Johnson, K. C., Mai, X., Sarto, G. E., Wakelee, H., Boffetta, P., Wactawski-Wende, J.
2018; 29 (6): 1476–85
- **Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer** *JOURNAL OF THORACIC ONCOLOGY*
Tseng, D., Padda, S. K., Wakelee, H. A.
2018; 13 (6): 741–44
- **Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer**
Chaudhuri, A. A., Nabet, B. Y., Merriott, D. J., Jin, M., Chen, E. L., Chabon, J. J., Newman, A. M., Stehr, H., Say, C., Carter, J. N., Walters, S., Becker, H., Das, et al
ELSEVIER SCIENCE INC.2018: E1–E2
- **Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Tseng, D., Padda, S. K., Wakelee, H. A.
2018; 13 (6): 741–44
- **Incidence of lung cancer histologic cell-types according to neighborhood factors: A population based study in California** *PLOS ONE*
DeRouen, M. C., Hu, L., McKinley, M., Gali, K., Patel, M., Clarke, C., Wakelee, H., Haile, R., Gomez, S., Cheng, I.
2018; 13 (5): e0197146
- **eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients**
Horn, L., Wu, Y., Reck, M., Wakelee, H. A., Liang, C., Tan, F., Harrow, K., Oertel, V., Dukart, G., Mok, T.
AMER SOC CLINICAL ONCOLOGY.2018
- **Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).**
Marcoux, N., Gettinger, S. N., O'Kane, G. M., Arbour, K., Neal, J. W., Husain, H., Evans, T. L., Brahmer, J. R., Muzikansky, A., Bonomi, P., Del Prete, S. A., Wurtz, A., Farago, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **A multicenter study of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors.**
Hong, D. S., Rasco, D. W., Veeder, M. H., Luke, J. J., Chandler, J., Balmanoukian, A., George, T. J., Munster, P., Berlin, J., Gutierrez, M., Mita, A. C., Wakelee, H. A., Samakoglu, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Real-world treatment patterns and survival of BRAF V600-mutated metastatic non-small cell lung cancer patients.**
Horn, L., Bauml, J., Forde, P. M., Davis, K. L., Myall, N., Sasane, M., Dalal, A., Culver, K. W., Wozniak, A. J., Baik, C. S., Mutebi, A., Zhang, P., Wakelee, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer.**
Padda, S., Brzezniak, C. E., Waqar, S., Wakelee, H. A., Ma, P. C., Rose, M. G., Reid, T., Spira, A. I., Wong, E., Zeman, K., Oronsky, B., Abrouk, N. D., Morgensztern, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Real-world treatment patterns and survival of BRAF V600-mutated metastatic non-small cell lung cancer patients.**
Horn, L., Bauml, J., Forde, P. M., Davis, K. L., Myall, N., Sasane, M., Dalal, A., Culver, K. W., Wozniak, A. J., Baik, C. S., Mutebi, A., Zhang, P., Wakelee, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer.**
Padda, S., Brzezniak, C. E., Waqar, S., Wakelee, H. A., Ma, P. C., Rose, M. G., Reid, T., Spira, A. I., Wong, E., Zeman, K., Oronsky, B., Abrouk, N. D., Morgensztern, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors** *JOURNAL OF THORACIC IMAGING*

- Padda, S. K., Terrone, D., Tian, L., Khuong, A., Neal, J. W., Riess, J. W., Berry, M. F., Hoang, C. D., Burt, B. M., Leung, A. N., Schwartz, E. J., Shrager, J. B., Wakelee, et al
2018; 33 (3): 176–83
- **Circulating tumor DNA testing in advanced non-small cell lung cancer** *LUNG CANCER*
Moding, E. J., Diehn, M., Wakelee, H. A.
2018; 119: 42–47
 - **Circulating tumor DNA testing in advanced non-small cell lung cancer.** *Lung cancer (Amsterdam, Netherlands)*
Moding, E. J., Diehn, M., Wakelee, H. A.
2018; 119: 42–47
 - **A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors** *CLINICAL CANCER RESEARCH*
Miller, J. S., Morishima, C., McNeel, D. G., Patel, M. R., Kohrt, H. E. K., Thompson, J. A., Sondel, P. M., Wakelee, H. A., Disis, M. L., Kaiser, J. C., Cheever, M. A., Streicher, H., Creekmore, et al
2018; 24 (7): 1525–35
 - **Population-based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease** *CANCER MEDICINE*
Varlotta, J., Volland, R., McKie, K., Flickinger, J. C., DeCamp, M. M., Maddox, D., Rava, P., Fitzgerald, T. J., Graeber, G., Rassaei, N., Oliveira, P., Ali, S., Belani, et al
2018; 7 (4): 1211–20
 - **Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy.** *Clinical lung cancer*
Shukla, N. D., Salahudeen, A. A., Taylor, G. A., Ramalingam, S. S., Vokes, E. E., Goss, G. D., Decker, R. H., Kelly, K., Scagliotti, G. V., Mok, T. S., Wakelee, H. A.
2018
 - **EGFR Genotyping of Matched Urine, Plasma , and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor** *JCO PRECISION ONCOLOGY*
Goldman, J. W., Karlovich, C., Sequist, L., Melnikova, V., Franovic, A., Gadgeel, S. M., Reckamp, K. L., Camidge, D., Perol, M., Ou, S., Liu, S., Yu, H. A., Soria, et al
2018; 2: 1–13
 - **Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer** *LUNG CANCER*
Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V., Rosovsky, R. P., Lilenbaum, R. C., Bastos, B. R., Huang, C., Johnson, M. L., Hesketh, P. J., Subramaniam, et al
2018; 117: 44–49
 - **Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database** *JOURNAL OF THORACIC ONCOLOGY*
Padda, S. K., Yao, X., Antonicelli, A., Riess, J. W., Shang, Y., Shrager, J. B., Korst, R., Detterbeck, F., Huang, J., Burt, B. M., Wakelee, H. A., Badve, S. S.
2018; 13 (3): 436–46
 - **Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma** *ANNALS OF ONCOLOGY*
Krug, A. K., Enderle, D., Karlovich, C., Priewasser, T., Bentink, S., Spiel, A., Brinkmann, K., Emenegger, J., Grimm, D. G., Castellanos-Rizaldos, E., Goldman, J. W., Sequist, L. V., Soria, et al
2018; 29 (3): 700–706
 - **Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer** *JOURNAL OF THORACIC ONCOLOGY*
Socinski, M. A., Obasaju, C., Gandara, D., Hirsch, F. R., Bonomi, P., Bunn, P. A., Kim, E. S., Langer, C. J., Natale, R. B., Novello, S., Paz-Ares, L., Perol, M., Reck, et al
2018; 13 (2): 165–83
 - **Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Donington, J. S., Kim, Y. T., Tong, B. n., Moreira, A. L., Bessich, J. n., Weiss, K. D., Colson, Y. L., Wigle, D. n., Osarogiagbon, R. U., Zweig, J. n., Wakelee, H. n., Blasberg, J. n., Daly, et al

2018; 13 (6): 767–78

- **Treatment of Thymic Neoplasms by Drug Therapy** *MODERN THORACIC ONCOLOGY, VOL 3: ESOPHAGUS, MEDIASTINUM, CHEST WALL, AND DIAPHRAGM*
Padda, S. K., Wakelee, H. A.
edited by Cameron, R. B., Gage, D. L., Olevsky, O.
2018: 229-241
- **Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.** *The oncologist*
Xie, L. n., Nagpal, S. n., Wakelee, H. A., Li, G. n., Soltys, S. G., Neal, J. W.
2018
- **Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer.** *Clinical lung cancer*
Chin, A. L., Kumar, K. A., Guo, H. H., Maxim, P. G., Wakelee, H. n., Neal, J. W., Diehn, M. n., Loo, B. W., Gensheimer, M. F.
2018
- **A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy** *JOURNAL OF THORACIC DISEASE*
Gubens, M. A., Chuang, J. C., Akerley, W., Langer, C. J., Clement-Duchene, C., San Pedro-Salcedo, M., Colevas, A., Dragnev, K., Socinski, M. A., Wakelee, H. A.
2018; 10 (1): 219–27
- **Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS** *CURRENT TREATMENT OPTIONS IN ONCOLOGY*
Niu, X., Chuang, J. C., Berry, G. J., Wakelee, H. A.
2017; 18 (12): 71
- **Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial** *LANCET ONCOLOGY*
Wakelee, H. A., Dahlberg, S. E., Keller, S. M., Tester, W. J., Gandara, D. R., Graziano, S. L., Adjei, A. A., Leighl, N. B., Aisner, S. C., Rothman, J. M., Patel, J. D., Sborov, M. D., McDermott, et al
2017; 18 (12): 1610–23
- **Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma**
Gao, R. W., Berry, M. F., Kunder, C. A., Khuong, A. A., Wakelee, H., Neal, J. W., Backhus, L. M., Shrager, J. B.
MOSBY-ELSEVIER.2017: 2092+
- **Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer** *RADIOTHERAPY AND ONCOLOGY*
Gensheimer, M. F., Hong, J. C., Chang-Halpenny, C., Zhu, H., Eclow, N. C. W., To, J., Murphy, J. D., Wakelee, H. A., Neal, J. W., Le, Q., Hara, W. Y., Quon, A., Maxim, et al
2017; 125 (2): 338–43
- **Response to Ensartinib in TKI Naive ALK plus NSCLC Patients**
Wakelee, H., Sanborn, R., Nieva, J., Waqar, S., Brzezniak, C., Bauman, J., Neal, J., Dukart, G., Tan, F., Harrow, K., Liang, C., Horn, L.
ELSEVIER SCIENCE INC.2017: S1826
- **Activity of Ensartinib after Second Generation Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKI)**
Horn, L., Leal, T. A., Oxnard, G., Wakelee, H., Blumenschein, G. R., Waqar, S., Gandhi, L., Chiappori, A. A., Dukart, G., Harrow, K., Liang, C., Tan, F., Gockerman, et al
ELSEVIER SCIENCE INC.2017: S1556
- **Oral Bisphosphonate Use and Lung Cancer Incidence among Postmenopausal Women**
Tao, M., Chen, S., Freudenheim, J. L., Cauley, J. A., Johnson, K. C., Ma, X., Sarto, G. E., Wakelee, H., Boffetta, P., Wactawski-Wende, J.
ELSEVIER SCIENCE INC.2017: S1564–S1565
- **A Phase 1b Study of Erlotinib and Mometinib for TKI-Naive EGFR-Mutated Metastatic Non-Small Cell Lung**
Padda, S., Reckamp, K., Koczywas, M., Neal, J., Kawashima, J., Kong, S., Xin, Y., Huang, D., Wakelee, H.
ELSEVIER SCIENCE INC.2017: S2142–S2143
- **IMpower010: A Phase III Study of Atezolizumab vs Best Supportive Care Following Adjuvant Chemotherapy in Completely Resected NSCLC**

Felip, E., Wakelee, H., Vallieres, E., Zhou, C., Zuo, Y., Xia, F., Sandler, A., Altorki, N.
ELSEVIER SCIENCE INC.2017: S2398–S2399

- **Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC)**
Yang, J. C., Reckamp, K., Kim, Y., Novello, S., Smit, E., Lee, J., Su, W., Akerley, W., Blakely, C., Bazhenova, L., Chiari, R., Hsia, T., Golsorkhi, et al
ELSEVIER SCIENCE INC.2017: S2397
- **Clinical and Pathological Variables Influencing Noninvasive Detection of Early Stage Lung Cancer Using Circulating Tumor DNA**
Chabon, J., Chaudhuri, A., Azad, T., Kurtz, D., Stehr, H., Liu, C. L., Martin, J., Merriott, D., Carter, J., Ayers, K., Mansfield, A., Jen, J., Ren, et al
ELSEVIER SCIENCE INC.2017: S1851
- **Characterization of Autoantibody Responses in Thymoma with Myasthenia Gravis by Single-Cell Sequencing of B-cells**
Gomez, A., Adamska, J., Padda, S., Preiss, J., Lingampalli, N., Wakelee, H., Robinson, W.
ELSEVIER SCIENCE INC.2017: S1866–S1867
- **First-Line Ensartinib (X396) versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study**
Wu, Y., Mok, T., Reck, M., Wakelee, H., Liang, C., Tan, F., Harrow, K., Oertel, V., Dukart, G., Ding, L., Horn, L.
ELSEVIER SCIENCE INC.2017: S2402
- **Liquid Biopsy**
Wakelee, H.
ELSEVIER SCIENCE INC.2017: S1666–S1667
- **Comparison of Circulating Tumor DNA Analysis and Surveillance Imaging After Treatment for Localized Lung Cancer**
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A., Stehr, H., Azad, T. D., Carter, J. N., Merriott, D. J., Liu, C. L., Kurtz, D. M., Gensheimer, M. F., Shrager, J. B., Wakelee, et al
ELSEVIER SCIENCE INC.2017: S114
- **Outcomes of Moderately Hypofractionated Intensity-Modulated Thoracic Radiotherapy with Concurrent Chemotherapy for Treatment of Non-Small Cell Lung Cancer**
Xiang, M., Gensheimer, M. F., Maxim, P. G., Wakelee, H. A., Neal, J. W., Diehn, M., Loo, B. W.
ELSEVIER SCIENCE INC.2017: E504
- **Mid-radiation Therapy PET/CT for Prognostication and Detection of Early Progression in Patients With Stage III Non-small Cell Lung Cancer**
Gensheimer, M. F., Hong, J. C., Chang-Halpenny, C. N., Eclow, N., To, J., Murphy, J. D., Wakelee, H. A., Neal, J. W., Le, Q. T., Hara, W., Quon, A., Maxim, P. G., Graves, et al
ELSEVIER SCIENCE INC.2017: E456
- **Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer**
Merriott, D. J., Chaudhuri, A. A., Jin, M., Chabon, J. J., Newman, A., Stehr, H., Say, C., Carter, J. N., Walters, S., Becker, H. R., Das, M., Padda, S., Loo, et al
ELSEVIER SCIENCE INC.2017: S20–S21
- **Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome**
Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Merriott, D. J., Carter, J. N., Azad, T. D., Padda, S., Gensheimer, M. F., Wakelee, H. A., Neal, J. W., Loo, et al
ELSEVIER SCIENCE INC.2017: S1–S2
- **Monitoring Neutropenia for Cancer Patients at the Point of Care. *Small methods***
Inan, H., Kingsley, J. L., Ozen, M. O., Tekin, H. C., Hoerner, C. R., Imae, Y., Metzner, T. J., Preiss, J. S., Durmus, N. G., Ozsoz, M., Wakelee, H., Fan, A. C., Tüzel, et al
2017; 1 (9)
- **The Evolution of Frontline Therapy in ALK-Positive Advanced NSCLC: Which ALK TKI to Use Upfront? *AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY***
Zweig, J., Wakelee, H.
2017; 13 (9): 32–36
- **Risk Stratification for Second Primary Lung Cancer *JOURNAL OF CLINICAL ONCOLOGY***
Han, S. S., Rivera, G. A., Tammemagi, M. C., Plevritis, S. K., Gomez, S. L., Cheng, I., Wakelee, H. A.

2017; 35 (25): 2893-+

- **The J-ALEX trial-is frontline alectinib a new standard of care?** *JOURNAL OF THORACIC DISEASE*
Zweig, J., Wakelee, H. A.
2017; 9 (8): 2242-45
- **Does Plasma-Based Molecular Testing Have a Role in the Routine Care of Lung Cancer?** *CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY*
Wakelee, H.
2017; 15 (8): 599-601
- **Calcium plus vitamin D supplementation and lung cancer incidence among postmenopausal women in the Women's Health Initiative** *LUNG CANCER*
Tao, M., Dai, Q., Chen, S., Freudenheim, J. L., Rohan, T., Wakelee, H., Datta, M., Wactawski-Wende, J.
2017; 110: 42-47
- **Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging**
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Zhou, L., Liu, C., Scherer, F., Kurtz, D. M., Esfahani, M. S., Say, C., Carter, et al
ELSEVIER SCIENCE INC.2017: E4
- **Heather Wakelee on the role of checkpoint inhibitors in advanced lung cancer** *ONCOLOGY-NEW YORK*
Wakelee, H.
2017; 31 (6): 440-+
- **A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer** *LUNG CANCER*
Harris, J. P., Patel, M. I., Loo, B. W., Wakelee, H. A., Diehn, M.
2017; 108: 173-82
- **Lung cancer incidence trends in California by race/ethnicity, histology, sex, and neighborhood socioeconomic status: An analysis spanning 28 years** *LUNG CANCER*
Patel, M. I., McKinley, M., Cheng, I., Haile, R., Wakelee, H., Gomez, S.
2017; 108: 140-49
- **Scientific Advances in Thoracic Oncology 2016.** *Journal of thoracic oncology*
Soo, R. A., Stone, E. C., Cummings, K. M., Jett, J. R., Field, J. K., Groen, H. J., Mulshine, J. L., Yatabe, Y., Bubendorf, L., Dacic, S., Rami-Porta, R., Detterbeck, F. C., Lim, et al
2017
- **The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC) and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (WTLC)**
Ziel, K., Birrer, M. J., Hecht, J., Wakelee, H. A., Chen, G., Deutsch, M., Picton, M., Rodriguez, E., Willmott, L., Kelly, G., Miller, K., Moss, J., Paley, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010.**
Wakelee, H. A., Altorki, N. K., Vallieres, E., Zhou, C., Zuo, Y., Howland, M., Xia, F., Sandler, A., Felip, E.
AMER SOC CLINICAL ONCOLOGY.2017
- **A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010.**
Wakelee, H. A., Altorki, N. K., Vallieres, E., Zhou, C., Zuo, Y., Howland, M., Xia, F., Sandler, A., Felip, E.
AMER SOC CLINICAL ONCOLOGY.2017
- **-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.** *oncologist*
Baik, C. S., Myall, N. J., Wakelee, H. A.
2017

- **-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.** *oncologist*
Baik, C. S., Myall, N. J., Wakelee, H. A.
2017
- **Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry** *JOURNAL OF CLINICAL ONCOLOGY*
Gautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D., Camidge, R., Narayanan, V., Doebele, R. C., Besse, B., Remon-Masip, J., Janne, P. A., Awad, et al
2017; 35 (13): 1403-?
- **METLung: a disappointing result in a challenging patient population** *TRANSLATIONAL CANCER RESEARCH*
Zweig, J., Wakelee, H.
2017; 6: S489–S493
- **A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Wakelee, H. A., Gettinger, S., Engelman, J., Janne, P. A., West, H., Subramaniam, D. S., Leach, J., Wax, M., Yaron, Y., Miles, D. R., Lara, P. N.
2017; 79 (5): 923-932
- **Case Series of MET Exon 14 Skipping Mutation-positive Non-Small Cell Lung Cancers and Response to Crizotinib.** *International journal of radiation oncology, biology, physics*
Wang, S. X., Zhang, B., Wakelee, H. A., Diehn, M., Kunder, C., Neal, J. W.
2017; 98 (1): 239-?
- **CNS activity of ensartinib in ALK1 non-small cell lung cancer (NSCLC) patients (pts)**
Reckamp, K. L., Wakelee, H. A., Patel, S., Blumenschein, G., Neal, J. W., Gitlitz, B., Waqar, S. N., Tan, F., Harrow, K., Horn, L.
OXFORD UNIV PRESS.2017
- **The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC), and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (WTLC)**
Love, N., Birrer, M. J., Hecht, J., Wakelee, H. A., Chen, G., Deutsch, M., Picton, M., Rodriguez, E., Willmott, L., Kelly, G., Miller, K., Moss, J., Paley, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Elusive Target of Angiogenesis in Small-Cell Lung Cancer.** *Journal of clinical oncology*
Neal, J. W., Wakelee, H. A.
2017: JCO2016716084-?
- **ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.** *Journal of thoracic oncology*
Chuang, J. C., Stehr, H., Liang, Y., Das, M., Huang, J., Diehn, M., Wakelee, H. A., Neal, J. W.
2017
- **Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*
Chuang, J. C., Liang, Y., Wakelee, H. A.
2017; 31 (1): 31-?
- **Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry** *JOURNAL OF THORACIC ONCOLOGY*
Burt, B. M., Yao, X., Shrager, J., Antonicelli, A., Padda, S., Reiss, J., Wakelee, H., Su, S., Huang, J., Scott, W.
2017; 12 (1): 129-136
- **Chart Review Versus an Automated Bioinformatic Approach to Assess Real-World Crizotinib Effectiveness in Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer** *JCO: Clinical Cancer Informatics*
Bui, N., Henry, S., Wood, D., Wakelee, H. A., Neal, J. W.
2017
- **The CD47 Macrophage Checkpoint as a New Immunotherapy Target**
Sikic, B. I., Padda, S. K., Shah, S. A., Colevas, D., Narayanan, S., Fisher, G. A., Supan, D., Wakelee, H. A., Aoki, R., Pegram, M. D., Villalobos, V. M., Liu, J., Takimoto, et al
ELSEVIER SCIENCE INC.2017: S108–S109

- **IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC**
Wakelee, H., Altorki, N., Vallieres, E., Zhou, C., Zuo, Y., Howland, M., Xia, F., Hoang, T., Sandler, A., Felip, E.
ELSEVIER SCIENCE INC.2017: S1305
- **Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers**
Gautschi, O., Milia-Baron, J., Filleron, T., Wolf, J., Carbone, D., Owen, D., Camidge, D., Narayanan, V., Doebele, R., Besse, B., Remon, J., Janne, P., Awad, et al
ELSEVIER SCIENCE INC.2017: S435–S436
- **Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.** *Cancer discovery*
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H. n., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L. n., Scherer, F. n., Kurtz, D. M., Say, et al
2017
- **Monitoring Neutropenia for Cancer Patients at the Point of Care** *Small Methods*
Inan, H., et al
2017
- **Clinical Activity of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib**
Gadgeel, S., Chen, W., Piotrowska, Z., Goldman, J. W., Wakelee, H., Camidge, D., Varga, A., Yu, H., Papadimitrakopoulou, V., Nea, J., Soria, J., Wozniak, A., Riely, et al
ELSEVIER SCIENCE INC.2017: S1263
- **Smoking Behavior in Patients with Early Stage Non-Small Cell Lung Cancer: A Report from ECOG-ACRIN 1505 Trial**
Ramalingam, S., Dahlberg, S., Wakelee, H., Keller, S., Tester, W., Gandara, D. R., Graziano, S., Adjei, A., Butts, C., Schiller, J.
ELSEVIER SCIENCE INC.2017: S256
- **Perspectives of Targeted Therapies and Immunotherapy in Completely Resected NSCLC**
Wakelee, H.
ELSEVIER SCIENCE INC.2017: S45–S46
- **Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer**
Chaudhuri, A., Lovejoy, A., Chabon, J., Newman, A., Stehr, H., Say, C., Carter, J., Zhou, L., West, R., Shrager, J., Neal, J., Wakelee, H., Loo, et al
ELSEVIER SCIENCE INC.2017: S445
- **A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma**
Wakelee, H., Melnikova, V., Karlovich, C., Gadgeel, S., Reckamp, K., Goldman, J. W., Camidge, D., Perol, M., Ou, S., Liu, S., Yu, H., Socinski, M., Mekhai, et al
ELSEVIER SCIENCE INC.2017: S384–S385
- **A Phase Ib Study of Erlotinib and Momelotinib for EGFR TKI Naive EGFR Mutated Metastatic Non-Small Cell Lung Cancer**
Padda, S., Reckamp, K., Koczywas, M., Neal, J., Brachmann, C., Kawashima, J., Kong, S., Xin, Y., Huang, D., Wakelee, H.
ELSEVIER SCIENCE INC.2017: S1070–S1071
- **A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer**
Nagpal, S., Wakelee, H., Padda, S., Bertrand, S., Acevedo, B., Tisch, A., Pagtama, J., Soltys, S., Neal, J.
ELSEVIER SCIENCE INC.2017: S940
- **Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK plus NSCLC**
Horn, L., Wakelee, H., Reckamp, K., Blumenschein, G., Infante, J., Carter, C., Waqar, S., Neal, J., Gockerman, J., Harrow, K., Dukart, G., Liang, C., Gibbons, et al
ELSEVIER SCIENCE INC.2017: S1159
- **Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.** *International journal of radiation oncology, biology, physics*
Choi, C. Y., Wakelee, H. A., Neal, J. W., Pinder-Schenck, M. C., Yu, H. M., Chang, S. D., Adler, J. R., Modlin, L. A., Harsh, G. R., Soltys, S. G.
2017; 99 (1): 16–21
- **Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non Small-Cell Lung Cancer** *CLINICAL LUNG CANCER*

- Wakelee, H., Zvirbulis, Z., de Braud, F., Kingsley, C. D., Mekhail, T., Lowe, T., Schuette, W., Lena, H., Lawler, W., Braiteh, F., Cosgriff, T., Kaen, D., Boyer, et al
2017; 18 (1): 50-59
- **Reply to Comment on 'Statin use and all-cancer survival: prospective results from the Women's Health Initiative'. *British journal of cancer***
Wang, A., Aragaki, A. K., Tang, J. Y., Kurian, A. W., Manson, J. E., Chlebowski, R. T., Simon, M., Desai, P., Wassertheil-Smoller, S., Liu, S., Kritchevsky, S., Wakelee, H. A., Stefanick, et al
2017; 116 (3)
 - **Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe. *Clinical lung cancer***
Salahudeen, A. A., Patel, M. I., Baas, P., Curran, W. J., Bradley, J. D., Gandara, D. R., Goss, G. D., Mok, T. S., Ramalingam, S. S., Vokes, E. E., Malik, S. M., Wakelee, H. A.
2017; 18 (1): 5-12
 - **Molecular profiling of single circulating tumor cells from lung cancer patients *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA***
Park, S., Wong, D. J., Ooi, C. C., Kurtz, D. M., Vermesh, O., Aalipour, A., Suh, S., Pian, K. L., Chabon, J. J., Lee, S. H., Jamali, M., Say, C., Carter, et al
2016; 113 (52): E8379-E8386
 - **Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients? *Current atherosclerosis reports***
Wang, A., Wakelee, H. A., Aragaki, A. K., Tang, J. Y., Kurian, A. W., Manson, J. E., Stefanick, M. L.
2016; 18 (12): 72-?
 - **IMpower010: A Phase III trial investigating atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in patients (pts) with completely resected NSCLC**
Zhou, C., Altorki, N., Vallieres, E., Felip, E., Zuo, Y., Howland, M., Xia, F., Hoang, T., Sandler, A., Wakelee, H.
OXFORD UNIV PRESS.2016
 - **Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial *LANCET ONCOLOGY***
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Huang, Y., Carbone, D. P., Gerstner, G. J., Lerner, R. E., Rubin, J. L., Owonikoko, T. K., Stella, P. J., Steen, et al
2016; 17 (12): 1661-1671
 - **Physical activity and sedentary behavior in relation to lung cancer incidence and mortality in older women: The Women's Health Initiative. *International journal of cancer***
Wang, A., Qin, F., Hedlin, H., Desai, M., Chlebowski, R., Gomez, S., Eaton, C. B., Johnson, K. C., Qi, L., Wactawski-Wende, J., Womack, C., Wakelee, H. A., Stefanick, et al
2016; 139 (10): 2178-2192
 - **Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. *Nature communications***
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C. A., Harding, T. C., Durkin, K. A., Otterson, et al
2016; 7: 13513-?
 - **Adding to the targeted therapy toolbox: BRAF and MEK inhibition in the treatment of BRAF V600E metastatic non-small cell lung cancer *TRANSLATIONAL CANCER RESEARCH***
Myall, N. J., Wakelee, H. A.
2016; 5: S1233-S1240
 - **MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology. *Journal of thoracic oncology***
Horn, L., Wakelee, H., Reckamp, K. L., Blumenschein, G., Infante, J. R., Carter, C. A., Waqar, S. N., Neal, J. W., Harrow, K., Gockerman, J. P., Dukart, G., Liang, C., Gibbons, et al
2016; 11 (11S): S256-S257
 - **PS01.22: Novel 3-Dimensional Preclinical Models: Topic: Medical Oncology. *Journal of thoracic oncology***
Salahudeen, A., De La O, S., Padda, S. K., Neal, J. W., Wakelee, H., Kuo, C.
2016; 11 (11S): S282-?

- **PS01.55: IMpower010: Phase III Study of Atezolizumab vs BSC After Adjuvant Chemotherapy in Patients with Completely Resected NSCLC: Topic: Medical Oncology.** *Journal of thoracic oncology*
Vallieres, E., Felip, E., Altorki, N., Zhou, C., Zuo, Y., Howland, M., Xia, F., Hoang, T., Sandler, A., Wakelee, H.
2016; 11 (11S): S304-?
- **PS01.04: A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Medical Oncology.** *Journal of thoracic oncology*
Neal, J. W., Wakelee, H., Padda, S. K., Bertrand, S., Acevedo, B., Holmes Tisch, A., Pagtama, J. Y., Soltys, S. G., Nagpal, S.
2016; 11 (11S): S271-S272
- **PS01.67: Case Series of MET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancers and Response to Crizotinib: Topic: Medical Oncology.** *Journal of thoracic oncology*
Wang, S. X., Zhang, B. M., Wakelee, H., Diehn, M., Kunder, C. A., Neal, J. W.
2016; 11 (11S): S312-S313
- **PS01.77: Risk-Stratification for Second Primary Lung Cancer: Topic: Medical Oncology.** *Journal of thoracic oncology*
Han, S., Rivera, G. A., Cheng, I., Gomez, S., Plevritis, S. K., Wakelee, H.
2016; 11 (11S): S319-S320
- **PS01.66: Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated Advanced NSCLC: Topic: Medical Oncology.** *Journal of thoracic oncology*
Wakelee, H., Goldman, J. W., Gadgeel, S., Camidge, D. R., Reckamp, K. L., Ou, S. I., Yu, H. A., Solomon, B., Liu, S. V., Pérol, M., Dupuis, N. F., Nickel, A., Karlovich, et al
2016; 11 (11S): S311-S312
- **ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology.** *Journal of thoracic oncology*
Wakelee, H., Patel, J. D., Heist, R., Balmanoukian, A., Besse, B., Felip, E., Carcereny Costa, E., Chow, L. Q., Koczywas, M., Garassino, M. C., Christoph, D., Toh, C. K., Johnson, et al
2016; 11 (11S): S251-S252
- **The Burden of Cancer in Asian Americans: A Report of National Mortality Trends by Asian Ethnicity** *CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION*
Thompson, C. A., Gomez, S. L., Hastings, K. G., Kappahn, K., Yu, P., Shariff-Marco, S., Bhatt, A. S., Wakelee, H. A., Patel, M. I., Cullen, M. R., Palaniappan, L. P.
2016; 25 (10): 1371-1382
- **Phase I/II trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)**
Horn, L., Wakelee, H., Blumenschein, G., Reckamp, K., Waqar, S., Carter, C. A., Gitlitz, B. J., Infante, J. R., Sanborn, R. E., Neal, J., Gockerman, J. P., Dukart, G., Harrow, et al
OXFORD UNIV PRESS.2016
- **Rociletinib-associated cataracts in EGFR-mutant NSCLC**
Piotrowska, Z., Liu, E., Varga, A., Thakur, M., Narayanan, V., Liu, S. V., Neal, J., Spiegel, M., Solomon, B., Yu, H., Ou, S. I., Papadimitrakopoulou, V. A., Gadgeel, et al
OXFORD UNIV PRESS.2016
- **A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.** *Journal of thoracic oncology*
Reckamp, K. L., Melnikova, V. O., Karlovich, C., Sequist, L. V., Camidge, D. R., Wakelee, H., Perol, M., Oxnard, G. R., Kosco, K., Croucher, P., Samuels, E., Vibat, C. R., Guerrero, et al
2016; 11 (10): 1690-1700
- **Phase I/II trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)**
Horn, L., Wakelee, H., Blumenschein, G., Reckamp, K., Waqar, S., Carter, C. A., Gitlitz, B. J., Infante, J. R., Sanborn, R. E., Neal, J., Gockerman, J. P., Dukart, G., Harrow, et al
OXFORD UNIV PRESS.2016
- **Rociletinib-associated cataracts in EGFR-mutant NSCLC**

Piotrowska, Z., Liu, E., Varga, A., Thakur, M., Narayanan, V., Liu, S. V., Neal, J., Spiegel, M., Solomon, B., Yu, H., Ou, S. I., Papadimitrakopoulou, V. A., Gadgeel, et al
OXFORD UNIV PRESS.2016

- **A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.** *Journal of thoracic oncology*
Reckamp, K. L., Melnikova, V. O., Karlovich, C., Sequist, L. V., Camidge, D. R., Wakelee, H., Perol, M., Oxnard, G. R., Kosco, K., Croucher, P., Samuels, E., Vibat, C. R., Guerrero, et al
2016; 11 (10): 1690-1700
- **Clinicopathologic Features of Advanced Squamous NSCLC.** *Journal of thoracic oncology*
Socinski, M. A., Obasaju, C., Gandara, D., Hirsch, F. R., Bonomi, P., Bunn, P., Kim, E. S., Langer, C. J., Natale, R. B., Novello, S., Paz-Ares, L., Pérol, M., Reck, et al
2016; 11 (9): 1411-1422
- **Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment.** *Journal of thoracic oncology*
Langer, C. J., Obasaju, C., Bunn, P., Bonomi, P., Gandara, D., Hirsch, F. R., Kim, E. S., Natale, R. B., Novello, S., Paz-Ares, L., Pérol, M., Reck, M., Ramalingam, et al
2016
- **Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry.** *Journal of thoracic oncology*
Burt, B. M., Yao, X., Shrager, J., Antonicelli, A., Padda, S., Reiss, J., Wakelee, H., Su, S., Huang, J., Scott, W.
2016
- **Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.** *Journal of clinical oncology*
Crinò, L., Ahn, M., De Marinis, F., Groen, H. J., Wakelee, H., Hida, T., Mok, T., Spigel, D., Felip, E., Nishio, M., Scagliotti, G., Branle, F., Emeremni, et al
2016; 34 (24): 2866-2873
- **Pretreatment biopsy for thymic epithelial tumors-does histology subtype matter for treatment strategy?** *Journal of thoracic disease*
Padda, S. K., Keijzers, M., Wakelee, H. A.
2016; 8 (8): 1895-1900
- **Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.** *Clinical therapeutics*
Chuang, J. C., Shrager, J. B., Wakelee, H. A., Neal, J. W.
2016; 38 (7): 1567-1576
- **Statin use and all-cancer survival: prospective results from the Women's Health Initiative** *BRITISH JOURNAL OF CANCER*
Wang, A., Aragaki, A. K., Tang, J. Y., Kurian, A. W., Manson, J. E., Chlebowski, R. T., Simon, M., Desai, P., Wassertheil-Smoller, S., Liu, S., Kritchevsky, S., Wakelee, H. A., Stefanick, et al
2016; 115 (1): 129-135
- **Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients** *NATURE COMMUNICATIONS*
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C. A., Harding, T. C., Durkin, K. A., Otterson, et al
2016; 7
- **Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization** *ONCOLOGIST*
Ali, S. M., Hensing, T., Schrock, A. B., Allen, J., Sanford, E., Gowen, K., Kulkarni, A., He, J., Suh, J. H., Lipson, D., Elvin, J. A., Yelensky, R., Chalmers, et al
2016; 21 (6): 762-770
- **Plasma genotyping of patients enrolled on the expansion phase VII trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC).**
Horn, L., Wakelee, H. A., Reckamp, K. L., Blumenschein, G. R., Infante, J. R., Carter, C., Waciar, S., Neal, J. W., Gockerman, J. P., Harrow, K., Dukart, G., Liang, C., Gibbons, et al

AMER SOC CLINICAL ONCOLOGY.2016

- **E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC-Outcomes based on chemotherapy subsets.**
Wakelee, H. A., Dahlberg, S., Keller, S. M., Tester, W. J., Gandara, D. R., Graziano, S. L., Adjei, A. A., Leighl, N. B., Butts, C., Aisner, S. C., Rothman, J. M., Patel, J. D., Sborov, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy.**
Yang, J., Popat, S., Novello, S., Groen, H. J. M., Perol, M., Felip, E., Griesinger, F., Reckamp, K. L., Lee, J., Smit, E. F., Blakely, C. M., Akerley, W. L., Kim, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.**
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D., Chabon, J. J., Scherer, F., Stehr, H., Liu, C., Bratman, S., Say, C., Zhou, L., Carter, J. N., West, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.**
Wakelee, H. A., Gadgeel, S. M., Goldman, J., Reckamp, K. L., Karlovich, C., Melnikova, V., Soria, J., Yu, H., Solomon, B. J., Perol, M., Neal, J. W., Liu, S. V., Raponi, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naive patients with advanced non small-cell lung cancer.**
Antonia, S., Kim, S., Spira, A. I., Ahn, M., Ou, S., Stjepanovic, N., Fasolo, A., Jagert, D., Ott, P., Wainberg, Z. A., Wakelee, H. A., Goldman, J., Kurland, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.**
Chabon, J., Simmons, A., Newman, A. M., Lovejoy, A. F., Esfahani, M. S., Haringsma, H., Kurtz, D., Stehr, H., Scherer, F., Durkin, K. A., Otterson, G., Purcell, W. T., Camidge, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers**
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Updated results from TIGER-X, a phase open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).**
Goldman, J., Soria, J., Wakelee, H. A., Camidge, D., Gadgeel, S. M., Yu, H., Reckamp, K. L., Papadimitrakopoulou, V., Perol, M., Ou, S., Matheny, S. L., Despaigne, D., Isaacson, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686) CLINICAL CANCER RESEARCH**
Karlovich, C., Goldman, J. W., Sun, J., Mann, E., Sequist, L. V., Konopa, K., Wen, W., Angenendt, P., Horn, L., Spigel, D., Soria, J., Solomon, B., Camidge, et al
2016; 22 (10): 2386-2395
- **Integrated digital error suppression for improved detection of circulating tumor DNA NATURE BIOTECHNOLOGY**
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., Stehr, H., Liu, C. L., Bratman, S. V., Say, C., Zhou, L., Carter, J. N., West, et al
2016; 34 (5): 547-555
- **Association of non-melanoma skin cancer with second non-cutaneous malignancy in the Women's Health Initiative**
Ransohoff, K., Stefanick, M., Li, S., Kurian, A., Wakelee, H., Wang, A., Hedlin, H., Paskett, E., Han, J., Tang, J.
ELSEVIER SCIENCE INC.2016: S36

- **Scientific Advances in Lung Cancer 2015** *JOURNAL OF THORACIC ONCOLOGY*
Tsao, A. S., Scagliotti, G. V., Bunn, P. A., Carbone, D. P., Warren, G. W., Bai, C., de Koning, H. J., Yousaf-Khan, A. U., McWilliams, A., Tsao, M. S., Adusumilli, P. S., Rami-Porta, R., Asamura, et al
2016; 11 (5): 613-638
- **Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.** *Journal of cutaneous pathology*
Schaberg, K. B., Novoa, R. A., Wakelee, H. A., Kim, J., Cheung, C., Srinivas, S., Kwong, B. Y.
2016; 43 (4): 339-346
- **Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.** *Clinical lung cancer*
Myall, N. J., Neal, J. W., Cho-Phan, C. D., Zhou, L. Y., Stehr, H., Zhou, L., Diehn, M., Wakelee, H. A.
2016; 17 (2): e17-21
- **Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health Initiative.** *Journal of clinical oncology*
Patel, M. I., Wang, A., Kapphahn, K., Desai, M., Chlebowski, R. T., Simon, M. S., Bird, C. E., Corbie-Smith, G., Gomez, S. L., Adams-Campbell, L. L., Cote, M. L., Stefanick, M. L., Wakelee, et al
2016; 34 (4): 360-368
- **Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK plus non-small cell lung cancer (NSCLC)**
Reckamp, K. L., Infante, J. R., Blumenschein, G. R., Wakelee, H., Carter, C. A., Gockerman, J. P., Lovly, C., Dukart, G., Harrow, K., Liang, C., Gibbons, J. J., Horn, L.
ELSEVIER SCIENCE INC.2016: S36-S37
- **Differences in Active and Passive Smoking Exposures and Lung Cancer Incidence Between Veterans and Non-Veterans in the Women's Health Initiative** *GERONTOLOGIST*
Bastian, L. A., Gray, K. E., Derycke, E., Mirza, S., Gierisch, J. M., Haskell, S. G., Magruder, K. M., Wakelee, H. A., Wang, A., Ho, G. Y., LaCroix, A. Z.
2016; 56: S102-S111
- **Lung Cancer Survival Among Chinese Americans, 2000 to 2010.** *Journal of global oncology*
Gomez, S. L., Yang, J., Lin, S., McCusker, M., Sandler, A., Patel, M., Cheng, I., Wakelee, H. A., Clarke, C. A.
2016; 2 (1): 30-38
- **Resistance to Therapy.** *Cancer treatment and research*
Rivera, G., Wakelee, H. A.
2016; 170: 183-202
- **Lung Cancer in Never Smokers** *LUNG CANCER AND PERSONALIZED MEDICINE: CURRENT KNOWLEDGE AND THERAPIES*
Rivera, G., Wakelee, H.
edited by Ahmad, A., Gadgeel, S.
2016; 893: 43-57
- **Efficacy of Rociletinib (CO-1686) in Centrally Confirmed T790M-positive and T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients (Pts)**
Sequist, L. V., Goldman, J. W., Wakelee, H., Camidge, D. R., Gadgeel, S., Yu, H. A., Varga, A., Solomon, B., Oxnard, G. R., Ou, S. I., Papadimitrakopoulou, V., Liu, S. V., Reckamp, et al
KARGER.2016: 121
- **Association of non-melanoma skin cancer with second non-cutaneous malignancy in the Women's Health Initiative.** *The British journal of dermatology*
Ransohoff, K. J., Stefanick, M. L., Li, S. n., Kurian, A. W., Wakelee, H. n., Wang, A. n., Paskett, E. n., Han, J. n., Tang, J. Y.
2016
- **Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial** *CLINICAL LUNG CANCER*
Chlebowski, R. T., Wakelee, H., Pettinger, M., Rohan, T., Liu, J., Simon, M., Tindle, H., Messina, C., Johnson, K., Schwartz, A., Gass, M., Wactawski-Wende, J.
2016; 17 (1): 10-?
- **Survival among Never-Smokers with Lung Cancer in the Cancer Care Outcomes Research and Surveillance Study.** *Annals of the American Thoracic Society*

Clément-Duchêne, C., Stock, S., Xu, X., Chang, E. T., Gomez, S. L., West, D. W., Wakelee, H. A., Gould, M. K.
2016; 13 (1): 58-66

- **Lung Cancer in Never Smokers.** *Advances in experimental medicine and biology*
Rivera, G. A., Wakelee, H.
2016; 893: 43-57
- **Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions** *EXPERT OPINION ON PHARMACOTHERAPY*
Chuang, J. C., Salahudeen, A. A., Wakelee, H. A.
2016; 17 (7): 989-993
- **Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens** *JOURNAL OF THORACIC ONCOLOGY*
Paz-Ares, L., Hirsh, V., Zhang, L., De Marinis, F., Yang, J. C., Wakelee, H. A., Seto, T., Wu, Y., Novello, S., Juhasz, E., Aren, O., Sun, Y., Schmelter, et al
2015; 10 (12): 1745-1753
- **Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Paz-Ares, L., Hirsh, V., Zhang, L., de Marinis, F., Yang, J. C., Wakelee, H. A., Seto, T., Wu, Y. L., Novello, S., Juhász, E., Arén, O., Sun, Y., Schmelter, et al
2015; 10 (12): 1745-53
- **MISSION Trial - A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens.** *Journal of thoracic oncology*
Paz-Ares, L., Hirsh, V., Zhang, L., De Marinis, F., Yang, J. C., Wakelee, H. A., Seto, T., Wu, Y., Novello, S., Juhász, E., Arén, O., Sun, Y., Schmelter, et al
2015: -?
- **Pruritus as a Paraneoplastic Symptom of Thymoma** *JOURNAL OF THORACIC ONCOLOGY*
Padda, S. K., Shrager, J. B., Riess, J. W., Pagtama, J. Y., Tisch, A. J., Kwong, B. Y., Liang, Y., Schwartz, E. J., Loo, B. W., Neal, J. W., Hardy, R., Wakelee, H. A.
2015; 10 (11): E110-E112
- **Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose-Escalation Trial**
Modlin, L. A., Choi, C. H., Gibbs, I. C., Wakelee, H. A., Neal, J., Pinder-Schenck, M. C., Chang, S. D., Adler, J. R., Harsh, G. R., Soltys, S. G.
ELSEVIER SCIENCE INC.2015: S178
- **Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.** *Lung cancer*
Chuang, J. C., Neal, J. W., Niu, X., Wakelee, H. A.
2015; 90 (1): 1-7
- **Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.** *American journal of ophthalmology*
Leung, L. B., Neal, J. W., Wakelee, H. A., Sequist, L. V., Marmor, M. F.
2015; 160 (4): 799-805 e1
- **Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.** *American journal of ophthalmology*
Leung, L. B., Neal, J. W., Wakelee, H. A., Sequist, L. V., Marmor, M. F.
2015; 160 (4): 799-805 e1
- **Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction** *LUNG CANCER*
Das, M., Padda, S. K., Frymoyer, A., Zhou, L., Riess, J. W., Neal, J. W., Wakelee, H. A.
2015; 89 (3): 280-286
- **Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer With T790M Mutations** *CLINICAL LUNG CANCER*
Castellanos, E. H., Rivera, G., Wakelee, H., Horn, L.
2015; 16 (5): E97-E99

- **Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer** *CLINICAL LUNG CANCER*
Liang, Y., Wakelee, H. A., Neal, J. W.
2015; 16 (5): 366-373
- **Randomized Phase III Trial of Adjuvant Chemotherapy with or without Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC): Results of E1505**
Wakelee, H. A., Dahlberg, S. E., Keller, S. M., Tester, W. J., Gandara, D. R., Graziano, S. L., Adjei, A., Leighl, N., Aisner, S. C., Rothman, J. M., Patel, J., Sborov, M. D., Mcdermott, et al
ELSEVIER SCIENCE INC.2015: S796
- **Rociletinib treatment and outcomes in non-small cell lung cancer (NSCLC) patients with negative central testing for T790M**
Solomon, B., Wakelee, H., Sequist, L. V., Gadgeel, S., Soria, J. C., Goldman, J. W., Yu, H., Camidge, D. R., Papadimitrakopoulou, V., Matheny, S., Despain, D., Besse, B.
ELSEVIER SCI LTD.2015: S636
- **Rociletinib in NSCLC Patients with Negative Central Testing for T790M in TIGER-X**
Wakelee, H. A., Sequist, L. V., Gadgeel, S., Soria, J., Goldman, J. W., Yu, H., Camidge, D. R., Solomon, B. J., Matheny, S., Despain, D., Papadimitrakopoulou, V.
ELSEVIER SCIENCE INC.2015: S271–S272
- **Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement**
Varga, A., Camidge, D. R., Sequist, L. V., Wakelee, H., Ou, S. H., Goldman, J. W., Papadimitrakopoulou, V., Gadgeel, S., Mekhail, T., Oxnard, G. R., Socinski, M., Solomon, B., Yu, et al
ELSEVIER SCI LTD.2015: S598
- **Dose Optimization of Rociletinib for EGFR Mutated NSCLC**
Goldman, J. W., Wakelee, H. A., Gadgeel, S., Camidge, D. R., Solomon, B. J., Yu, H., Oxnard, G. R., Ou, S., Papadimitrakopoulou, V., Perol, M., Reckamp, K., Soria, J., Varga, et al
ELSEVIER SCIENCE INC.2015: S318–S319
- **Activity of Rociletinib in EGFR Mutant NSCLC Patients with a History of CNS Involvement**
Camidge, D. R., Sequist, L. V., Soria, J., Wakelee, H. A., Ou, S., Goldman, J. W., Papadimitrakopoulou, V., Gadgeel, S., Mekhail, T., Oxnard, G. R., Socinski, M. A., Solomon, B. J., Varga, et al
ELSEVIER SCIENCE INC.2015: S319
- **Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test**
Gadgeel, S., Soria, J. C., Goldman, J. W., Wakelee, H., Camidge, D. R., Yu, H., Varga, A., Solomon, B., Oxnard, G. R., Ou, S. H., Papadimitrakopoulou, V., Liu, S. V., Reckamp, et al
ELSEVIER SCI LTD.2015: S628
- **Ceritinib in ALK plus NSCLC Metastatic to Brain and/or Leptomeninges: The ASCEND-7 Study**
Chow, L. Q., Barlesi, F., Bertino, E. M., Kim, D., Van Den Bent, M. J., Wakelee, H. A., Wen, P. Y., Arratia, P., Shen, J., Branle, F.
ELSEVIER SCIENCE INC.2015: S550–S551
- **Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial**
Soria, J. C., Goldman, J. W., Wakelee, H., Gadgeel, S., Camidge, D. R., Solomon, B., Yu, H., Oxnard, G. R., Ou, S. H., Papadimitrakopoulou, V., Perol, M., Reckamp, K., Varga, et al
ELSEVIER SCI LTD.2015: S637
- **Symptoms and QOL with Ceritinib in ALK plus NSCLC Patients with/without Brain Metastases**
Crino, L., Ahn, M., De Marinis, F., Groen, H. M., Wakelee, H. A., Hida, T., Mok, T., Shaw, A., Felip, E., Nishio, M., Scagliotti, G. V. V., Branle, F., Emeremni, et al
ELSEVIER SCIENCE INC.2015: S379
- **TIGER-3: A Phase 3 Open-Label, Randomized Study of Rociletinib vs Chemotherapy in NSCLC**
Yang, J., Popat, S., Bazhenova, L., Blakely, C. M., Dichman, R., Felip, E., Griesinger, F., Groen, H. J. M., Gurubhagavatula, S., Leach, J. W., Novello, S., Perol, M., Patel, et al
ELSEVIER SCIENCE INC.2015: S430
- **Lung Cancer Incidence by Histology, Gender, Race/Ethnicity and Socioeconomic Status**
Patel, M. I., Mckinley, M., Cheng, I., Wakelee, H. A., Gomez, S.

ELSEVIER SCIENCE INC.2015: S460–S461

- **An Update on Clinical Trials: Is Tumor Angiogenesis Still a Viable Target in Advanced NSCLC?**
Wakelee, H. A.
ELSEVIER SCIENCE INC.2015: S94–S95
- **A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: ECOG-ACRIN E1512**
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Carbone, D. P., Ramalingam, S. S.
ELSEVIER SCIENCE INC.2015: S373
- **Phase II Trial of Single Agent Amrubicin in Patients with Previously Treated Advanced Thymic Malignancies**
Wakelee, H. A., Padda, S. K., Burns, M., Spittler, A. J., Riess, J. W., San Pedro-Salcedo, M., Ramchandran, K. J., Gubens, M. A., Neal, J. W., Loehrer, P. J.
ELSEVIER SCIENCE INC.2015: S195
- **VeriStrat (R) and Epidermal Growth Factor Receptor Mutation Status in a Phase 1b/2 Study of Cabozantinib plus +/- Erlotinib in Non-Small Cell Lung Cancer**
Padda, S. K., Lara, P., Gettinger, S. N., Engelman, J. A., Jaenne, P. A., West, H., Zhou, L. Y., Subramaniam, D. S., Leach, J. W., Wax, M. B., Neal, J. W., Clary, D. O., Goodman, et al
ELSEVIER SCIENCE INC.2015: S291
- **Case Series of HER2 Mutated Metastatic Lung Adenocarcinoma and Response to HER2 Targeted Therapies**
Chuang, J., Neal, J. W., Wakelee, H. A.
ELSEVIER SCIENCE INC.2015: S549
- **Computed Tomography (CT) Characteristics Associated with the Proposed IASLC/ITMIG TNM Pathologic Staging System for Thymoma**
Padda, S. K., Terrone, D., Khuong, A., Tian, L., Neal, J. W., Riess, J. W., Berry, M., Leung, A. N., Schwartz, E. J., Shrager, J. B., Wakelee, H. A.
ELSEVIER SCIENCE INC.2015: S196
- **Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer With T790M Mutations** *CLINICAL LUNG CANCER*
Castellanos, E. H., Rivera, G., Wakelee, H., Horn, L.
2015; 16 (5): E97-E99
- **Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer** *CLINICAL LUNG CANCER*
Liang, Y., Wakelee, H. A., Neal, J. W.
2015; 16 (5): 366-373
- **Incidence Trends of Lung Cancer by Immigration Status among Chinese Americans** *CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION*
Gomez, S. L., Yang, J., Lin, S., McCusker, M., Sandler, A., Cheng, I., Wakelee, H. A., Patel, M., Clarke, C. A.
2015; 24 (8): 1157-1164
- **COPD and risk of lung cancer in post-menopausal women: findings from the Women's Health Initiative**
Cote, M. L., Lehman, A., Chlebowski, R., Haynes, B., Ho, G., Patel, M., Sakoda, L., Simon, M., Wakelee, H., Schwartz, A.
AMER ASSOC CANCER RESEARCH.2015
- **Pretreatment and serial plasma assessments of EGFR mutations in NSCLC patients treated with rociletinib (CO-1686)**
Goldman, J. W., Karlovich, C., Mann, E., Rolfe, L., Matheny, S., Despain, D., Angenendt, P., Stamm, C., Wakelee, H. A., Soria, J., Solomon, B., Camidge, D. R., Dziadziuszko, et al
AMER ASSOC CANCER RESEARCH.2015
- **Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy** *CURRENT MEDICAL RESEARCH AND OPINION*
Guerin, A., Sasane, M., Wakelee, H., Zhang, J., Culver, K., Dea, K., Nitulescu, R., Galebach, P., Macalalad, A. R.
2015; 31 (8): 1587-1597
- **Hormone Use, Reproductive History, and Risk of Lung Cancer The Women's Health Initiative Studies** *JOURNAL OF THORACIC ONCOLOGY*
Schwartz, A. G., Ray, R. M., Cote, M. L., Abrams, J., Sokol, R. J., Hendrix, S. L., Chen, C., Chlebowski, R. T., Hubbell, F. A., Kooperberg, C., Manson, J. E., O'Sullivan, M. J., Rohan, et al

2015; 10 (7): 1004-1013

- **Heterogeneity Underlies the Emergence of EGFR T790M Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.** *Cancer discovery*
Piotrowska, Z., Niederst, M. J., Karlovich, C. A., Wakelee, H. A., Neal, J. W., Mino-Kenudson, M., Fulton, L., Hata, A. N., Lockerman, E. L., Kalsy, A., Digumarthy, S., Muzikansky, A., Raponi, et al
2015; 5 (7): 713-722
- **A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies** *LUNG CANCER*
Gubens, M. A., Burns, M., Perkins, S. M., Pedro-Salcedo, M. S., Althouse, S. K., Loehrer, P. J., Wakelee, H. A.
2015; 89 (1): 57-60
- **ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer** *CANCER EPIDEMIOLOGY*
Guerin, A., Sasane, M., Zhang, J., Macalalad, A. R., Galebach, P., Jarvis, J., Kageleiry, A., Culver, K., Wu, E. Q., Wakelee, H.
2015; 39 (3): 307-312
- **Cabozantinib (C), erlotinib (E) or the combination (E plus C) as second-or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512).**
Neal, J. W., Dahlberg, S., Wakelee, H. A., Aisner, S. C., Bowden, M., Carbone, D., Ramalingam, S. S.
AMER SOC CLINICAL ONCOLOGY.2015
- **Recreational activity and sedentary behavior in relation to lung cancer incidence and mortality in the Women's Health Initiative**
Wang, A., Qin, F., Hedlin, H., Desai, M., Chlebowski, R. T., Gomez, S., Eaton, C., Johnson, K., Qi, L., Wactawski-Wende, J., Womack, C., Wakelee, H. A., Stefanick, et al
AMER SOC CLINICAL ONCOLOGY.2015
- **Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).**
Sequist, L. V., Goldman, J., Wakelee, H. A., Camidge, D., Yu, H., Varga, A., Solomon, B., Oxnard, G. R., Ou, S., Papadimitrakopoulou, V., Chao, B. H., Liu, S. V., Reckamp, et al
AMER SOC CLINICAL ONCOLOGY.2015
- **ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK plus) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).**
Mok, T., Spigel, D., Felip, E., deMarinis, F., Ahn, M., Groen, H. J. M., Wakelee, H. A., Hida, T., Crino, L., Nishio, M., Scagliotti, G. V., Branle, F., Emeremni, et al
AMER SOC CLINICAL ONCOLOGY.2015
- **TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.**
Yang, J., Papat, S., Georgiou, P., Miyamoto, E., Isaacson, J. D., Wakelee, H. A.
AMER SOC CLINICAL ONCOLOGY.2015
- **Statin use and all-cancer mortality: Prospective results from the Women's Health Initiative**
Wang, A., Aragaki, A. K., Tang, J. Y., Kurian, A. W., Manson, J. E., Chlebowski, R. T., Simon, M. S., Desai, P. M., Wassertheil-Smoller, S., Liu, S., Kritchevsky, S., Wakelee, H. A., Stefanick, et al
AMER SOC CLINICAL ONCOLOGY.2015
- **Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM).**
Wakelee, H. A., Padda, S., Burns, M., Spittler, A., Riess, J., San Pedro-Salcedo, M., Ramchandran, K., Gubens, M. A., Neal, J. W., Loehrer, P. J.
AMER SOC CLINICAL ONCOLOGY.2015
- **Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer** *NEW ENGLAND JOURNAL OF MEDICINE*
Sequist, L. V., Soria, J., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., SOLOMON, B. J., Oxnard, G. R., Dziadziuszko, R., Aisner, D. L., Doebele, R. C., Galasso, et al
2015; 372 (18): 1700-1709
- **GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray.** *Anticancer research*
Riess, J. W., West, R., Dean, M., Klimowicz, A. C., Neal, J. W., Hoang, C., Wakelee, H. A.
2015; 35 (2): 669-676

- **GLI1, CTNNB1 and NOTCH1 Protein Expression in a Thymic Epithelial Malignancy Tissue Microarray.** *Anticancer research*
Riess, J. W., West, R., Dean, M., Klimowicz, A. C., Neal, J. W., Hoang, C., Wakelee, H. A.
2015; 35 (2): 669-676
- **Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.** *Lung cancer*
Liang, Y., Padda, S. K., Riess, J. W., West, R. B., Neal, J. W., Wakelee, H. A.
2015; 87 (1): 34-38
- **Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Wang, A., Kubo, J., Luo, J., Desai, M., Hedlin, H., Henderson, M., Chlebowski, R., Tindle, H., Chen, C., Gomez, S., Manson, J. E., Schwartz, A. G., Wactawski-Wende, et al
2015; 26 (1): 221-30
- **Novel Treatments for Thymoma and Thymic Carcinoma.** *Frontiers in oncology*
Rajan, A., Wakelee, H., Giaccone, G.
2015; 5: 267-?
- **Are Patients With Thoracic Malignancies at Risk for Uncontrolled Symptoms?** *Journal of oncology practice / American Society of Clinical Oncology*
Patel, M. I., Williams, D. C., Wohlforth, C., Fisher, G., Wakelee, H. A., Blayney, D. W.
2015; 11 (1): e98-e102
- **Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort†.** *Annals of oncology*
Wang, A., Kubo, J., Luo, J., Desai, M., Hedlin, H., Henderson, M., Chlebowski, R., Tindle, H., Chen, C., Gomez, S., Manson, J. E., Schwartz, A. G., Wactawski-Wende, et al
2015; 26 (1): 221-230
- **Angiogenesis and lung cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC.** *Translational lung cancer research*
Das, M., Wakelee, H.
2014; 3 (6): 397-399
- **Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing**
Diehn, M., Bratman, S. V., Newman, A. M., Neal, J. W., Wakelee, H. A., Merritt, R. E., Shrager, J. B., Loo, B. W., Alizadeh, A.
ELSEVIER SCIENCE INC.2014: S75
- **Racial/Ethnic Variations in Lung Cancer Incidence and Mortality, Adjusted for Smoking Behavior: Results From the Women's Health Initiative**
Patel, M. I., Wang, A., Kapphahn, K., Kubo, J., Desai, M., Chlebowski, R., Simon, M., Bird, C., Corbie-Smith, G., Gomez, S., Adams-Campbell, L., Cote, M., Stefanick, et al
ELSEVIER SCIENCE INC.2014: S56
- **Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821)**
Wakelee, H. A., Zvirbule, Z., De Braud, F., Kingsley, C. D., Mekhail, T., Schuette, W., Lena, H., Lawler, W., Braiteh, F., Cosgriff, T., Kaen, D., Boyer, M., Hsu, et al
ELSEVIER SCIENCE INC.2014: S37-S38
- **Description of ALK plus NSCLC Patient Characteristics and ALK Testing Patterns**
Wakelee, H. A., Sasane, M., Zhang, J., Macalalad, A. R., Galebach, P., Jarvis, J., Kageleiry, A., Huang, Q., Culver, K., Wu, E. Q., Guerin, A.
ELSEVIER SCIENCE INC.2014: S60-S61
- **A Phase 1 Trial of X-396, a Novel ALK Inhibitor, in Patients With Advanced Solid Tumors**
Horn, L., Blumenscheine, G., Wakelee, H. A., Arkenau, T. H., Dukart, G., Harrow, K., Liang, C., Gibbons, J. J., Lovly, C. M., Infante, J. R.
ELSEVIER SCIENCE INC.2014: S52-S53
- **Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)**
Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V., Rosovsky, R., Lilenbaum, R., Bastos, B. R., Huang, C., Johnson, M. L., Hasketh, P. J., Subramaniam, et al

ELSEVIER SCIENCE INC.2014: S36

- **Lung Cancer Incidence Trends by Histology Type among Asian American, Native Hawaiian, and Pacific Islander Populations in the United States, 1990-2010** *CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION*
Cheng, I., Le, G. M., Noone, A., Gali, K., Patel, M., Haile, R. W., Wakelee, H. A., Gomez, S. L.
2014; 23 (11): 2250-2265
- **Lung cancer incidence trends by histology type among Asian American, Native Hawaiian, and Pacific Islander populations in the United States, 1990-2010.** *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*
Cheng, I., Le, G. M., Noone, A. M., Gali, K., Patel, M., Haile, R. W., Wakelee, H. A., Gomez, S. L.
2014; 23 (11): 2250-65
- **Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer**
Soria, J., Sequist, L. V., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Yu, H. A., Solomon, B. J., Ou, S. H., Papadimitrakopoulou, V., Oxnard, G. R., Horn, L., Dziadziuszko, et al
ELSEVIER SCI LTD.2014: 199
- **Review of the current targeted therapies for non-small-cell lung cancer.** *World journal of clinical oncology*
Nguyen, K. H., Neal, J. W., Wakelee, H.
2014; 5 (4): 576-587
- **Review of the current targeted therapies for non-small-cell lung cancer** *WORLD JOURNAL OF CLINICAL ONCOLOGY*
Nguyen, K. H., Neal, J. W., Wakelee, H.
2014; 5 (4): 576-87
- **Development of the International Thymic Malignancy Interest Group International Database: An Unprecedented Resource for the Study of a Rare Group of Tumors** *JOURNAL OF THORACIC ONCOLOGY*
Huang, J., Ahmad, U., Antonicelli, A., Catlin, A. C., Fang, W., Gomez, D., Loehrer, P., Lucchi, M., Marom, E., Nicholson, A., Ruffini, E., Travis, W., Van Schil, et al
2014; 9 (10): 1573-1578
- **Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686**
Dziadziuszko, R., Karlovich, C., Wen, W., Sun, J., Chien, S., Mann, E., O'Donnell, P., Angenendt, P., Wakelee, H., Horn, L., Spigel, D., Sequist, L., Soria, et al
AMER ASSOC CANCER RESEARCH.2014
- **Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC**
Modlin, L. A., Bratman, S. V., Newman, A. M., Eclow, N. W., Neal, J. W., Wakelee, H. A., Shrager, J. B., Loo, B. W., Alizadeh, A. A., Diehn, M.
ELSEVIER SCIENCE INC.2014: S812
- **PROGRAMMED DEATH RECEPTOR LIGAND-1 (PD-L1) EXPRESSION IN A THYMOMA TISSUE MICROARRAY (TMA)**
Padda, S., Riess, J. W., Schwartz, E., Tian, L., Kohrt, H., Neal, J. W., West, R., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2014: S212
- **PEMETREXED IN PATIENTS WITH THYMIC MALIGNANCIES PREVIOUSLY TREATED WITH CHEMOTHERAPY**
Liang, Y., Padda, S., Riess, J. W., West, R., Neal, J. W., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2014: S226
- **COMPUTED TOMOGRAPHY (CT) CHARACTERISTICS ASSOCIATED WITH MASAOKA-KOGA PATHOLOGIC STAGE IN THYMOMA**
Padda, S., Terrone, D., Khuong, A., Tian, L., Neal, J. W., Riess, J. W., Hoang, C. D., Burt, B. M., Leung, A. N., Shrager, J. B., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2014: S222
- **PRURITUS AS A PARANEOPLASTIC SYMPTOM OF THYMOMA**
Padda, S., Pagtama, J. Y., Tisch, A. H., Neal, J. W., Riess, J. W., Loo, B. W., Hardy, R., Shrager, J. B., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2014: S240-S241
- **A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC)**

- Neal, J. W., Wakelee, H. A., Feliciano, J., Goldberg, S. B., Morgensztern, D., Das, M., Heist, R., Lennes, I., Muzikansky, A., Edelman, M. J., Gettinger, S. N., Sequist, L. V.
AMER SOC CLINICAL ONCOLOGY.2014
- **Racial/ethnic variations in lung cancer incidence and mortality, adjusted for smoking behavior: Results from the Women's Health Initiative.**
Patel, M. I., Wang, A., Kapphahn, K., Kubo, J., Desai, M., Chlebowski, R. T., Simon, M. S., Bird, C. E., Corble-Smith, G., Gomez, S., Adams-Campbell, L. L., Cote, M. L., Stefanick, et al
AMER SOC CLINICAL ONCOLOGY.2014
 - **A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors.**
Horn, L., Infante, J. R., Blumenschein, G. R., Wakelee, H. A., Arkenau, H., Dukart, G., Liang, C., Harrow, K., Gibbons, J., Lovly, C., Pao, W.
AMER SOC CLINICAL ONCOLOGY.2014
 - **Description of ALK plus NSCLC patient characteristics and ALK testing patterns**
Wakelee, H. A., Sasane, M., Zhang, J., Macalalad, A. R., Galebach, P. J., Jarvis, J., Kageleiry, A., Huang, Q., Culver, K. W., Wu, E., Guerin, A.
AMER SOC CLINICAL ONCOLOGY.2014
 - **A population-based study of incidence and survival trends of 1,261 thymic malignancies (TM): Results from the California Cancer Registry (CCR).**
Riess, J., Chen, Y., Lara, P., Wakelee, H. A., Gubens, M. A., Cress, R.
AMER SOC CLINICAL ONCOLOGY.2014
 - **First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)**
Sequist, L. V., Soria, J., Gadgeel, S. M., Wakelee, H. A., Camidge, D., Varga, A., Solomon, B. J., Papadimitrakopoulou, V., Jaw-Tsai, S. S., Caunt, L., Kaur, P., Rolfe, L., Allen, et al
AMER SOC CLINICAL ONCOLOGY.2014
 - **Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA)**
Padda, S., Riess, J., Schwartz, E., Tian, L., Kohrt, H., Neal, J. W., Natkunam, Y., West, R. B., Wakelee, H. A.
AMER SOC CLINICAL ONCOLOGY.2014
 - **SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.**
Pennell, N. A., Neal, J. W., Chaff, J. E., Azzoli, C. G., Janne, P. A., Govindan, R., Evans, T. L., Costa, D., Rosovsky, R., Wakelee, H. A., Heist, R., Shaw, A., Temel, et al
AMER SOC CLINICAL ONCOLOGY.2014
 - **Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing.**
Bratman, S., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H. A., Shrager, J. B., Loo, B. W., Diehn, M., Alizadeh, A. A.
AMER SOC CLINICAL ONCOLOGY.2014
 - **Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. *Clinical lung cancer***
Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Ramchandran, K., Neal, J. W., Wakelee, H. A.
2014; 15 (3): 202-206
 - **TREATMENT AND SURVIVAL PATTERNS AMONG ALK plus NSCLC PATIENTS FOLLOWING CRIZOTINIB DISCONTINUATION**
Guerin, A., Wakelee, H., Sasane, M., Zhang, J., Galebach, P., Jarvis, J., Kageleiry, A., Huang, Q., Culver, K., Wu, E. Q., Macalalad, A. R.
ELSEVIER SCIENCE INC.2014: A73
 - **An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. *Nature medicine***
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., Shrager, J. B., Loo, B. W., Alizadeh, et al
2014; 20 (5): 548-554
 - **An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage *NATURE MEDICINE***
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., Shrager, J. B., Loo, B. W., Alizadeh, et al
2014; 20 (5): 552-558
 - **Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. *Immunopharmacology and immunotoxicology***

- Riess, J. W., Bhattacharya, N., Blenman, K. R., Neal, J. W., Hwang, G., Pultar, P., San-Pedro Salcedo, M., Engleman, E., Lee, P. P., Malik, R., Wakelee, H. A.
2014; 36 (2): 182-186
- **FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M)**
Wakelee, H., Soria, J., Camidge, R., Gadgeel, S., Goldman, J., Varga, A., Solomon, B., Papadimitrakopoulou, V., Kaur, P., Sequist, L. V.
LIPPINCOTT WILLIAMS & WILKINS.2014: S38
 - **A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.** *British journal of cancer*
Chen, H., Modiano, M. R., Neal, J. W., Brahmer, J. R., Rigas, J. R., Jotte, R. M., Leigh, N. B., Riess, J. W., Kuo, C. J., Liu, L., Gao, B., DiCioccio, A. T., Adjei, et al
2014; 110 (3): 602-608
 - **Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy.** *Seminars in oncology*
Padda, S. K., Burt, B. M., Trakul, N., Wakelee, H. A.
2014; 41 (1): 40-56
 - **[Chemotherapy definitions and policies for thymic malignancies].** *Zhongguo fei ai za zhi = Chinese journal of lung cancer*
Girard, N., Lal, R., Wakelee, H., Riely, G. J., Loehrer, P. J.
2014; 17 (2): 116-121
 - **50 Years of progress in the systemic therapy of non-small cell lung cancer.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting*
Wakelee, H., Kelly, K., Edelman, M. J.
2014: 177-89
 - **Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips** *LAB ON A CHIP*
Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., Zhou, L. Y., Humke, E. W., Xu, L., Wong, D. J., Willingham, S. B., Schwartz, E. J., Weissman, I. L., Jeffrey, et al
2014; 14 (1): 78-88
 - **Commentary: highlights in NSCLC from the 15th World Conference on Lung Cancer.** *Clinical advances in hematology & oncology : H&O*
Wakelee, H. A.
2014; 12 Suppl 3 (1): 17-21
 - **Commentary: Highlights in NSCLC From the 15th World Conference on Lung Cancer** *CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY*
Wakelee, H. A.
2014; 12 (1): 17-21
 - **Anti-angiogenic Agents in Metastatic NSCLC** *LUNG CANCER,4TH EDITION*
Das, M., Wakelee, H.
edited by Roth, J. A., Hong, W. K., Komaki, R. U., Tsao, A. S., Chang, J. Y., Blackmon, S. H.
2014: 527-40
 - **Response.** *Chest*
Xu, Y., Zheng, M., Khuong, A., Merritt, R. E., Shrager, J. B., Wakelee, H. A., Kratzke, R. A., Hoang, C. D.
2013; 144 (6): 1971-1972
 - **Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips.** *Lab on a chip*
Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., Zhou, L. Y., Humke, E. W., Xu, L., Wong, D. J., Willingham, S. B., Schwartz, E. J., Weissman, I. L., Jeffrey, et al
2013; 14 (1): 78-88
 - **miR-1 Induces Growth Arrest and Apoptosis in Malignant Mesothelioma** *CHEST*
Xu, Y., Zheng, M., Merritt, R. E., Shrager, J. B., Wakelee, H. A., Kratzke, R. A., Hoang, C. D.
2013; 144 (5): 1632-1643

- **ARE PATIENTS' NEEDS BEING MET AFTER-HOURS? AN EVALUATION OF PHONE CALLS MADE AFTER HOURS FOR PATIENTS WITH THORACIC MALIGNANCIES.**
Patel, M. I., Williams, D., Wohlforth, C., Fisher, G. A., Blayney, D., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2013: S709
- **LUNG CANCER INCIDENCE TRENDS AMONG ASIAN-AMERICAN ETHNIC POPULATIONS IN THE UNITED STATES, 1990-2010**
Gomez, S., Cheng, I., Gali, K., Patel, M. I., Haile, R., Noone, A., Wakelee, H.
LIPPINCOTT WILLIAMS & WILKINS.2013: S233
- **INCREASED GALECTIN-1 EXPRESSION IN A THYMIC EPITHELIAL TUMOR TISSUE MICROARRAY (TMA) AND GALECTIN-1 KNOCKDOWN STUDIES IN A THYMOMA CELL LINE**
Riess, J. W., Kuo, P., Kong, C., Wakelee, H. A., West, R., Quynh Le
LIPPINCOTT WILLIAMS & WILKINS.2013: S269
- **ARE THERE DISPARITIES IN LUNG CANCER INCIDENCE TRENDS AMONG HISPANICS AND AFRICAN AMERICANS? AN ANALYSIS OF THE SURVEILLANCE EPIDEMIOLOGY AND END RESULTS DATABASE 1992-2010**
Patel, M. I., Cheng, I., Gomez, S., Gali, K., Haile, R., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2013: S1293
- **GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA)**
Riess, J. W., West, R., Padda, S. K., Dean, M., Klimowicz, A., Huong, C., Neal, J. W., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2013: S944
- **PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER**
Ramchandran, K. J., Fronk, J., Trieu, S., Wakelee, H. A., Das, M., Neal, J. W., Harman, S., Dwyer, P., Bosch, J., Shaw, H., Safari, S., Oden, R., Morrison, et al
LIPPINCOTT WILLIAMS & WILKINS.2013: S1324
- **VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS**
Nguyen, K. H., Das, M., Ramchandran, K., Shrager, J., Merritt, R. E., Hoang, C., Burt, B., Tisch, A., Pagtama, J., Zehnder, J., Berry, G., Wakelee, H. A., Anh-Hoa Nguyen, et al
LIPPINCOTT WILLIAMS & WILKINS.2013: S208–S209
- **FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY, SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M)**
Soria, J., Sequist, L. V., Gadgeel, S., Goldman, J., Wakelee, H., Varga, A., Fidias, P., Wozniak, A. J., Neal, J. W., Doebele, R. C., Garon, E. B., Jaw-Tsai, S., Caunt, et al
LIPPINCOTT WILLIAMS & WILKINS.2013: S141–S142
- **STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES**
Wakelee, H. A., Riess, J. W., San Pedro-Salcedo, M., Padda, S. K., Ramchandran, K., Gubens, M. A., Neal, J. W.
LIPPINCOTT WILLIAMS & WILKINS.2013: S731
- **CORRELATIVE ANALYSIS OF CIRCULATING BIOMARKERS FROM A PHASE 1B/2 TRIAL OF CABOZANTINIB (C) WITH OR WITHOUT ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)**
Padda, S. K., Rosenberg-Hasson, Y., Neal, J. W., Gettinger, S. N., Engelman, J. A., Jaenne, P. A., West, H. L., Subramaniam, D., Leach, J. W., Lara, P. N., Wax, M. B., Wakelee, H. A., Clary, et al
LIPPINCOTT WILLIAMS & WILKINS.2013: S1072–S1073
- **ENERGY METABOLISM IN LUNG ADENOCARCINOMA**
Hoang, C., Xu, Y., Shi, Z., Lin, Y., Merritt, R. E., Shrager, J., Das, M., Neal, J. W., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2013: S1036–S1037
- **ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION**
Das, M., Padda, S. K., Zhou, L., Frymoyer, A., Neal, J. W., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2013: S1185–S1186

● **STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES**

Wakelee, H. A., Riess, J. W., San Pedro-Salcedo, M., Padda, S. K., Ramchandran, K., Gubens, M. A., Neal, J. W.
LIPPINCOTT WILLIAMS & WILKINS.2013: S731

● **CORRELATIVE ANALYSIS OF CIRCULATING BIOMARKERS FROM A PHASE 1B/2 TRIAL OF CABOZANTINIB (C) WITH OR WITHOUT ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)**

Padda, S. K., Rosenberg-Hasson, Y., Neal, J. W., Gettinger, S. N., Engelman, J. A., Jaenne, P. A., West, H. L., Subramaniam, D., Leach, J. W., Lara, P. N., Wax, M. B., Wakelee, H. A., Clary, et al
LIPPINCOTT WILLIAMS & WILKINS.2013: S1072–S1073

● **ENERGY METABOLISM IN LUNG ADENOCARCINOMA**

Hoang, C., Xu, Y., Shi, Z., Lin, Y., Merritt, R. E., Shrager, J., Das, M., Neal, J. W., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2013: S1036–S1037

● **ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION**

Das, M., Padda, S. K., Zhou, L., Frymoyer, A., Neal, J. W., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2013: S1185–S1186

● **How do social factors explain outcomes in non-small-cell lung cancer among hispanics in california? Explaining the Hispanic paradox. *Journal of clinical oncology***

Patel, M. I., Schupp, C. W., Gomez, S. L., Chang, E. T., Wakelee, H. A.
2013; 31 (28): 3572-3578

● **How do social factors explain outcomes in non-small-cell lung cancer among Hispanics in California? Explaining the Hispanic paradox. *Journal of clinical oncology***

Patel, M. I., Schupp, C. W., Gomez, S. L., Chang, E. T., Wakelee, H. A.
2013; 31 (28): 3572-3578

● **Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC) *TRANSLATIONAL LUNG CANCER RESEARCH***

Liang, Y., Wakelee, H. A.
2013; 2 (5): 403–10

● **Management of early stage non-small cell lung cancer *TRANSLATIONAL LUNG CANCER RESEARCH***

Wakelee, H.
2013; 2 (5): 315

● **Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing**

Bratman, S. V., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H., Shrager, J., Loo, B. W., Alizadeh, A. A., Diehn, M.
ELSEVIER SCIENCE INC.2013: S92

● **A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements. *Clinical lung cancer***

Riess, J. W., Padda, S. K., Bangs, C. D., Das, M., Neal, J. W., Adrouny, A. R., Cherry, A., Wakelee, H. A.
2013; 14 (5): 592-595

● **INCREASED GALECTIN-1 EXPRESSION IN A THYMIC EPITHELIAL TUMOR TISSUE MICROARRAY (TMA)**

Riess, J., Kuo, P., Kong, C., West, R., Padda, S., Wakelee, H., Le, Q.
LIPPINCOTT WILLIAMS & WILKINS.2013: 25–26

● **GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA)**

Riess, J., West, R., Padda, S., Dean, M., Klimowicz, A., Huong, C., Neal, J., Wakelee, H.
LIPPINCOTT WILLIAMS & WILKINS.2013: 25

● **STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES**

Wakelee, H., Riess, J., Pedro-Salcedo, M., Padda, S., Ramchandran, K., Gubens, M., Neal, J.
LIPPINCOTT WILLIAMS & WILKINS.2013: 22–23

- **Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.** *Anti-cancer drugs*
Padda, S. K., Chhatwani, L., Zhou, L., Jacobs, C. D., Lopez-Anaya, A., Wakelee, H. A.
2013; 24 (7): 731-735
- **First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.**
Sequist, L. V., Soria, J., Gadgeel, S. M., Wakelee, H. A., Camidge, D., Varga, A., Fidias, P., Wozniak, A. J., Neal, J. W., Doebele, R., Garon, E. B., Jaw-Tsai, S. S., Stern, et al
AMER SOC CLINICAL ONCOLOGY.2013
- **Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative prospective cohort study.**
Wang, A., Kubo, J., Luo, J., Desai, M., Henderson, M. T., Chlebowski, R. T., Tindle, H., Chen, C., Manson, J. E., Schwartz, A. G., Cote, M. L., Wactawski-Wende, J., Gomez, et al
AMER SOC CLINICAL ONCOLOGY.2013
- **Are needs of stakeholders in cancer care being met? A novel approach to assessing needs to improve value in cancer care**
Patel, M. I., Moore, D., Randolph, S., Wakelee, H. A., Blayney, D. W., Milstein, A.
AMER SOC CLINICAL ONCOLOGY.2013
- **Smoking and estrogen plus progestin (E plus P) and lung cancer incidence and mortality.**
Chlebowski, R. T., Wakelee, H. A., Rohan, T. E., Liu, J., Simon, M. S., Tindle, H., Messina, C. R., Wactawski-Wende, J., Johnson, K., Schwartz, A. G., Gass, M.
AMER SOC CLINICAL ONCOLOGY.2013
- **A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Riess, J. W., Nagpal, S., Neal, J. W., Wake, H. A.
2013; 11 (4): 389-394
- **A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab.** *Journal of thoracic oncology*
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., Wakelee, H. A.
2013; 8 (2): e17-8
- **A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab** *JOURNAL OF THORACIC ONCOLOGY*
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., Wakelee, H. A.
2013; 8 (2): E17-E18
- **Aflibercept in lung cancer** *EXPERT OPINION ON BIOLOGICAL THERAPY*
Neal, J. W., Wakelee, H. A.
2013; 13 (1): 115-120
- **Treatment of Leptomeningeal Spread of NSCLC: A Continuing Challenge** *CURRENT TREATMENT OPTIONS IN ONCOLOGY*
Nagpal, S., Riess, J., Wakelee, H.
2012; 13 (4): 491-504
- **MET inhibitors in combination with other therapies in non-small cell lung cancer** *TRANSLATIONAL LUNG CANCER RESEARCH*
Padda, S., Neal, J. W., Wakelee, H. A.
2012; 1 (4): 238-53
- **Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study** *JOURNAL OF THORACIC DISEASE*
Das, M., Wakelee, H.
2012; 4 (6): 558-561
- **MET inhibitors in combination with other therapies in non-small cell lung cancer.** *Translational lung cancer research*
Padda, S., Neal, J. W., Wakelee, H. A.
2012; 1 (4): 238-253
- **Angiogenesis inhibitors.** *Journal of thoracic oncology*

Das, M., Wakelee, H.
2012; 7 (16): S397-8

● **PRIMARY CHEMOTHERAPY FOR THYMIC MALIGNANCIES**

Wakelee, H.
ELSEVIER SCIENCE INC.2012: S412

● **BIOMARKERS FOR ANTI-ANGIOGENIC THERAPY**

Das, M., Wakelee, H.
ELSEVIER SCIENCE INC.2012: S442-S443

● **A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer** *LUNG CANCER*

Clement-Duchene, C., Natale, R. B., Jahan, T., Krupitskaya, Y., Osarogiagbon, R., Sanborn, R. E., Bernstein, E. D., Dudek, A. Z., Latz, J. E., Shi, P., Wakelee, H. A.
2012; 78 (1): 57-62

● **A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43-9006) in Previously Treated Non-Small-Cell Lung Cancer Patients Eastern Cooperative Oncology Group Study E2501** *JOURNAL OF THORACIC ONCOLOGY*

Wakelee, H. A., Lee, J., Hanna, N. H., Traynor, A. M., Carbone, D. P., Schiller, J. H.
2012; 7 (10): 1574-1582

● **Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*

Trakul, N., Chang, C. N., Harris, J., Chapman, C., Rao, A., Shen, J., Quinlan-Davidson, S., Filion, E. J., Wakelee, H. A., Colevas, A. D., Whyte, R. I., Dieterich, S., Maxim, et al
2012; 84 (1): 231-237

● **A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ONARTUZUMAB (METMAB) WITH EITHER BEVACIZUMAB plus PLATINUM plus PACLITAXEL OR PEMETREXED plus PLATINUM AS FIRST-LINE TREATMENT FOR PATIENTS (PTS) WITH STAGE IIIB OR IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)**

Wakelee, H., Yu, W., Rittweger, K., Paton, V. E.
OXFORD UNIV PRESS.2012: 445

● **Prolonged Survival in Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Metastases (LM) in the Modern Treatment Era**

Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Neal, J. W., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2012: S243-S243

● **How Do Social Factors Explain Outcomes In Non-small Cell Lung Cancer Among Hispanic/latinos In California?**

Patel, M. I., Chang, E., Gomez, S., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2012: S216-S216

● **A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours** *BRITISH JOURNAL OF CANCER*

Diaz-Padilla, I., Siu, L. L., San Pedro-Salcedo, M., Razak, A. R., Colevas, A. D., Shepherd, F. A., Leighl, N. B., Neal, J. W., Thibault, A., Liu, L., Lisano, J., Gao, B., Lawson, et al
2012; 107 (4): 604-611

● **ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.** *Lung cancer*

Das, M., Riess, J. W., Frankel, P., Schwartz, E., Bennis, R., Hsieh, H. B., Liu, X., Ly, J. C., Zhou, L., Nieva, J. J., Wakelee, H. A., Bruce, R. H.
2012; 77 (2): 421-426

● **ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy** *LUNG CANCER*

Das, M., Riess, J. W., Frankel, P., Schwartz, E., Bennis, R., Ben Hsieh, H., Liu, X., Ly, J. C., Zhou, L., Nieva, J. J., Wakelee, H. A., Bruce, R. H.
2012; 77 (2): 421-426

● **Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab** *LUNG CANCER*

Wakelee, H. A., DAHLBERG, S. E., Brahmer, J. R., Schiller, J. H., Perry, M. C., Langer, C. J., Sandler, A. B., Belani, C. P., Johnson, D. H.

2012; 76 (3): 410-415

- **How do social factors explain outcomes in non-small cell lung cancer among Hispanics/Latinos in California?** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Patel, M. I., Chang, E. T., Gomez, S. L., Schupp, C., Wakelee, H. A.
AMER SOC CLINICAL ONCOLOGY.2012
- **Correlation of ERCC1 expression on circulating tumor cells with progression-free survival in metastatic non-small cell lung cancer patients treated with platinum-based chemotherapy** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Riess, J., Das, M. S., Frankel, P. H., Schwartz, E., Bennis, R., Ben Hsieh, H., Liu, X., Ly, J., Zhou, L. Y., Nieva, J. J., Bruce, R., Wakelee, H. A.
AMER SOC CLINICAL ONCOLOGY.2012
- **A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Chen, H., Modiano, M. R., Neal, J. W., Brahmer, J. R., Rigas, J. R., Jotte, R. M., Leighl, N. B., Liu, L., Lisano, J. M., Adjei, A. A., Wakelee, H. A.
AMER SOC CLINICAL ONCOLOGY.2012
- **Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms**
Davidzon, G., Wakelee, H., Neal, J., Mitra, E., Quon, A., Igaru, A.
SOC NUCLEAR MEDICINE INC.2012
- **Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.** *Clinical advances in hematology & oncology : H&O*
Riess, J. W., Wakelee, H. A.
2012; 10 (4): 226-234
- **Targeting VEGF in lung cancer** *EXPERT OPINION ON THERAPEUTIC TARGETS*
Das, M., Wakelee, H.
2012; 16 (4): 395-406
- **A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Padda, S. K., Krupitskaya, Y., Chhatwani, L., Fisher, G. A., Colevas, A. D., Pedro-Salcedo, M. S., Decker, R., Latz, J. E., Wakelee, H. A.
2012; 69 (4): 1013-1020
- **A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Wakelee, H. A., Middleton, G., Dunlop, D., Ramlau, R., Leighl, N., Hao, D., Lopez-Anaya, A., Zatloukal, P., Jacobs, C. D.
2012; 69 (3): 815-824
- **Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer** *CANCER INVESTIGATION*
Riess, J. W., Logan, A. C., Krupitskaya, Y., Padda, S., Clement-Duchene, C., Ganjoo, K., Colevas, A. D., San Pedro-Salcedo, M., Kuo, C. J., Wakelee, H. A.
2012; 30 (3): 231-235
- **A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Rodon, J., Jacobs, C. D., Chu, Q., Rowinsky, E. K., Lopez-Anaya, A., Takimoto, C. H., Wakelee, H. A.
2012; 69 (3): 825-834
- **The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Wakelee, H. A., Takimoto, C. H., Lopez-Anaya, A., Chu, Q., Middleton, G., Dunlop, D., Ramlau, R., Leighl, N., Rowinsky, E. K., Hao, D., Zatloukal, P., Jacobs, C. D., Rodon, et al
2012; 69 (2): 563-571
- **Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non-Small-Cell Lung Cancer** *CLINICAL LUNG CANCER*
Lee, P., Bazan, J. G., Lavori, P. W., Weerasuriya, D. K., Quon, A., Quynh-Thu Le, Q. T., Wakelee, H. A., Graves, E. E., Loo, B. W.
2012; 13 (1): 52-58

- **Adjuvant Chemotherapy for Early-Stage Non-Small Cell Lung Cancer** *LUNG CANCER*
Patel, M. I., Wakelee, H. A.
edited by Argiris, A.
2012; 3 (1): 129–40
- **XL647-A Multitargeted Tyrosine Kinase Inhibitor Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib** *JOURNAL OF THORACIC ONCOLOGY*
Pietanza, M. C., Lynch, T. J., Lara, P. N., Cho, J., Yanagihara, R. H., Vrindavanam, N., Chowhan, N. M., Gadgeel, S. M., Pennell, N. A., Funke, R., Mitchell, B., Wakelee, H. A., Miller, et al
2012; 7 (1): 219-226
- **Current Management of Small Cell Lung Cancer** *CLINICS IN CHEST MEDICINE*
Neal, J. W., Gubens, M. A., Wakelee, H. A.
2011; 32 (4): 853-?
- **Angiogenesis Inhibitors** *JOURNAL OF THORACIC ONCOLOGY*
Das, M., Wakelee, H.
2011; 6 (11): S1801-S1802
- **Results from a Single Institution Phase II Trial of Concurrent Docetaxel/Carboplatin/Radiotherapy Followed by Surgical Resection and Consolidation Docetaxel/Carboplatin in Stage III Non-Small-Cell Lung Cancer** *CLINICAL LUNG CANCER*
Das, M., Donington, J. S., Murphy, J., Kozak, M., Eclov, N., Whyte, R. I., Hoang, C. D., Zhou, L., Le, Q., Loo, B. W., Wakelee, H.
2011; 12 (5): 280-285
- **Chemotherapy Definitions and Policies for Thymic Malignancies** *JOURNAL OF THORACIC ONCOLOGY*
Girard, N., Lal, R., Wakelee, H., Riely, G. J., Loehrer, P. J.
2011; 6 (7): S1749-S1755
- **MAINTENANCE BEVACIZUMAB MONOTHERAPY INCREASES HEMOGLOBIN (HGB) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG ADENOCARCINOMA (NSCLC-AD)**
Riess, J. W., Logan, A., Krupitskaya, Y., Clement-Duchene, C., Kuo, C., Wakelee, H.
LIPPINCOTT WILLIAMS & WILKINS.2011: S962–S963
- **MID-RADIATION THERAPY PET CORRELATES WITH SURVIVAL IN LOCALLY ADVANCED NSCLC**
Loo, B. W., Chang, C., Hong, J., Wakelee, H., Quynh Thu Le, Hara, W. Y., Quon, A., Maxim, P. G., Graves, E. E., Diehn, M., Olson, M.
LIPPINCOTT WILLIAMS & WILKINS.2011: S694–S695
- **INTERIM REPORT OF ON-STUDY DEMOGRAPHICS AND TOXICITY FROM EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) E1505, A PHASE III RANDOMIZED TRIAL OF ADJUVANT CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB FOR COMPLETELY RESECTED EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC)**
Wakelee, H. A., Dahlberg, S. E., Keller, S. M., Gandara, D. R., Graziano, S., Leighl, N. B., Adjei, A. A., Schiller, J.
LIPPINCOTT WILLIAMS & WILKINS.2011: S464
- **A POOLED ANALYSIS OF ADVANCED NONSQUAMOUS NSCLC PATIENTS WITH STABLE TREATED BRAIN METASTASES IN TWO PHASE II TRIALS RECEIVING BEVACIZUMAB AND PEMETREXED AS SECOND-LINE THERAPY**
Gubens, M., Akerley, W., Lynch, T., Langer, C. J., Socinski, M. A., Colevas, A., Clement-Duchene, C., Wakelee, H.
LIPPINCOTT WILLIAMS & WILKINS.2011: S1224–S1225
- **American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy** *JOURNAL OF CLINICAL ONCOLOGY*
Keedy, V. L., Temin, S., Somerfield, M. R., Beasley, M. B., Johnson, D. H., McShane, L. M., Milton, D. T., Strawn, J. R., Wakelee, H. A., Giaccone, G.
2011; 29 (15): 2121-2127
- **Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC).**
Wakelee, H. A., Dahlberg, S. E., Keller, S. M., Gandara, D. R., Graziano, S. L., Leighl, N. B., Adjei, A. A., Schiller, J. H., Eastern Cooperative Oncology Grp
AMER SOC CLINICAL ONCOLOGY.2011

- **Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.**
Sikic, B. I., Eckhardt, S. G., Gallant, G., Burris, H. A., Camidge, D. R., Colevas, A. D., Jones, S. F., Messersmith, W. A., Wakelee, H. A., Li, H., Kaminker, P. G., Morris, S., Infante, et al
AMER SOC CLINICAL ONCOLOGY.2011
- **Tumor Volume as a Potential Imaging-Based Risk-Stratification Factor in Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer** *JOURNAL OF THORACIC ONCOLOGY*
Kozak, M. M., Murphy, J. D., Schipper, M. L., Donington, J. S., Zhou, L., Whyte, R. I., Shrager, J. B., Hoang, C. D., Bazan, J., Maxim, P. G., Graves, E. E., Diehn, M., Hara, et al
2011; 6 (5): 920-926
- **Survival following Non-Small Cell Lung Cancer among Asian/Pacific Islander, Latina, and Non-Hispanic White Women Who Have Never Smoked** *CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION*
Gomez, S. L., Chang, E. T., Shema, S. J., Fish, K., Sison, J. D., Reynolds, P., Clement-Duchene, C., Wrench, M. R., Wiencke, J. L., Wakelee, H. A.
2011; 20 (3): 545-554
- **Changes in FDG-PET/CT Parameters on Serial Pre-radiotherapy Scans Predict Disease Progression and Survival in Patients with Non-small Cell Lung Cancer**
Bazan, J. G., Chung, M. P., Eastham, D. V., Wakelee, H., Hara, W. Y., Maxim, P. G., Graves, E., Le, Q. T., Diehn, M., Loo, B. W.
ELSEVIER SCIENCE INC.2011: S579-S580
- **Stage IIIB and IV NSCLC: Primary Therapy** *LUNG CANCER: A MULTIDISCIPLINARY APPROACH TO DIAGNOSIS AND MANAGEMENT*
Das, M., Wakelee, H., Kernstine, K., Reckamp, K.
2011: 183-95
- **Adjuvant chemotherapy for early stage non-small cell lung cancer.** *Frontiers in oncology*
Patel, M. I., Wakelee, H. A.
2011; 1: 45-?
- **A Quantitative Assay of ERCC1 Expression in Circulating Tumor Cells (CTCs) in Non-small Cell Lung Cancer (NSCLC): A Potential Predictor of Treatment Response**
Das, M., Hsieh, B. H., Krivacic, R. T., Lazarus, N., Bennis, R., Ly, J., Schwartz, E., Zhou, L., Bruce, R. H., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2010: S535-S535
- **Vascular Disrupting Agents** *JOURNAL OF THORACIC ONCOLOGY*
Das, M., Wakelee, H.
2010; 5 (12): S482-S483
- **A Phase II Study Of Saracatinib (AZD0530), A Src Inhibitor, Administered Orally Daily To Patients With Advanced Thymic Malignancies**
Wakelee, H. A., Gubens, M. A., Burns, M., Barbeau, S. L., Perkins, S., Pedro-Salcedo, M. G., Loehrer, P. J.
LIPPINCOTT WILLIAMS & WILKINS.2010: S528-S528
- **A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer** *JOURNAL OF THORACIC ONCOLOGY*
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., McMillan, A., Kumar, A., Zhao, G., Padda, S., Zhou, L., San Pedro-Salcedo, M., Colevas, A. D., Wakelee, H. A.
2010; 5 (11): 1821-1825
- **Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized Trial** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Chlebowski, R. T., Anderson, G. L., Manson, J. E., Schwartz, A. G., Wakelee, H., Gass, M., Rodabough, R. J., Johnson, K. C., Wactawski-Wende, J., Kotchen, J. M., Ockene, J. K., O'Sullivan, M. J., Hubbell, et al
2010; 102 (18): 1413-1421
- **AMG-386, a selective angiotensin-1/2-neutralizing peptidomimetic for the potential treatment of cancer** *CURRENT OPINION IN MOLECULAR THERAPEUTICS*
Neal, J., Wakelee, H.
2010; 12 (4): 487-495
- **A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).**

Wakelee, H. A., Gettinger, S. N., Engelman, J. A., Janne, P. A., West, H. J., Subramaniam, D. S., Leach, J. W., Wax, M. B., Yaron, Y., Lara, P.
AMER SOC CLINICAL ONCOLOGY.2010

- **Thymic malignancies (TM) in the United States: A population-based study of incidence and survival trends**
Gubens, M. A., Clement-Duchene, C., Wakelee, H. A.
AMER SOC CLINICAL ONCOLOGY.2010
- **Survival among never and ever smokers with lung cancer in the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) study**
Clement-Duchene, C., Xu, X., Gomez, S. L., Chang, E. T., West, D. W., Wakelee, H. A., Gould, M. K.
AMER SOC CLINICAL ONCOLOGY.2010
- **Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors.**
Eckhardt, S. G., Gallant, G., Sikic, B. I., Camidge, D. R., Burris, H. A., Wakelee, H. A., Messersmith, W. A., Jones, S. F., Colevas, A. D., Infante, J. R.
AMER SOC CLINICAL ONCOLOGY.2010
- **A phase I study of aflibercept, pemetrexed (P), and cisplatin (C) in patients with advanced solid tumors.**
Townsend, C. A., Siu, L. L., Pedro-Salcedo, M., Liu, L., Wakelee, H. A.
AMER SOC CLINICAL ONCOLOGY.2010
- **Estrogen Alone and Lung Cancer in Postmenopausal Women**
Chlebowski, R., Anderson, G., Manson, J., Schwartz, A., Wakelee, H., Gass, M., Rodabough, R., Johnson, K., Wactawski-Wende, J., Stefanick, M.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2010: 394–94
- **Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules** *CLINICAL CANCER RESEARCH*
Advani, R. H., Hurwitz, H. I., Gordon, M. S., Ebbinghaus, S. W., Mendelson, D. S., Wakelee, H. A., Hoch, U., Silverman, J. A., Havrilla, N. A., Berman, C. J., Fox, J. A., Allen, R. S., Adelman, et al
2010; 16 (7): 2167-2175
- **Anti-angiogenesis drugs in lung cancer** *RESPIROLOGY*
Lee, S., Baas, P., Wakelee, H.
2010; 15 (3): 387–92
- **Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors** *ANNALS OF ONCOLOGY*
Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M., Fox, N. L., Miceli, R., Ullrich, S. J., Fisher, G. A., Tolcher, A. W.
2010; 21 (2): 376-381
- **Lung cancer and hormone replacement therapy reply** *LANCET*
Chlebowski, R. T., Schwartz, A. G., Wakelee, H., Anderson, G. L.
2010; 375 (9709): 118–19
- **Antiangiogenic Agents and Vascular Disrupting Agents for the Treatment of Lung Cancer A Review** *JOURNAL OF THORACIC ONCOLOGY*
Clement-Duchene, C., Wakelee, H.
2010; 5 (1): 129-139
- **Lung Cancer Sex Differences** *FEMALE SEX HORMONES AND CANCERS*
Hsu, J. Y., Wakelee, H. A.
edited by Chen, G. G.
2010: 149–70
- **Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis.** *Lung Cancer (Auckland, N.Z.)*
Gubens, M. A., Wakelee, H. A.
2010; 1: 63-76
- **Marked Tumor Response and Fatal Hemoptysis During Radiation for Lung Cancer in a Human Immunodeficiency Virus-Positive Patient Taking Nelfinavir** *JOURNAL OF THORACIC ONCOLOGY*
Chapman, C. H., Shen, J., Filion, E. J., Tran, P. T., Hara, W., Asuncion, A., Marko, D., Wakelee, H., Berry, G. J., Dimmick, K. W., Loo, B. W., Green, J.

2009; 4 (12): 1587-1589

- **Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress** *CLINICAL LUNG CANCER*
Wakelee, H., Loo, B. W., Kernstine, K. H., Putnam, J. B., Edelman, M. J., Vokes, E. E., Schiller, J. H., Baas, P., Saijo, N., Adjei, A., Goss, G., Choy, H., Gandara, et al
2009; 10 (6): 395-404
- **Vascular Endothelial Growth Factor Pathway** *JOURNAL OF THORACIC ONCOLOGY*
Krupitskaya, Y., Wakelee, H.
2009; 4 (11): S1071-S1073
- **Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial** *LANCET*
Chlebowski, R. T., Schwartz, A. G., Wakelee, H., Anderson, G. L., Stefanick, M. L., Manson, J. E., Rodabough, R. J., Chien, J. W., Wactawski-Wende, J., Gass, M., Kotchen, J. M., Johnson, K. C., O'Sullivan, et al
2009; 374 (9697): 1243-1251
- **A phase II first line study of gemcitabine, carboplatin and bevacizumab in advanced stage non-squamous non-small cell lung cancer**
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., Kumar, A., Zhao, G., Padda, S., San Pedro-Salcedo, M., Wakelee, H.
LIPPINCOTT WILLIAMS & WILKINS.2009: S674-S674
- **A randomized discontinuation phase II study of sorafenib vs placebo in patients with non-small cell lung cancer (NSCLC) who failed at least two prior chemotherapy regimens: E2501**
Schiller, J., Lee, J., Hanna, N. H., Traynor, A. M., Wakelee, H., Carbone, D. P.
LIPPINCOTT WILLIAMS & WILKINS.2009: S355-S356
- **Angiogenesis in lung cancer: role of anti-angiogenic TKI's**
Wakelee, H. A., Clement-Duchene, C.
LIPPINCOTT WILLIAMS & WILKINS.2009: S24-S26
- **Survival after non-small cell lung cancer in never-smoking Asian/Pacific Islander and Latina women**
Wakelee, H. A., Chang, E. T., Shema, S., Reynolds, P., Clement-Duchene, C., Wiencke, J., Gomez, S. L.
LIPPINCOTT WILLIAMS & WILKINS.2009: S310
- **A single arm phase 2 study of enzastaurin in combination with erlotinib, both administered orally daily, to patients with advanced non-small cell lung cancer (NSCLC)**
Wakelee, H. A., Dubey, S., Krupitskaya, Y., Osarogiagbon, R. U., Sanborn, R. E., Bernstein, E. D., Dudek, A. Z., Latz, J. E., Yuan, Z., Natale, R. B.
LIPPINCOTT WILLIAMS & WILKINS.2009: S445-S445
- **Mid-treatment PET predicts progression in hypofractionated accelerated radiation therapy for lung tumors**
Chang, C. N., Fillion, E., Chapman, C., Rao, A., Wakelee, H., Ganjoo, K., Le, Q., Maxim, P., Quon, A., Graves, E. E., Loo, B. W.
LIPPINCOTT WILLIAMS & WILKINS.2009: S939-S939
- **Excellent early local control with tumor volume adapted dosing of stereotactic body radiation therapy for pulmonary tumors**
Chang, C. N., Zhou, L. Y., MacFarlane, G., Tran, P., Rao, A., Chapman, C., Le, Q., Wakelee, H., Colevas, A. D., Whyte, R., Hristov, D., Dieterich, S., Maxim, et al
LIPPINCOTT WILLIAMS & WILKINS.2009: S938-S939
- **Quantification of pre-treatment metabolic tumor growth rate in lung cancer**
Eastham, D., Chapman, C. H., Rao, A. K., Balasubramanian, N., Quon, A., Vasanawala, M. S., Wakelee, H., Le, Q., Colevas, D. A., Maxim, P. A., Graves, E., Loo, B. W.
LIPPINCOTT WILLIAMS & WILKINS.2009: S733-S733
- **Uncovering Disparities in Survival after Non-Small-Cell Lung Cancer among Asian/Pacific Islander Ethnic Populations in California** *CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION*
Chang, E. T., Shema, S. J., Wakelee, H. A., Clarke, C. A., Gomez, S. L.
2009; 18 (8): 2248-2255
- **Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*

Chlebowski, R. T., Schwartz, A., Wakelee, H., Anderson, G. L., Stefanick, M. L., Manson, J. E., Chien, J. W., Chen, C., Wactawski-Wende, J., Gass, M.

AMER SOC CLINICAL ONCOLOGY.2009

- **Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer** *CURRENT OPINION IN INVESTIGATIONAL DRUGS*
Krupitskaya, Y., Wakelee, H. A.
2009; 10 (6): 597-605
- **A phase II first-line study of gemcitabine, carboplatin, and bevacizumab (GCB) in advanced (adv) stage non-squamous non-small cell lung cancer (NSCLC)** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Krupitskaya, Y., Ganjoo, K., Lavori, P. W., Kumar, A., Clement-Duchene, C., Zhao, G., Padda, S., San Pedro-Salcedo, M., Wakelee, H. A.
AMER SOC CLINICAL ONCOLOGY.2009
- **Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Chlebowski, R. T., Schwartz, A., Wakelee, H., Anderson, G. L., Stefanick, M. L., Manson, J. E., Chien, J. W., Chen, C., Wactawski-Wende, J., Gass, M.
AMER SOC CLINICAL ONCOLOGY.2009
- **Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial** *ANNALS OF ONCOLOGY*
West, H. L., Wakelee, H. A., Perry, M. C., Belt, R. J., Chen, R., Obasaju, C.
2009; 20 (5): 850-856
- **Y Quantification of multiple biomarker expression in circulating tumor cells**
Hsieh, H., Bethel, K., Curry, D., Jeffrey, S., Krivacic, R., Kuhn, P., Lazarus, N., Marrinucci, D., Nieva, J., Schwartz, E., Somlo, G., Wakelee, H., Bruce, et al
AMER ASSOC CANCER RESEARCH.2009
- **Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy** *JOURNAL OF THORACIC ONCOLOGY*
Krupitskaya, Y., Eslamy, H. K., Nguyen, D. D., Kumar, A., Wakelee, H. A.
2009; 4 (3): 429-431
- **Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor Current Status and Future Challenges in Cancer Therapy** *BIODRUGS*
Hsu, J. Y., Wakelee, H. A.
2009; 23 (5): 289-304
- **Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer?** *51st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)*
Eastham, D. V., Chapman, C. H., Rao, A. K., Narasimhan, B., Quon, A., Vasanawala, M. S., Wakelee, H., Le, Q., Colevas, A. D., Loo, B. W.
ELSEVIER SCIENCE INC.2009: S446-S446
- **Systemic VEGF Inhibition Induces Hepatic EPO Production and Erythrocytosis Via HIF-2a-Dependent and -Independent Mechanisms** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
Wei, K., Logan, A. C., Wakelee, H., Simon, M. C., Kuo, C. J.
AMER SOC HEMATOLOGY.2008: 183-84
- **Cooperative Group Research Efforts in Lung Cancer 2008: Focus on Advanced-Stage Non-Small-Cell Lung Cancer** *CLINICAL LUNG CANCER*
Wakelee, H., Kernstine, K., Vokes, E., Schiller, J., Baas, P., Saijo, N., Adjei, A., Goss, G., Gaspar, L., Gandara, D. R., Choy, H., Putnam, J. ".
2008; 9 (6): 346-351
- **Adjuvant chemotherapy for resected non-small cell lung cancer.** *Seminars in thoracic and cardiovascular surgery*
Wakelee, H., Chhatwani, L.
2008; 20 (3): 198-203
- **A phase I study of enzastaurin (ENZ), an oral PKC inhibitor, in combination with erlotinib (ERL) administered orally daily to patients with advanced solid malignancies**
Wakelee, H. A., Padda, S. K., Chhatwani, L., Pedro-Salcedo, M., Krupitskaya, Y., Musib, L., Latz, J. E.

PERGAMON-ELSEVIER SCIENCE LTD.2008: 126

- **PEMETREXED DISODIUM FOR THE TREATMENT OF NSCLC: AN UPDATE** *DRUGS OF TODAY*
Hsu, J. Y., Wakelee, H.
2008; 44 (9): 669-678
- **Sex differences in lung-cancer susceptibility: a smoke screen?** *LANCET ONCOLOGY*
Wakelee, H. A., Gomez, S. L., Chang, E. T.
2008; 9 (7): 609-610
- **Summary statement - Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference assessing opportunities for combination therapy** *JOURNAL OF THORACIC ONCOLOGY*
Lynch, T. J., Blumenschein, G. R., Engelman, J. A., Espinoza-Delgado, I., Govindan, R., Hanke, J., Hanna, N. H., Heymach, J. V., Hirsch, F. R., Janne, P. A., Lilienbaum, R. C., Natale, R. B., Riely, et al
2008; 3 (6): S107-S112
- **Antibodies to vascular endothelial growth factor in non-small cell lung cancer** *JOURNAL OF THORACIC ONCOLOGY*
Wakelee, H.
2008; 3 (6): S113-S118
- **A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM)**
Wakelee, H. A., Fehling, J. M., Molina, J. R., Lensing, J. L., Funke, R. P., Miles, D., Sikic, B. I.
AMER SOC CLINICAL ONCOLOGY.2008
- **Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial**
Miller, V. A., Wakelee, H. A., Lara, P. N., Cho, J., Chowhan, N. M., Costa, D., Vrindavanam, N., Yanagihara, R., Pennell, N., Lynch, T. J.
AMER SOC CLINICAL ONCOLOGY.2008
- **Complications of ablative therapies in lung cancer** *CLINICAL LUNG CANCER*
Padda, S., Kothary, N., Donington, J., Cannon, W., Loo, B. W., Kee, S., Wakelee, H.
2008; 9 (2): 122-126
- **Diagnosis in oncology - Lung cancer presenting with amegakaryocytic thrombocytopenia** *JOURNAL OF CLINICAL ONCOLOGY*
Witteles, W. H., Schrier, S. L., Wakelee, H. A.
2008; 26 (7): 1171-1174
- **Cooperative group portfolio in locally advanced non-small-cell lung cancer: Are we making progress?** *CLINICAL LUNG CANCER*
Langer, C. J., Wakelee, H., Schiller, J., Choy, H., Shepherd, F., Vokes, E. E., Adjei, A. A., Baas, P., Saijo, N., Gandara, D. R.
2008; 9 (2): 85-91
- **Lung cancer presenting with amegakaryocytic thrombocytopenia.** *Journal of clinical oncology*
Witteles, W. H., Schrier, S. L., Wakelee, H. A.
2008; 26 (7): 1171-1174
- **Cooperative group research efforts in lung cancer: Focus on early-stage non-small-cell lung cancer** *CLINICAL LUNG CANCER*
Wakelee, H., Langer, C., Vokes, E., Schiller, J., Baas, P., Saijo, N., Adjei, A., Shepherd, F., Choy, H., Gandara, D. R.
2008; 9 (1): 9-15
- **Tumor size is a critical determinant of local control in single fraction stereotactic radiotherapy of pulmonary tumors** *50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology (ASTRO)*
Loo, B. W., Shen, J., Quinlan-Davidson, S., Fillion, E., Dieterich, S., Maxim, P. G., Wakelee, H. A., Whyte, R. I., Le, Q.
ELSEVIER SCIENCE INC.2008: S467-S468
- **Review of erlotinib in the treatment of advanced non-small cell lung cancer.** *Biologics : targets & therapy*
Ganjoo, K. N., Wakelee, H.
2007; 1 (4): 335-346
- **A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI.**
Sikic, B. I., Wakelee, H. A., Von Mehren, M., Lewis, N. L., Plummer, E., Calvert, A., Fox, N., Kumm, E. A., Jones, S. F., Burris, H. A.

AMER ASSOC CANCER RESEARCH.2007: 3454S–3455S

- **A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients with advanced solid malignancies (ASM)**
Molina, J., Wakelee, H. A., Fehling, J. M., Lensingi, J. L., Calcagni, J., Funke, R. F., Miles, D., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2007: 3508S–3509S
- **Metabolic tumor burden predicts for disease progression and death in lung cancer** *47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology*
Lee, P., Weerasuriya, D. K., Lavori, P. W., Quon, A., Hara, W., Maxim, P. G., Le, Q., Wakelee, H. A., Donington, J. S., Graves, E. E., Loo, B. W.
ELSEVIER SCIENCE INC.2007: 328–33
- **Adjuvant chemotherapy of stage I non-small cell lung cancer in North America** *Workshop on Development of an International Cooperative Clinical Trial Comparing Stereotactic Radiation Therapy with Surgery for Stage I NSCLC*
Gandara, D. R., Wakelee, H., Calhoun, R., Jablons, D.
LIPPINCOTT WILLIAMS & WILKINS.2007: S125–S127
- **A phase 1b study to assess the safety of lexatimumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI**
Sikic, B. I., Wakelee, H. A., von Mehren, M., Lewis, N., Calvert, A. H., Plummer, E. R., Fox, N. L., Howard, T., Jones, S. F., Burris, H. A.
AMER SOC CLINICAL ONCOLOGY.2007
- **Lung cancer incidence in never smokers** *JOURNAL OF CLINICAL ONCOLOGY*
Wakelee, H. A., Chang, E. T., Gomez, S. L., Keegan, T. H., Feskanich, D., Clarke, C. A., Holmberg, L., Yong, L. C., Kolonel, L. N., Gould, M. K., West, D. W.
2007; 25 (5): 472-478
- **Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.** *Current treatment options in oncology*
Cabebe, E., Wakelee, H.
2007; 8 (1): 15-27
- **Optimal adjuvant therapy for non-small cell lung cancer - How to handle stage I disease** *ONCOLOGIST*
Wakelee, H., Dubey, S., Gandara, D.
2007; 12 (3): 331-337
- **Mid-treatment FDG-PET predicts disease progression in patients with non-small cell lung cancer**
Olson, M. R., Weerasuriya, D. K., Wakelee, H. A., Quon, A., Maxim, P. G., Le, Q., Graves, E. E., Loo, B. W.
ELSEVIER SCIENCE INC.2007: S504
- **Quantification of progression of non-small cell lung cancer in the interval between diagnostic and radiotherapy treatment planning PET scans**
Eastham, D. V., Weerasuriya, D., Wakelee, H., Quon, A., Maxim, P., Le, Q., Graves, E. E., Loo, B. W.
ELSEVIER SCIENCE INC.2007: S520–S521
- **A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally to patients with advanced solid malignancies (ASM)**
Sikic, B. I., Wakelee, H. A., Adjei, A. A., Halsey, J., Lensing, J. L., Dugay, J. D., Hanson, L. J., Reid, J. M., Piens, J. R.
PERGAMON-ELSEVIER SCIENCE LTD.2006: 106–7
- **Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors** *47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology*
Le, Q., Loo, B. W., Ho, A., Cotrutz, C., Koong, A. C., Wakelee, H., Kee, S. T., Constantinescu, D., Whyte, R. I., Donington, J.
LIPPINCOTT WILLIAMS & WILKINS.2006: 802–9
- **A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinoma** *CLINICAL LUNG CANCER*
Roy, M. S., Le, Q., Donington, J. S., Wakelee, H. A.
2006; 8 (2): 146-148
- **Lung cancer in women: Exploring sex differences in susceptibility, biology, and therapeutic response** *CLINICAL LUNG CANCER*
Donington, J. S., Le, Q., Wakelee, H. A.

2006; 8 (1): 22-29

- **Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: Implications for the new intergroup trial** *CLINICAL LUNG CANCER*
Wakelee, H. A., Schiller, J. H., Gandara, D. R.
2006; 8 (1): 18-21
- **A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM).** *42nd Annual Meeting of the American-Society-of-Clinical-Oncology*
Wakelee, H. A., Adjei, A. A., Halsey, J., Lensing, J. L., Dugay, J. D., Hanson, L. J., Reid, J. M., Piens, J. R., Sikic, B. I.
AMER SOC CLINICAL ONCOLOGY.2006: 131S-131S
- **SNS-595 demonstrates clinical activity and dose-proportional pharmacokinetics (PK) in two phase I clinical studies.**
Hurwitz, H., Gordon, M., Advani, R., Ebbinghaus, S., Mendelson, D., Wakelee, H., Hoch, U., Silverman, J., Havrilla, N., Adelman, D.
AMER SOC CLINICAL ONCOLOGY.2006: 136S
- **HGS-ETR2 - A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors.**
Patnaik, A., Wakelee, H., Mita, M., Fitzgerald, A., Hill, M., Fox, N., Howard, T., Ullrich, S., Tolcher, A., Sikic, B.
AMER SOC CLINICAL ONCOLOGY.2006: 123S
- **Front line therapy with gemcitabine(G) administered immediately prior to pemetrexed (P) for patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Final report of a phase II clinical**
West, H. J., Belt, R. J., Wakelee, H. A., Monberg, M. J., Frye, L. A., Ye, Z., Obasaju, C. K.
AMER SOC CLINICAL ONCOLOGY.2006: 393S
- **Sunitinib: A newly approved small-molecule inhibitor of angiogenesis** *DRUGS OF TODAY*
Cabebe, E., Wakelee, H.
2006; 42 (6): 387-398
- **Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594** *11th World Conference on Lung Cancer*
Wakelee, H. A., Wang, W., Schiller, J. H., Langer, C. J., Sandler, A. B., Belani, C. P., Johnson, D. H.
LIPPINCOTT WILLIAMS & WILKINS.2006: 441-46
- **Changes in the natural history of nonsmall cell lung cancer (NSCLC) - Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990** *38th Annual Meeting of the American-Society-of-Clinical-Oncology*
Wakelee, H. A., Bernardo, P., Johnson, D. H., Schiller, J. H.
JOHN WILEY & SONS INC.2006: 2208-17
- **A phase 1 trial of weekly SNS-595 in patients (PTS) with refractory cancer**
Ebbinghaus, S., Gordon, M., Advani, R., Hurwitz, H., Mendelson, D., Wakelee, H., Hoch, U., Silverman, J., Havrilla, N., Adelman, D.
AMER ASSOC CANCER RESEARCH.2006
- **An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers** *CLINICAL CANCER RESEARCH*
Le, Q. T., Chen, E., Salim, A., Cao, H. B., Kong, C. S., Whyte, R., Donington, J., Cannon, W., Wakelee, H., Tibshirani, R., Mitchell, J. D., Richardson, D., O'Byrne, et al
2006; 12 (5): 1507-1514
- **Second- and third-line treatments in non-small cell lung cancer.** *Current treatment options in oncology*
Kumar, A., Wakelee, H.
2006; 7 (1): 37-49
- **A phase 1 dose-escalation and pharmacokinetic (PK) study of a novel spectrum-selective kinase inhibitor (SSKI), XL647, in patients with advanced solid malignancies.** *17th EORTC/AACR/NCI International Conference on Molecular Targets and Cancer Therapeutics*
Wakelee, H., Adjei, A. A., Halsey, J., Lensing, J., Dugay, J., Hanson, L., Reid, J., Hutchison, S., Piens, J., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2005: 9029S-9029S
- **Phase I trial of SNS-595 in patients (pts) with advanced malignancies.**
Advani, R., Gordon, M., Hurwitz, H., Mendelson, D., Wakelee, H., Ebbinghaus, S., Hoch, U., Silverman, J., Havrilla, N., Adelman, D.

AMER ASSOC CANCER RESEARCH.2005: 9056S

- **HGS-ETR2-ST02: A phase 1 clinical trial of HGS-ETR2, a fully-human activating monoclonal antibody to TRAIL-R2, in patients with advanced solid tumors.**
Sarantopoulos, J., Wakelee, H., Mita, M., Fitzgerald, A., Hill, M., Fox, N. L., Howard, T., Ullrich, S., Tolcher, A. W., Sikic, B.
AMER ASSOC CANCER RESEARCH.2005: 9104S
- **Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: Novel agents with potential in lung cancer** *CLINICAL LUNG CANCER*
Wakelee, H. A., Schiller, J. H.
2005; 7: S31-S38
- **Activity of novel cytotoxic agents in lung cancer: Epothilones and topoisomerase I inhibitors** *CLINICAL LUNG CANCER*
Wakelee, H. A., Sikic, B. I.
2005; 7: S6-S12
- **Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer** *40th Annual Meeting of the American-Society-of-Clinical-Oncology*
Kuo, T., Cho, C. D., Halsey, J., Wakelee, H. A., Advani, R. H., Ford, J. M., Fisher, G. A., Sikic, B. I.
AMER SOC CLINICAL ONCOLOGY.2005: 5613-19
- **Effect of bexarotene on vinorelbine and cisplatin pharmacokinetics during a Phase I study in patients with advanced non-small cell lung cancer (NSCLC)** *11th World Conference on Lung Cancer*
Wakelee, H., Middleton, G., Dunlop, D., Kelly, C., Ramlau, R., Leighl, N., Hao, D., Zatloukal, P., Cox, K., Loewen, G.
ELSEVIER IRELAND LTD.2005: S274-S274
- **Survival differences by gender for patients with advanced non-small cell lung cancer in Eastern Cooperative Oncology Group trial 1594**
Wakelee, H., Wang, W., Schiller, J., Langer, C., Sandler, A., Belani, C., Johnson, D.
ELSEVIER IRELAND LTD.2005: S22
- **Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590** *39th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Wakelee, H. A., Stephenson, P., Keller, S. M., Wagner, H., Herskovic, A., Komaki, R., Marks, R. S., Perry, M. C., Livingston, R. B., Johnson, D. H.
ELSEVIER IRELAND LTD.2005: 389-97
- **Phase I trial of SNS-595 in patients with advanced malignancies.**
Advani, R., Gordon, M., Hurwitz, H., Mendelson, D., Wakelee, H., Ebbinghaus, S., Hoch, U., Silverman, J., Havrilla, N., Adelman, D.
AMER SOC CLINICAL ONCOLOGY.2005: 159S
- **A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies** *41st Annual Meeting of the American-Society-of-Clinical-Oncology*
Fisher, G., Advani, R., Wakelee, H., Jacobs, C., Gladysheva, K., Fitzgerald, A. M., Sikic, B.
AMER SOC CLINICAL ONCOLOGY.2005: 234S-234S
- **A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies** *41st Annual Meeting of the American-Society-of-Clinical-Oncology*
Wakelee, H., Adjei, A. A., Keer, H., Halsey, J., Hanson, L., Reid, J., Hutchison, S., Piens, J., Lacy, S., Sikic, B. I.
AMER SOC CLINICAL ONCOLOGY.2005: 227S-227S
- **A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer** *INVESTIGATIONAL NEW DRUGS*
Wakelee, H., Fisher, G. A.
2005; 23 (3): 241-242
- **Docetaxel in advanced non-small cell lung cancer** *EXPERT REVIEW OF ANTICANCER THERAPY*
Wakelee, H., Ramalingam, S., Belani, C. P.
2005; 5 (1): 13-24
- **Optimizing first-line treatment options for patients with advanced NSCLC** *ONCOLOGIST*
Wakelee, H., Belani, C. P.
2005; 10: 1-10

- **Results of a phase I dose escalation study using single fraction stereotactic radiosurgery (SFSR) for lung tumors** *47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology*
Le, Q. X., Ho, A., Cotrutz, C., Loo, B., Petrik, D., Wakelee, H., Kee, S. T., Whyte, R. I., Donington, J. S.
ELSEVIER SCIENCE INC.2005: S226–S226
- **Single fraction stereotactic radiosurgery (SFSR) for lung tumors - A phase I dose escalation trial.** *40th Annual Meeting of the American-Society-of-Clinical-Oncology*
Le, Q. T., Ho, A., Cotrutz, C., Wakelee, H., Kee, S. T., Donington, I., Whyte, R. I.
AMER SOC CLINICAL ONCOLOGY.2004: 673S–673S
- **A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer.** *40th Annual Meeting of the American-Society-of-Clinical-Oncology*
Fishe, G. A., Kuo, T., Cho, C. D., Halsey, J., Jambalos, C. N., Schwartz, E. J., Robert, R. V., Advani, R. H., Wakelee, H. A.
AMER SOC CLINICAL ONCOLOGY.2004: 248S–248S
- **Novel approaches for the treatment of small cell lung cancer** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*
Wakelee, H., Kelly, K.
2004; 18 (2): 499-?
- **A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer.** *AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics*
Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J., Rouse, R. V., Advani, R. H., Wakelee, H. A., Lum, B. L., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2003: 6103S–6103S
- **Delta F508-CFTR channels: Kinetics, activation by forskolin, and potentiation by xanthines** *AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY*
HAWES, C. M., Nepomuceno, I. B., Krouse, M. E., Wakelee, H., Law, T., Xia, Y., Nguyen, H., Wine, J. J.
1996; 270 (5): C1544-C1555
- **Delta F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines.** *The American journal of physiology*
Haws, C. M., Nepomuceno, I. B., Krouse, M. E., Wakelee, H., Law, T., Xia, Y., Nguyen, H., Wine, J. J.
1996; 270 (5 Pt 1): C1544-55